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The work presented in this thesis investigates the effectiveness of a smoking 
cessation program for smokers suffering from chronic obstructive pulmonary 
disease (COPD) who are treated in general practice, i.e. the  SMOking Cessation 
for patients with COPD (SMOCC). The SMOCC program consists of an 
implementation intervention aimed at professionals in general practice and a 
smoking cessation protocol for COPD smokers (appendix). 
 
COPD, smoking and smoking cessation 
Smoking can be regarded as the most important single risk factor for developing 
COPD. There is a clear dose-response relationship between the extent of 
exposure to tobacco smoke (expressed in pack-years) and the prevalence of 
COPD.1-3 the more and the longer a person smokes, the greater the risk to 
develop COPD. In 2007, the prevalence of COPD in the Netherlands was 
estimated to be 1.55% in women and 1.83% in men (276,100 patients);4 however, 
the prevalence markedly increases with increasing age.5 A recent Dutch study 
including (ever) smokers and never smokers, estimated that 7.4% of people aged 
40-49 years and up to 41.6% of people older than 69 years have developed 
COPD. The estimated prevalence of COPD in people older than 39 years was 
23.7%, while only 8.8% was physician-diagnosed.2  
 COPD is a chronic, multi-morbid condition: COPD patients older than 54 years 
can also suffer from coronary heart disease (27.4%), diabetes mellitus (25.8%), 
heart failure (24.0%) and arthritis (20.5%).6 In 2010, 5,984 patients died with 
COPD as primary cause of death: 40.0 and 32.1 per 100,000 males and females, 
respectively.4  
 The severity of COPD is described in several grades, referring to lung function 
which is assessed with spirometry. A spirometry test provides three outcomes: 
a) the percentage of predicted forced expiratory volume in one second (%FEV1) 
is used as an indication of disease severity,  
b) the forced vital capacity (FVC) refers to the amount of air exhaled, and  
c) the forced expiratory flow (FEF) at 25-75% of maximal lung volume.  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies 
COPD into four grades7 (Table 1). 
 According to the Dutch national guidelines for the treatment of COPD, patients 
with GOLD grade I and II should be treated in general practice. However, there are 
indications that about 50% of the COPD patients are treated in primary care.8 
Because lung function correlates weakly with symptom severity and quality of life, 
Introduction | 9 
newly-developed standards for care focus not only on lung function but also on 
disease burden as a whole to classify disease severity.  
 
Table 1. COPD severity defined according to the GOLD grade 
 
GOLD grade Criteria 
Grade I (mild) - FEV1/FVC < 0.70 
- FEV1 ≥ 80% predicted 
Grade II (moderate) - FEV1/FVC < 0.70 
 50% ≤ FEV1 < 80% predicted 
Grade III (severe) - FEV1/FVC < 0.70 
- 30% ≤ FEV1 < 50% predicted 
Grade IV (very severe) - FEV1/FVC < 0.70 
- FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure 
 
Three general factors influence the development and progression of COPD: 1) 
increased airway inflammation, 2) imbalance in proteases/anti-proteases, and 3) 
oxidative stress.9-11 Smoking plays a role in all three of these processes. 
Compared to non-smokers, the relative risk for developing COPD is 14.2 for 
women and 13.8 for men, taking other unhealthy lifestyles into account.12 As 
COPD develops slowly, three main symptoms may appear: 1) chronic coughing, 2) 
sputum production, and 3) dyspnoea. Smoking cessation decreases respiratory 
symptoms, exacerbations and lung function decline.1,13-15 The Fletcher curve 
(Figure 1) graphically shows the improved prognosis of lung function after smoking 
cessation.16 Life expectancy of current COPD smokers is significantly reduced 
compared to COPD patients who formerly smoked.17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 | Chapter 1 
Figure 1. The Fletcher curve: adopted from Fletcher & Peto, 1977. (reproduced with permission) 
 Reprinted from Kotz et al.18 
 
In spite of the large body of evidence that smoking cessation is the primary focus 
of the treatment for COPD, it is apparent that stopping smoking in this patient 
group is difficult. One-year follow-up success rates show only modest effects of 
interventions aimed at supporting COPD patients to quit smoking. Higher success 
rates are generally associated with treatment intensity.19 However, smoking 
cessation studies among COPD smokers were often carried out with well-
motivated patients and were conducted in very strict experimental (and often 
hospital) environments, making it difficult to translate the results of these trials to 
daily general practice. A systematic review found five studies on smoking 
cessation in COPD patients but the outcomes were too heterogeneous to pool the 
data.20  
 Considering the central role of smoking cessation in the primary care treatment 
of COPD, we conducted a trial in a ‘normal’ care setting including both motivated 
and unmotivated patients with COPD who were supported with quitting smoking by 
their general practice. The main question was whether or not the smoking protocol 
in general practice was effective. Additional questions addressed the relationship 
with 1) smoking cessation motivation, 2) the discrepancy between self-reported 
smoking cessation and biochemically verified smoking status, 3) facilitators and 
barriers to apply the SMOCC protocol in daily practice, and 4) conducting a large-
scale implementation study in general practice. 
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Motivation to quit smoking and its correlates 
In healthy smokers, the development of smoking-related health problems is a 
primary motive to quit smoking.21-24 Interestingly, one study compared COPD 
smokers to healthy smokers and found no difference between these two groups 
regarding smoking cessation motivation.24 However, based on the literature on 
other smoking-related life-threatening diseases, one expects that a greater 
proportion of patients with COPD are motivated to quit smoking.25,26 To investigate 
the intention to quit smoking in a large sample of COPD smokers, we used the 
Integrate Model for Behavioural Change (i.e. the I-Change Model)27 as a 
theoretical framework. The I-Change Model is derived from the Attitude – Social 
Influence – Self-Efficacy Model,28 which integrates ideas of several social 
cognition models such as the Theory of Reasoned Action,29 the Social Cognitive 
Theory,30 the Transtheoretical model,31 the Health Belief Model32 and 
metacognition.33 The I-Change Model discerns three phases of the behavioural 
change process: the premotivational phase (determined by becoming aware of the 
problem and a person’s own level of risk behaviour), the motivational phase 
(becoming motivated to change; determined by attitudes, social influence 
perceptions and self-efficacy beliefs) and the postmotivational phase (goal-setting 
processes, influences of self-efficacy beliefs, action plans, and skill building). 
According to the model, these phases are determined by four distal types of 
influence: behavioural factors (e.g. acquisition of skills and previous experience 
with the same and related behaviours), psychological factors (e.g. self-esteem, 
anxiety, and depressed affect), biological factors (e.g. gender, age, and disease 
variables), and social and cultural variables (e.g. social climate, and 
socioeconomic status).  
 Although COPD smokers may suffer more from nicotine dependence than 
smokers in the general population, the motivation to quit smoking does not differ 
between these two groups.24 To improve support for smoking cessation among 
patients with COPD, more insight in the associations between patient and disease 
characteristics and smoking cessation motivation would be valuable. Therefore, 
these topics are addressed in Chapter 2. 
 
Effectiveness of smoking cessation interventions for patients with COPD 
Many patients with COPD are treated in general practice where a variety of 
cessation aids can be used, e.g. simple advice to quit,34 pharmacological agents 
such as nicotine replacement therapy (NRT), antidepressants and varenicline,35-37 
minimal intervention (counselling),38 and proactive telephone counseling.39 Several 
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interventions to support COPD patients to quit smoking are available. For 
example, combinations of pharmacological and behavioural strategies are 
recommended for COPD smokers.20 Bupropion-SR and counselling for motivated 
patients with COPD yielded better 6-month quit rates than placebo,40 but there 
was no significant effect after 12 months. Counselling combined with NRT 
compared to placebo doubled the chance to quit after 12 months.41 Additional 
bupropion-SR to NRT proved to be effective,42 although a replication study 
showed no additional effect.43 However, to date, there is no clear evidence for the 
additional benefit from NRT.35 
 In general, behavioural counselling combined with NRT compared to placebo 
doubles the chance of quitting.35 Therefore, effective behavioural counselling 
strategies are needed to help COPD smokers to effectively quit with smoking. 
Various behavioural counselling strategies have been developed 
internationally19,44,45 as well as in the Netherlands, that were based on the 
principles of the I-Change Model.46-48 
 
We developed the SMOCC program to implement a smoking cessation protocol in 
general practice. Implementation should be tuned to known barriers and stimuli 
and should make use of the knowledge base of effective implementation 
strategies. Training of health professionals improves their performance of smoking 
cessation activities, but organisational factors also need to be addressed.49 
Implementation research shows that interactive education of professionals is 
mostly effective, and suggests that multifaceted interventions and especially 
outreach visits are useful to implement guidelines.49 Hence we designed a 
multifaceted intervention including professional training and outreach visits to 
implement a smoking cessation protocol.  
 The smoking cessation protocol aimed at supporting patients with COPD to quit 
smoking. This protocol was a modified version of the minimal intervention strategy 
(MIS) in general practice.38 Components of this protocol are counselling, the 
advice to use NRT, and telephone follow-up counselling for those who made an 
attempt to quit smoking. Effectiveness of the smoking cessation intervention has 
been demonstrated for general practice patients in general and cardiac patients.50 
However, considering the reported difficulty to quit smoking in COPD patients, it is 
not known if such an approach in general practice is effective for this group of 
patients. Therefore, we expanded the MIS with more consultations and COPD-
related feedback, and added an extra intervention arm to investigate the additional 
value of the use of bupropion-SR. Chapter 3 reports the 6-month results of the 
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smoking cessation protocol (counselling + the recommendation to use NRT) and 
Chapter 4 reports on the impact of the same smoking cessation protocol and the 
recommendation to use additional bupropion-SR at 12-month follow-up.  
 
Biochemical verification of self-reported smoking cessation 
When physicians assist their patients to quit smoking, it is difficult for them to 
confirm whether or not their support was successful. In community surveys the 
self-reported quit rates are generally valid.51 In smokers with increased health 
risks, the self-reported smoking status is less reliable51-55 and biochemical testing 
is recommended for specific populations where quitting is both desirable and 
difficult.56 
 Although the rationale for biochemical verification of the smoking status of 
patients with increased health risks is evident, the Lung Health Study found little 
discrepancy between self-reports and cotinine measurement (the biochemical 
marker) of patients with early-staged COPD.57 The patients who received smoking 
cessation support more often misreported their smoking status than patients who 
had not (6% vs. 1%), suggesting that participation in a smoking cessation program 
increases social desirability bias. However, the participation of COPD patients in 
an intensive smoking cessation program in a controlled setting had higher rates 
(52%) of misreporting after biochemical testing of their smoking status.55 Data on 
misreport in normal daily care for COPD patients are currently lacking. Smoking 
cessation interventions, as carried out in general practice during routine follow-up, 
are generally less ‘strict’ than the intensive smoking cessation programs. 
Therefore, doubts remain about how accurate the self-reports of COPD patients 
are in such a setting. Chapter 5 examines the validity of the self-reported smoking 
status of COPD patients participating in a study on smoking cessation in routine 
general practice and investigates the use of biochemical testing in clinical practice.  
 
Facilitators and barriers 
The literature shows that implementation of an intervention can be facilitated or 
hampered by beliefs and the perceived support and competences of the 
professionals. Studies on the MIS show that compliance in general practice 
relapses after a while, and that specific recommendations (such as follow-up of 
patients during a cessation attempt) are rarely followed.58 Lack of conviction about 
the strategy’s effectiveness as well as lack of social support proved to be barriers 
for successful implementation of the MIS,59,60 while positive attitudes increased the 
adoption of a smoking cessation protocol among midwives.61 In a hospital setting, 
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positive attitudes, more positive social influences and higher self-efficacy were 
related to greater adoption.62  
 However, in general practice the fear of endangering the patient-doctor 
relationship, lack of time, and the difficulty to motivate patients, are perceived as 
barriers.63 Although COPD is a smoking-related condition, which makes it easier to 
discuss smoking cessation, COPD patients often consult their general practitioner 
(GP) – emphasising the importance of the therapeutic relationship. Nevertheless, it 
is important that GPs address smoking in this patient group. To understand why 
GPs and their co-workers do or do not apply the SMOCC protocol, we conducted 
telephone interviews (Chapter 6). 
 
Large-scale recruitment procedure of COPD smokers 
There is an ongoing debate about both the value and limitations of randomised 
controlled trials for real-world efficacy of interventions.64-67 A problem is both the 
dissemination and implementation of evidence-based interventions. A premise for 
general practice teams to offer effective smoking cessation support for COPD 
smokers is knowing how these patients can be best approached and involved in a 
smoking cessation program. Studies in general practice have shown difficulties in 
including sufficient participants.68-70 Recruitment appears to be more successful if 
it concerns prevalent cases instead of incident cases and if potential participants 
are invited by means of personalized letters.68 The SMOCC program made use of 
a recruitment procedure which included a software program to assist general 
practices to detect patients with COPD in their electronic patient record and a short 
questionnaire to assess their smoking status. This recruitment strategy was 
implemented in 152 general practices, however, for the large-scale implementation 
the support of the researchers was minimised. The feasibility of the recruitment 
procedure, and practice and patient characteristics that affected smokers’ 
willingness to be involved in the smoking cessation program were explored. Insight 
in these characteristics might give clues to better organize recruitment procedures 
for COPD smokers. The recruitment of smoking patients with COPD to be involved 
in a smoking cessation program and the factors influencing the outcome of the 
recruitment procedure, is the scope of the last study included in this thesis. 
 
Research aims and outline 
Chapter 2 presents information on the motivation to quit smoking and associated 
characteristics of 633 patients with COPD. Chapter 3 addresses the effectiveness 
of programmed smoking cessation counselling and the advice to use nicotine 
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replacement therapy (NRT) at 6-months follow-up. In Chapter 4 an evaluation is 
made of the effectiveness at 12 months of a combined intervention to implement 
the counselling program. Chapter 5 examines the biochemical verification of self-
reported smoking status and discusses the role of biochemical testing in clinical 
practice. Chapter 6 provides a process evaluation focusing on the experiences of 
the GPs and the general practice team, using structured questionnaires and 
qualitative interviews. Chapter 7 describes the barriers with regard to a recruitment 
procedure to involve COPD smokers in a smoking cessation program. Finally, 
Chapter 8 presents a general discussion of the work presented in this thesis. 
 
Box 1 presents the research methodologies and research questions addressed in 
this thesis. 
 
Box 1. Research methodology and research questions 
 
Chapter Methodology Research question 
2 Cross-sectional Are COPD smokers motivated to quit smoking and what 
are the associations with patient and disease 
characteristics? 
3-4 RCT Is the SMOCC program effective? 
5 Biochemical verification Are self-reported quit rates accurate? 
6 Pre-post questionnaires 
Qualitative telephone 
interviews 
What are the experienced barriers and stimuli to apply the 
smoking cessation protocol? 
7 Cross-sectional What are the barriers regarding to a recruitment 
procedure to involve COPD smokers in a smoking 
cessation program? 
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Abstract 
Objective: To characterise patients with chronic obstructive pulmonary disease 
(COPD) in different motivational stages related to smoking cessation. 
Methods: 633 smoking COPD patients from 67 general practices participated in a 
cross-sectional study. The patients were compared with respect to health 
indicators, demographics, self-efficacy, nicotine dependence, attitudes, and action 
plans. 
Results: In line with previous Dutch results, smokers in precontemplation 
associated significantly fewer advantages with smoking cessation than smokers 
contemplating quitting and preparing to quit. Preparers had significantly higher 
self-efficacy expectations about quitting than the other smokers. Patients 
preparing to quit suffered from more COPD complaints than precontemplators. 
Smokers contemplating quitting and preparing to quit developed more plans to 
turn intentions to quit into action. 
Conclusion: More than 50% of the smokers with COPD are amenable to smoking 
cessation support. Preparers and contemplators did not differ as much as previous 
studies found. It would be advantageous to tailor COPD counselling to two distinct 
groups (unmotivated smokers and smokers motivated to quit), to discuss the 
advantages of quitting with unmotivated smokers, and to increase self-efficacy, 
and action planning for smokers motivated to quit. 
Practice implications: COPD patients are amenable to counselling to quit smoking. 
Addressing COPD complaints may contribute to greater motivation. 
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Introduction 
Smoking is the main cause of chronic obstructive pulmonary disease (COPD).1,2 A 
recent study shows that 66.7% of the elderly smoking men (76–77 years) develop 
COPD;3 consequently, smoking cessation is a core treatment element.4 
Successful quitting reduces the deterioration of lung function, improves the COPD 
prognosis, and may increase life expectancy.5–8 Although patients with COPD may 
suffer more from nicotine dependence than smokers in the general population, the 
motivation to quit smoking does not differ between these two groups.9 Suffering 
from respiratory complaints also increases the intention to quit smoking.10 
 The present study aims to analyse motives of Dutch COPD smokers in order to 
identify relevant beliefs for inclusion in cessation materials tailored to this specific 
group. We used an integrated change model (the I-change model),11–13 derived 
from the attitude-social influence-self-efficacy model,14 which consists of the 
integrated ideas of several social cognition models.15–20 The I-change model 
(Figure 1) discerns three phases of the behavioral change process: the 
premotivational phase (determined by becoming aware of the problem and a 
person’s own level of risk behaviour), the motivational phase (becoming motivated 
to change, determined by attitudes, social influence perceptions, and self-efficacy 
beliefs) and the postmotivational phase (goal-setting processes, influences of self-
efficacy beliefs, action plans, and skill building). Four distal types of influence 
determine these phases: behavioural factors (e.g. acquisition of skills and previous 
experience with the same and related behaviours), psychological factors (e.g. self-
esteem, anxiety, and depressed affect), biological factors (e.g. gender, age, and 
disease variables) and social and cultural variables (e.g. parenting styles, social 
climate, and socioeconomic status). 
 Previous studies using the model found a differential significance of attitudes, 
social influences, and self-efficacy expectations. The result was a so-called 
Ø pattern, showing that transitions from an unmotivated to a motivated phase were 
best predicted by attitudes, while transitions from motivation to action were best 
predicted by self-efficacy. Evidence of these patterns was found cross-sectionally, 
longitudinally, and experimentally.21–23 Recently, the impact of the importance of 
action plans or implementation intentions as a specific form of goal has been 
reported in various publications for health behaviors in general24 as well as for 
smoking.25 However, research pertaining to COPD smokers integrating these 
various concepts is not available yet. Data about the potential role of action plans 
for successful quitting are important in fine-tuning materials for smoking cessation 
for smokers in general and for COPD patients in particular. 
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The primary goal of this study is to reveal the main differences between the COPD 
patients in three motivational stages. These differences are found in COPD 
symptom severity, attitudes, social influences, self-efficacy expectations, and 
action plans. The secondary goal is to facilitate the development of 
recommendations for interventions aimed at encouraging smoking COPD patients 
to quit. 
 
Methods 
Design and population 
This study is a cross-sectional survey that uses a short questionnaire to detect 
smoking patients with COPD listed in general practices, followed by a more 
extensive questionnaire. Recruitment took place in nine districts in The 
Netherlands among practices using one of four suitable general practice electronic 
information systems. 
 
Figure 1. The I-Chance Model 11-13 
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Software using anatomical therapeutical chemical (ATC) prescription codes and 
international classification of primary care (ICPC) diagnosis codes to identify 
patients with COPD guided the study enrolment. In addition to an age of 35 years 
or more, the selection criteria consisted of one or more of the following: 
(1)  diagnosis of COPD; 
(2)  use of medication with an ICPC code for COPD or asthma (ICPC code 
R95/96); 
(3)  prescription of at least three lots of bronchodilators in the preceding year 
(ATC code R03a/bc);  
(4)  prescription of at least two lots of anti-inflammatory medication in the 
preceding year (ATC code R03). 
This resulted in a final selection of patients that were classified as COPD patients 
by the software program and the general practitioner (n=5,245). These patients 
received a short questionnaire for assessment of their current smoking status, 
stage of motivation to stop smoking, severity of nicotine dependence, and quality 
of life. There were 4,773 responders (91.0%), 1,566 of whom (32.8%) reported 
that they currently smoked. These patients were requested to participate in the 
study. The participants were assured that study results would be treated 
confidentially and that they could discontinue participation at any time. The 
procedures followed satisfy the ethical codes of the Committee on Human 
Experimentation of the University of Maastricht and the Maastricht University 
Medical Centre, The Netherlands. 
 
Variables and instruments in the questionnaire  
The questionnaire was based on earlier studies of smoking cessation21–23,26–29 and 
assessed various constructs. Smoking behaviour was assessed by asking patients 
if they currently smoked. Smoking cessation motivation was assessed by asking 
the patients to classify themselves into one of the following stages: (1) intending to 
quit smoking within 1 month; (2) intending to quit within 6 months but not within 
1 month; (3) not intending to quit within 6 months. 
 Smoking addiction was assessed by asking the patients to answer six questions 
based on the Fagerström test of nicotine dependence (FTND).30 
 Attitudes were assessed by seven items on a four-point scale asking whether 
they did (3) or did not (0) associate a specific belief with smoking cessation. The 
three scales used for assessing the advantages of smoking cessation consisted 
of: 
 (1) seven items assessing the advantages of smoking (Cronbach’s alpha = .83); 
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 (2) eight items assessing the advantages of quitting (Cronbach’s alpha = .91); 
 (3) four items assessed the anticipated regret of not quitting (Cronbach’s alpha  
= .79). 
 Social influences were assessed by asking the patients to indicate whether they 
would receive no (0) or much (3) support if they quit smoking. 
 Self-efficacy expectations were measured by 11 items on a five-point scale 
about how confident (4) or unconfident (0) the patients felt about quitting. 
 Action plans were measured on five-point scales to assess how likely (4) or 
unlikely (0) it was that the patients would plan several actions. Three scales were 
constructed to assess the plans. A total of 18 questions assessed plans to use 
cessation support methods and strategies, five items measured whether they 
planned to tell others that they intended to quit (Cronbach’s alpha = .88), six items 
measured their plans to install specific no-smoking policies (Cronbach’s alpha = 
.89), and five items measured whether they planned to engage in alternative 
behaviours (Cronbach’s alpha = .73). The two items referring to plans to use 
bupropion and nicotine replacement therapy did not load any factor and were 
treated as separate items. 
 Severity of COPD was measured by the Dutch version of the British Medical 
Research Council Questionnaire (MRC–ECCS) assessing (1) severity of dyspnoea 
(sumscore range 0–3); (2) chronic coughing (yes/no); (3) chronic sputum 
production (yes/no).31 
 
Analyses 
Univariate techniques were used to describe the sample regarding relevant 
variables. To test bivariate differences among patients with different motivations to 
quit smoking, ANOVA, Kruskal-Wallis, and the Chi-square test were carried out; 
post hoc analyses were performed by means of the Tukey HSD test. Factor 
analyses (oblique rotation and maximum likelihood) were used to confirm the 
validity of the attitude and action plan scales, and Cronbach’s alpha was then 
calculated. 
 
Results 
Response 
Of the 1566 smoking patients detected, 753 (48.3%) gave informed consent. 
These patients did not differ from the remainder of the 1566 smoking patients 
detected regarding age and sex. Medical ethical rules forbade processing more 
information about the non-responders. A total of 672 of the 753 patients (89.2%) 
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returned the questionnaire. Four questionnaires were not completed, four patients 
reported that they were non-smokers, 31 patients (4.7%) reported that they had 
quit smoking. Consequently, the eligible sample for this study consisted of 633 
COPD patients who smoked at least weekly, and who had the same sex and age 
distribution as the 753 patients who gave informed consent. 
 
Sociodemographics and smoking characteristics 
Table 1 shows that our sample consisted of relatively older patients of whom 75% 
had a partner. Among them, 22.5% intended to quit within 1 month (preparers), 
31.4% wanted to stop smoking within 6 months (contemplators) and almost half of 
them (45.3%) did not intend to quit smoking (precontemplators). Patients in the 
first two groups had attempted to quit smoking significantly more often than the 
precontemplators. 
 
Table 1.  Characteristics of the smokers with COPD, specified by stage of motivation to stop 
smoking 
 
Variable 
 
Pr 
Preparer 
n = 143 
C 
Contemplator
n = 199 
Pc 
Precontemplator 
n = 287 
 
Totala 
n = 633 
 
Post hocb 
Demographics    
Male (%) 50.7 47.7 51.2 49.9 -- 
Age (years) [mean (SD)] 61.1 (11.9) 59.0 (10.8) 59.2 (12.2) 59.6 (11.7) -- 
Partner (%) 77.6 78.4 75.3 76.5 -- 
Education (%)      
 Primary level 55.9 50.3 44.6 49.0 -- 
 Secondary level 35.0 41.2 43.9 41.1  
 Advanced level   4.9   6.0   9.4   7.3  
Paid or volunteer job (%) 33.6 38.2 35.6 35.9  
Smoking    
Nicotine dependencec [mean (SD)]   4.5 (2.3)   4.6 (2.3)   4.4 (2.5)   4.5 (2.4) -- 
Number of cigarettes/shag per day 
[mean (SD)] 
16.0 (8.5) 17.8 (10.1) 16.9 (9.7) 17.1 (9.6) -- 
Ever attempted to quit smoking (%) 79.7 82.9 71.1 76.6** Pr, C > Pc 
Health      
Dyspnoead,e [mean (SD)]   1.7 (1.2)   1.5 (1.2)   1.4 (1.2)   1.5 (1.2)* Pr > Pc 
Chronic coughingd (%) 40.0 36.2 29.3 33.6 -- 
Chronic sputumd (%) 40.0 30.2 28.2 31.3* Pr > Pc 
Coughing or dyspnoea as reaction 
to tobacco smoke (%) 
39.2 35.2 26.1 32.7** Pr, C > Pc 
Ever suffered from asthma (%) 34.3 28.6 33.4 32.1 -- 
Ever consulted a lung specialist for 
airway complaints (%) 
62.2 57.8 58.5 59.1 -- 
Admitted to hospital for airway 
complaints (%) 
  7.7   4.5   6.3   6.0 -- 
a Due to missing the stage of motivation of six patients, the total sample is greater than the sum of the 
patients in the three categories. b Post hoc analyses with Tukey HSD, Mann-Whitney-U or Chi2: p<0.05. 
c Fagerström Test of Nicotine Dependence (FTND). d Medical Research Council (MRC-ECCS).  
e Sumscore range: 0-3. * p<.05; ** p≤.002. SD=standard deviation. 
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COPD symptoms 
Patients who wanted to quit smoking within 1 month experienced more severe 
dyspnoea symptoms and more of them had a burden of chronic sputum than the 
precontemplators. Preparers and contemplators reported coughing as a reaction 
to tobacco smoke more frequently than the precontemplators (Table 1). 
 
Attitudes and anticipated regret 
No overall differences in the attitudes towards not smoking emerged among the 
stages of motivation. Specific differences were found for two items. Preparers 
viewed smoking as a good strategy for coping with boredom significantly more 
often than contemplators. The latter group viewed smoking as significantly less 
sociable than precontemplators (Table 2). 
 Preparers and contemplators did not differ significantly in their attitudes toward 
smoking cessation, but they did have significantly more positive attitudes than 
those in precontemplation. The two groups were significantly more convinced that 
smoking cessation would reduce their chances of getting lung cancer and airway 
complaints and that it would result in improved physical condition, improved 
engagement in activities of daily living, increased satisfaction with themselves, 
feelings of pride, feeling wise, and benefit to the health of other people (Table 2). 
 Patients motivated to quit smoking had significantly more feelings of regret than 
the precontemplators; these regrets were anticipated more in general and 
consisted of not having listened to the warnings of others and to warning signals 
from their own bodies. All three groups differed significantly in their anticipation of 
regret of not quitting smoking when encountering physical complaints, and the 
preparers felt the most regret (Table 2). 
 
Social influences 
With regard to social influence perceptions, Table 2 reveals that both the 
preparers and the contemplators reported receiving significantly more social 
support for quitting smoking from significant others than precontemplators did. No 
differences between the preparers and the contemplators emerged. 
 
Self-efficacy 
Two general patterns of self-efficacy scores were found. Smokers prepared to quit 
smoking within 1 month were significantly more confident of their ability to quit 
smoking in a variety of stress-related situations (e.g. feeling tense) than 
contemplators and precontemplators. Physical complaints, such as suffering from 
 Characteristics of patients with COPD related to smoking cessation | 27 
airway complaints affected all three groups; more motivated patients had greater 
self-efficacy expectations. The sum score also differentiated the three groups 
(Table 2). 
 
Table 2.  Patients’ attitudes towards smoking and quitting, perceived social support and self-
efficacy expectations across the three stages of motivation: Z-scores and SDsa 
 
Variable 
 
Pr 
Preparer 
n= 143 
C 
Contemplator
n = 199 
Pc 
Precontemplator 
n = 287 
 
Post hocb 
 
Attitudes toward smoking   
Sumscore  .11 (.98) -.11 (.95) .02 (1.04)) -- 
Smoking…       
...is relaxing  .03 (.99) -.08 (.98) .03 (1.01) -- 
...helps me cope with stress .09 (.98) -.02 (.92) -.03 (1.07) -- 
...calms me when I’m angry .06 (.98) -.05 (.96) -.00 (1.04) -- 
...helps fight boredom  .21 (1.09) -.13 (.93) -.02 (.99) Pr > C 
...is sociable -.02 (1.01) -.19 (.98) .14 (.99) Pc > C c 
…helps when I feel down  .03 (1.02) .02 (1.05) -.03 (.96) -- 
…prevents too much weight gain .09 (.97) -.05 (.99) -.00 (1.02) -- 
Attitudes toward smoking cessation   
Sumscore [mean (standard deviation)] .30 (.95) .16 (.97) -.26 (.98) Pr, C > Pc 
Quitting smoking…     
...reduces chances of lung cancer  .23 (.80) .19 (.85) -.25 (1.13) Pr, C > Pc 
...improves my condition  .18 (.93) .14 (.92) -.19 (1.06) Pr, C > Pc 
...improves my engagement in activities of 
daily living  
.25 (1.04) .19 (.93) -.26 (.97) Pr, C > Pc 
...reduces my airway complaints  .31 (.89) .15 (.92) -26 (1.05) Pr, C > Pc 
...gives me satisfaction with myself .30 (1.03) .24 (.82) -.31 (1.01) Pr, C > Pc 
...makes me proud  .33 (.96) .17 (.95) -.28 (.98) Pr, C > Pc 
...is wise  .24 (.86) .14 (.88) -.22 (1.10) Pr, C > Pc 
…benefits the health of people in my 
surrounding 
.22 (1.01) .09 (.95) -.17 (1.01) Pr,C > Pc 
Anticipated regret   
Sumscore  .41 (.86) .21 (.82) -.39 (1.06) Pr, C > Pc 
If my airway complaints increase…     
...I will regret that I did not pay attention to the 
warnings 
.38 (.87) .17 (.85) -.31 (1.07) Pr, C > Pc 
...I will regret I ever started to smoke .29 (.97) .20 (.80) -.30 (1.06) Pr, C > Pc 
…I will regret that I did not pay attention to my 
body’s signals  
.36 (.84) .19 (.85) -.31 (1.08) Pr, C > Pc 
...I will regret that I never quitted smoking .42 (.85) .17 (.86) -.33 (1.06) Pr > C > Pc 
Social influence     
Sum score .21 (1.07) .13 (.98) -.20 (.95) Pr, C > Pc 
Partner .12 (1.02) .12 (.96) -.16 (1.00) C > Pc 
Children .19 (1.01) .13 (.99) -.19 (1.02) Pr, C > Pc 
Friends .13 (1.05) .12 (.98) -.16 (.96) Pr, C > Pc 
Family .19 (1.02) .13 (.99) -.19 (.97) Pr, C > Pc 
Colleagues  .22 (1.08) .01 (.94) -.11 (.99) - 
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Table 2.  Patients’ attitudes towards smoking and quitting, perceived social support and self-
efficacy expectations across the three stages of motivation: Z-scores and SDsa (continued) 
 
Variable 
 
Pr 
Preparer 
n= 143 
C 
Contemplator
n = 199 
Pc 
Precontemplator 
n = 287 
 
Post hocb 
 
Self-efficacy expectations 
Sumscore  
 
.53 (.88) 
 
.09 (.88) 
 
-.29 (1.02) 
 
Pr > C > Pc 
Do you think that you’ll succeed in not 
smoking when… 
    
… someone offers you a cigarette of your 
own brand 
.32 (1.05) .07 (.90) -.20 (1.00) Pr, C > Pc 
… you are at a party, visiting someone or in a 
bar 
.31 (1.02) .07 (98) -.20 (.96) Pr, C > Pc 
… you feel oppressed .25 (.91) .08 (.94) -.17 (1.05) Pr, C > Pc 
… you are angry .28 (1.04) -.02 (.95) -.11 (1.00) Pr > C, Pc 
… you are tense or stressed .36 (1.04) -.07 (.94) -.11 (.99) Pr > C, Pc 
… you feel down .37 (1.06) -.06 (.91) -.13 (.99) Pr > C, Pc 
… you are out with friends .41 (1.05) .08 (.96) -.25 (.93) Pr > C > Pc 
… you feel physically strong .37 (.89) .11 (.92) -.24 (1.03) Pr > C > Pc 
… you feel your lungs are fine .38 (.89) .10 (.94) -.25 (1.02) Pr > C > Pc 
… you suffer from airway complaints  less 
often 
.41 (.87) .12 (.89) -.27 (1.05) Pr > C > Pc 
… your lungs have been fine for some  time .39 (.92) .12 (.94) -.27 (1.00) Pr > C > Pc 
a Due to the missing stage of motivation of six patients, the total sample is greater than the sum of the 
patients in the three categories. b Post hoc analyses with Tukey HSD: p < 0.05. 
c Although there were more “agree” and “strongly agree” responses from the contemplators than from the 
preparers, the contemplators had a lower mean score than the preparers, which explains the result of the 
post hoc analysis.  
 
Action plans 
Table 3 shows the differences among the three motivational stages with respect to 
the plans to quit and the aids planned. Smokers preparing or contemplating 
quitting reported making plans to translate intentions into action significantly more 
often than precontemplators. Note that the action plans of preparers and 
contemplators did not differ. 
 Preparers and contemplators reported that they planned to tell the partner, 
children, friends, colleagues, and GP that they intended to quit smoking 
significantly more often than precontemplators. They also had more plans than 
precontemplators to change policies at home by asking guests not to smoke, 
developing non-smoking agreements with housemates and colleagues, using “no-
smoking” stickers, removing ashtrays, and making no-smoking agreements with 
themselves. Finally, preparers and contemplators also made more plans to deal 
with the temptation to smoke, such as “thinking of something else when you would 
like a cigarette”, “not giving up after a relapse”, “doing something else when you 
would like a cigarette”, and “distracting yourself when you would like a cigarette” 
(Table 3). 
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Table 3.  Action plans of patients with COPD to use – quitting aids and strategies across the three 
stages of motivation: Z-scores and SDsa 
 
Variable 
  
Pr 
Preparer 
n = 143 
C 
Contemplator
n = 199 
Pc 
Precontemplator 
n = 287 
 
Post hocb 
Smoking cessation aids     
Nicotine plasters or gum -.02 (.99) .14 (1.03) -.10 (.98) -- 
Bupropion .37 (.99) .22 (.94) -.37 (.93) Pr,C > Pc 
Telling      
Sumscore .44 (.84) .21 (.91) -.34 (1.01) Pr,C > Pc 
Telling your partner that you quit .33 (.69) .10 (.92) -.24 (1.12) Pr,C > Pc 
Telling your children that you quit .30 (.88) .12 (.94) -.23 (1.05) Pr,C > Pc 
Telling your friends that you quit .35 (.88) .14 (.97) -.27 (1.01) Pr,C > Pc 
Telling your colleagues that you quit .37 (.94) .15 (.94) -.28 (.99) Pr,C > Pc 
Telling your general practitioner that you quit .42 (.75) .27 (.85) -.43 (1.06) Pr,C > Pc 
Home no-smoking plans     
Sumscore  .27 (1.03) .18 (.97) -.25 (.96) Pr,C > Pc 
Asking your guests not to smoke .17 (1.07) .10 (1.00) -.16 (.95) Pr,C > Pc 
No-smoking agreement with housemates  .26 (1.10) .17 (.95) -.25 (.93) Pr,C > Pc 
No-smoking agreement with colleagues .17 (1.12) .21 (1.04) -.22 (.87) Pr,C > Pc 
Using “no smoking” stickers .15 (1.09) .12 (1.04) -.15 (.91) Pr,C > Pc 
Removing all ashtrays  .29 (1.11) .21 (1.00) -.29 (.86) Pr,C > Pc 
No-smoking agreement with yourself .37 (1.09) .25 (1.01) -.37 (.80) Pr,C > Pc 
Alternative behaviour     
Sumscore  .41 (.97) .19 (.79) -.31 (1.05) Pr,C > Pc 
Thinking of something else when you’d like a 
cigarette 
.34 (.90) .13 (.90) -.27 (1.05) Pr,C > Pc 
Not giving up after a relapse .25 (1.05) .09 (.93) -.20 (.93) Pr,C > Pc 
Doing something else when you’d like a 
cigarette  
.34 (.91) .18 (.74) -.30 (1.12) Pr,C > Pc 
Distracting yourself when you’d like a cigarette .42 (.69) .17 (.81) -.33 (1.14) Pr,C > Pc 
Thinking how to prevent weight gain .13 (.99) .06 (.97) -.10 (1.02) --  
a Due to the missing stage of motivation of four patients, the total sample is greater than the sum of the 
patients in the three categories. b Post hoc analyses with Chi2. 
 
Discussion and conclusion 
Discussion 
The present study investigates the motivation of patients with COPD to stop 
smoking and considers whether these patients in different motivational stages 
could be identified on the basis of health indicators, attitudes, social influences, 
self-efficacy beliefs, and action plans. Regarding the stages of change, we found 
that many were motivated to quit smoking (22.5%) within 1 month. Our group of 
smokers in preparation is larger than the group of preparers (approximately 7.0%) 
in the Dutch population.32 However, studies on risk populations report much 
greater percentages.33,34 The explanation may be that the patients in the present 
study may find themselves in a vulnerable health situation in which smoking plays 
a causal role. In fact, medical crises have been found to increase the concerns 
about smoking,34 and health concerns form the main reason for quitting.32,35,36 The 
30 | Chapter 2 
finding that preparers regret smoking, especially when their airway complaints 
increase, supports this explanation. This, combined with the common practice that 
patients with COPD are advised to quit, implies a window of opportunity for 
smoking cessation counselling for these patients. 
 Our results confirm previous findings suggesting that the most important 
increase in perceptions of the advantages of quitting is between the stages of 
precontemplation and contemplation. However, we also found this same pattern 
for both social influence and action plans, and our data showed that self-efficacy 
beliefs were linearly associated with a greater motivation to quit smoking, which 
we did not expect. One explanation may be that our specific study sample of 
COPD patients may consist of relatively more motivated contemplators. 
Interestingly, the attitudes of the groups about smoking and its advantages did not 
differ, whereas the attitudes of patients in precontemplation and contemplation 
about quitting clearly differed. This strengthens the argument that two distinct 
categories of attitudes were addressed and that the differing attitudes were merely 
groupspecific. Kraft et al. find that the preparation and contemplation stages 
cannot be regarded as separate stages.37 They argue that the cut-off points of 6 
months and 1 month lack any theoretical reasoning, while a continuous measure 
of intention provides more accuracy (see also Sutton38,39). Moreover, De Vries and 
Backbier used an intention scale to construe groups;21 other studies report 
evidence of an additional group that was not willing to give up smoking at all.22 
Some studies distinguish intrinsically motivated smokers from extrinsically 
motivated smokers40–43 where health concerns formed a factor of intrinsic 
motivation.41 Hence, in line with these research results, our study suggests that a 
different algorithm may be more sensitive to qualitatively different stages. 
 Action plans distinguished preparers and contemplators from precontemplators. 
Whereas these results are intuitively appealing and logical, relatively little empirical 
evidence reflecting the impact of goal-setting strategies is available. With the 
treatment guidelines for COPD in mind,4 it is encouraging that the more motivated 
patients had more plans to turn intentions into action. The use of temptation-
resisting strategies may reduce cues that trigger a relapse and increase 
commitment to quitting,44 lower chances of relapse,45 and increase chances of 
successful quitting.46 Moreover, discussing action plans during treatment 
contributes to increased cessation rates;47 hence, health professionals should 
facilitate these action plans and provide support to help the patient decrease the 
risk of relapse. 
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Furthermore, the burden of COPD complaints might be a factor that contributes to 
the motivation to stop smoking. Previous research reports on the association of 
readiness to quit smoking with suffering from symptoms caused by smoking.10,48–50 
The present study confirms this; more greatly motivated patients suffered from 
more severe COPD symptoms and regretted smoking more because of their 
COPD symptoms. The negative effects of smoking probably serve as an extra 
motivator to quit. Unfortunately, smokers unmotivated to quit are not yet convinced 
that they can be faced with these problems personally. However, assessment of 
the lung function (spirometry) can be used to provide feedback about the 
immediate impact of smoking and COPD symptoms. Using spirometry, in 
combination with showing the Fletcher curve (the curve shows the loss of lung 
function as a result of smoking years),51 may help motivate the smoker to quit.52 
 Despite its strengths, such as a large sample of patients and participation of 
many practices spread over The Netherlands, this study has its limitations. Firstly, 
we cannot rule out the fact that the dropout was greater among smokers 
unmotivated to quit. However, privacy reasons precluded the analysis of motives 
for not participating in this study. Secondly, we did not use the same attitude scale 
as previous studies did since our qualitative pilot study suggested that different 
items had to be included. Therefore, our attitude and self-efficacy scales were not 
completely comparable to those used in other studies. Thirdly, because of the 
crosssectional nature of our data, we can only conclude that there are 
associations between relevant factors and the motivational stage. Since most 
studies of stages of change have been cross-sectional,38 there is a need for 
longitudinal designs to find stage-specific factors in this population. 
 
Conclusion 
Taking the great percentage of smoking patients with COPD who are willing to quit 
smoking into account, it appears that more than 50% is amenable for smoking 
cessation counseling and that these smokers differ from precontemplators in many 
relevant ways. Furthermore, we conclude that the present sample of COPD 
patients differs from other populations with respect to the relevant variables 
described in the I-change model. Longitudinal study designs are needed to clarify 
the role of factors determining the motivation to quit smoking in this population. 
Finally, the present study reported on an association between the severity of 
airway symptoms and a greater motivation to quit. 
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Practice implications 
The results reveal a window of opportunity for smoking cessation counseling and 
stress the importance of outlining advantages of quitting to those unmotivated to 
do so. They highlight the role of increasing self-efficacy and action planning for 
smokers motivated to quit. These results may encourage health professionals to 
discuss smoking behaviour with their patients with COPD, as is recommended in 
the treatment guidelines, and to focus more on the distinction between smokers 
unmotivated and motivated to quit. The symptoms caused by smoking and the 
effects of smoking cessation should be clearly addressed in order to increase the 
motivation to quit. 
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Abstract 
Background. Chronic Obstructive Pulmonary Disease (COPD) forms an increasing 
health problem. Despite smoking cessation improving the prognosis of the 
disease, many patients persist smoking. The present study presents the results of 
a smoking cessation counseling protocol in general practice (Smoking Cessation 
in patients with COPD in general practice (SMOCC)). 
Methods. A randomised controlled trial of patients with COPD compared smoking 
cessation counselling according to an intensified minimal intervention strategy with 
usual care. In total 43 general practices with 392 patients participated in Nijmegen, 
The Netherlands, in 2001-2002. 
Results. Significantly more smokers in the experimental group made a quit attempt 
(44.9% versus 36.5%) and actually quitted smoking than in the control group 
(16.0% versus 8.8%). The motivation to stop smoking at baseline was not 
associated with smoking cessation. 
Conclusion. The SMOCC strategy doubled the self-reported quit rates and was 
complied well by the general practitioners. Implementation in general practice is 
recommended. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD), a life threatening and disabling 
disease, has become an increasing health problem.1,2 Smoking is the dominant 
risk factor, smoking cessation remains the major aspect of treatment.2 Quitting 
smoking reduces ongoing deterioration of the disease and improves the prognosis 
of COPD related complaints.3-5 A number of smoking cessation interventions can 
be incorporated in general practice: a simple physician’s advice to quit6 (in 
combination with spirometry7), pharmacological therapies (i.e. nicotine 
replacement therapy (NRT) and antidepressants),8,9 minimal intervention 
(counselling)10 and pro-active telephone counselling.11 In case of stop-smoking 
support for COPD patients, combinations of pharmacological and behavioral 
strategies are likely to be effective.12  
 The stages of change,13,14 a central concept in smoking cessation interventions, 
divides the process of behavioural change into five steps. Precontemplators do not 
consider any change (quitting smoking within the next six months). The next stage, 
contemplation, is the intention to quit smoking within the next six months. In the 
preparation stage, one is willing to quit within 1 month; the person is preparing to 
take action. The two other stages, action and maintenance, respectively, relate to 
the actual change of the behavior and the maintenance of this change.  
 The Minimal Intervention Strategy (MIS) is a so-called stage-based smoking 
cessation intervention for general practitioners.10 It can be applied during normal 
practice visits and is effective in decreasing smoking prevalence. Applications of 
the protocol for risk populations (cardiac patients and pregnant women) also 
showed effects.15,16 
 Approximately one third of patients with COPD still smokes of which 54% 
considers to quit smoking within six months or sooner.17 Despite the emphasis in 
treatment guidelines on smoking cessation, patients with COPD have been found 
to be a particularly difficult group regarding smoking cessation treatment.18-21 
Since the COPD patient should visit the general practitioner (GP) once in 6 months 
for a regular control consultation,2 the GP can contribute to the smoking cessation 
process. Therefore, we changed the MIS into an intensified strategy (SMOking 
Cessation in COPD in general practice (SMOCC)). The SMOCC program was 
embedded in normal daily practice as recommended in the COPD treatment 
guidelines.2 
 Implementation of guidelines should be tuned to barriers and stimuli already 
known and should make use of the knowledge base of effective implementation 
strategies. Training of health professionals improves their performance of smoking 
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cessation activities, however, organisational factors need also to be addressed.22 
Implementation research shows that interactive education of professionals is 
mostly effective and suggests that multifaceted interventions and especially 
outreach visits may be useful to implement guidelines.22,23 Therefore, we designed 
a multifaceted intervention including professional training and outreach visits to 
implement a smoking cessation counseling protocol. In the present study, the 
SMOCC strategy is evaluated on its effectiveness on self-reported quit rates after 
six months. 
 
Method 
Study design 
The study is a two-armed randomised controlled trial. General practices in the 
intervention group received support to implement the SMOCC program, whereas 
the control group practices delivered usual care. Randomisation took place on 
practice level. Practices were classified in four classes: with high or low task 
delegation from GP to practice nurses and either or not having experience with 
smoking cessation counselling. The practices in the classes were then randomly 
allocated to the groups. Power analysis showed that each group should contain a 
minimum of 25 general practices and at least 150 patients with COPD per group to 
find a statistical significant difference of 10% in quit rates (alpha=0.05, beta=0.20). 
 
Intervention and protocol  
The professional directed intervention consisted of a four h group training on 
COPD, smoking and smoking cessation. More individual support was provided by 
an outreach visitor by means of counselling and feedback about performance at 
the practice location (three visits by a outreach visitor). Furthermore, support 
materials were delivered. These included: 
–  Software for detecting patients with COPD; 
–  Information on COPD and smoking (cessation); 
–  Letter and patient questionnaire assessing smoking status; 
–  Smoking cessation counseling protocol (this protocol is available on request); 
and 
–  Educational tools for patients. 
The patient directed intervention (the SMOCC protocol) consisted of an extended 
version of the MIS and was specifically aimed at education and support of patients 
by the general practice. Patients in the intervention group were invited for a control 
visit in accordance with COPD treatment guidelines.2 The first control visit focused 
Smoking cessation in patients with COPD in daily general practice: Six months' results | 39 
on symptoms, health status and treatment, smoking behaviour and the 
motivational stage to quit smoking. Patients were divided into three categories: (1) 
preparers (willing to quit within 1 month), (2) contemplators (willing to quit within 6 
months) and (3) precontemplators (not willing to quit).17 Smokers unmotivated to 
quit received only information about the advantages of quitting. 
 Smokers motivated to quit received self-efficacy enhancing information by 
discussing how to cope with the various barriers to quit. Depending on their 
severity of nicotine dependence, they received additional information about NRT. 
These contemplators were invited again 2 weeks later. When patients were 
prepared to quit within one month, a next consultation was scheduled to set a quit 
date and to plan the follow-up visits to the GP (a maximum of two follow-up visits) 
and proactive telephone calls by the practice nurse/assistant (a maximum of three 
telephone calls). The patient education tools consisted of a booklet, especially 
developed for the COPD-population and a videotape; these materials were given 
to all patients, regardless their motivational stage. To obtain reliable self-report on 
smoking a Bogus Pipeline procedure was applied.24,25 
 
Subjects 
Recruitment of practices took place in nine districts in the Netherlands amongst 
practices using one out of four suitable general practice electronic information 
systems. Forty-nine practices enrolled in the study; one dropped out prior to 
randomization. By means of a software program using Anatomical Therapeutical 
Chemical (ATC) prescription codes and International Classification of Primary 
Care (ICPC) diagnosis codes a selection was made of potential COPD patients. 
Selection criteria were: (1) age >35 years; (2) diagnosed as having COPD; (3) 
recorded medication with ICPC code R95/96; (4) prescription of at least three 
times of bronchodilators in the past year (ATC code R03a/bc); (5) prescription of at 
least two times of inhaled anti-inflammatory medication in the past year (ATC code 
R03). To validate the selection results, GPs were asked to confirm the diagnosis. 
The patients were approached with a letter and a short questionnaire assessing 
their smoking status. Smokers were requested to give informed consent. 
 
Instruments 
The GPs received a questionnaire assessing baseline practice characteristics and 
policies concerning COPD as well as smoking cessation. The contact persons of 
each practice also completed a short questionnaire via telephone. At follow-up, 
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GPs received an evaluation questionnaire to assess the compliance with the parts 
of the protocol. 
The patients received two extensive questionnaires at baseline and at 6 months 
follow-up. The main outcome measure of this study was self-reported point 
prevalence (did not smoke in the last 7 days). We collected the following data. 
–  The motivation to quit smoking.14  
 Nicotine dependence was measured by the Fagerström Test of Nicotine 
Dependence (FTND).26 A number of studies found support for the validity.26,27 
–  Self-efficacy was measured with eleven items on a five-points scale (0–4) 
(Cronbach’s alpha .90). This scale was developed based on previous 
research.28-34 
–  Three constructs of the severity of COPD were measured using the Dutch 
version of the Medical Research Council Questionnaire;35 (1) severity of 
dyspnoea (sumscore range 0-3); (2) chronic coughing (yes/no); and (3) chronic 
sputum production (yes/no). This questionnaire has good psychometric 
properties.36,37 
 
Statistical analyses 
Bivariate analyses were used to describe group differences. Drop-out analyses 
were performed with backward logistic regression analysis. Effect analyses were 
carried out on an intention to treat basis. Because of the hierarchical structure of 
our study (patients nested within practices), we performed multilevel analyses. 
SPSS 11.0 and SAS V8.2 (PROC MIXED and GLIMMIX MACRO) were used. 
 
Results 
Inclusion of general practices 
Twenty-five practices were allocated to the control group and 23 practices to the 
intervention group, 5 of these practices dropped out (see Figure 1). Table 1 shows 
the baseline characteristics of the practices and the GPs, no differences between 
the arms were observed. 
 
Inclusion of the patients 
Of the 406 COPD patients included, two patients died during the study and two 
patients felt too ill for ongoing participation. After inclusion, 14 patients were 
excluded from the sample. The total sample consisted of 392 patients (148 in the 
control group and 244 in the intervention group) (see Figure 1). This difference 
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between the two groups resulted from the drop out of two large group practices in 
the control group.  
 
Figure 1. Consort figure of the study (Nijmegen, Maastricht, the Netherlands, 2001-2002) 
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Table 1.  Baseline characteristics of the included practices and GPs (Nijmegen, Maastricht, the 
Netherlands, 2001-2002) 
 
Variable SMOCC Control 
Practices (n)     21     22 
Practice form (%)   
   Single-handed     43     37 
   Dual practice     38     45 
   Group practice     14       9 
   Health centre     --       5 
Number of patients (median (SD)) 2900.0 (2946.0) 2975.0 (2291.0) 
Number of GPs (median (SD))       2.0 (1.3)       2.0 (0.9) 
Number of practice assistants (median (SD))       2.0 (1.3)       2.0 (1.0) 
Experience with research concerning COPD (%)     24     14 
Experience with smoking cessation intervention research (%)     10     -- 
GPs (n)     25     30 
Male (%)     72     87 
Age (mean (SD))     45.8 (7.0)     44.6 (6.8) 
Number of working hours in practice (mean (SD))     42.5 (13.7)     41.8 (11.1) 
Familiar with the MIS (%)     36     37 
Attention to smoking cessation in patients with COPD (% 
often – always) 
  
   Recommend use of NRT     28     33 
   Assess the severity of nicotine dependence     60     57 
   Assess the motivation to quit     80     80 
SMOCC: Smoking cessation in patients with COPD (intervention group) 
GPs: General Practitioners 
MIS: Minimal Intervention Strategy 
NRT: Nicotine Replacement Therapy 
COPD: Chronic Obstructive Pulmonary Disease  
 
Table 2 shows the baseline characteristics of the patients in the two groups. About 
50% of the sample was willing to quit smoking within six months; patients in the 
SMOCC group tended to be slightly more motivated (Chi2 = 5.7, df = 2, P = 0.059). 
 The 6-month questionnaire was returned by 323 patients (82.4%) (131 in the 
control group and 192 in the intervention group, Chi2 = 6.1, df = 1, P = 0.013). 
Dropped out patients were considered to be smokers to control for biased 
treatment effects due to patient selection.38 Backward logistic regression analysis 
showed that drop out was not associated with any main effect. 
 
Compliance with the protocol 
19 GPs from 18 practices returned the questionnaire evaluating the SMOCC 
protocol. Self-reported compliance with the different aspects of the protocol was 
good in 70–80%. 
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Table 2.  Baseline characteristics of the included patients with COPD (n=392) (Nijmegen, Maastricht, 
the Netherlands, 2001-2002) 
 
Variable 
 
SMOCC 
n = 244 
Control 
n = 148 
Demographics 
Male (%) 46.3 55.4 
Age (mean (SD)) 58.0 (12.1) 60.1 (11.5) 
Having a partner (%) 75.8 73.6 
Education (%)   
     Primary level 47.5 48.0 
     Secondary level 41.4 38.5 
     Advanced level   7.4   7.4 
Having a (voluntary) job (%) 37.7 34.5 
Smoking 
Stages of change (%)   
     Preparer 25.8 17.6 
     Contemplator 32.0 28.4 
     Precontemplator 39.8 50.7 
Self-efficacy (mean (SD)) 21.5 (10.5) 19.5 (9.3) 
Nicotine dependencea (mean (SD))   4.4 (2.3)   4.3 (2.6) 
Ever attempted to quit smoking (%) 75.0 71.6 
COPD   
Dyspnoeab,c (mean (SD))   1.5 (1.2)   1.6 (1.2) 
Chronic coughing& (%) 33.2 35.1 
Chronic sputum& (%) 34.8 28.4 
SMOCC: Smoking cessation in patients with COPD (intervention group) 
a  Fagerström Test of Nicotine Dependence (FTND) 26 
b  Medical Research Council (MRC-ECCS) 35 
c  Sum-score range: 0-3 
 
Smoking cessation 
More patients in the intervention group had attempted to quit at 6 months follow-up 
(44.9% versus 36.5%, Chi2 = 10.4, df = 1, P = 0.003); these patients also had 
significantly more quit attempts (median of 1.0 (SD = 1.6) versus 0.0 (SD = 1.3), U 
= 8305.5, z = -2.9, P = 0.019). Significantly more patients did not smoke in the 
intervention group (16.0%) than in the control group (8.8%) (Chi2 = 4.0, df = 1, P = 
.046; OR = 2.0, 95% CI = 1.0–3.9). The differences in quit rates between the 
motivational stages were not significant (Chi2 = 3.2, df = 2, P = 0.199) (Table 3). 
 
Stage transition 
Thirteen patients (5.3%) in the intervention group made a shift forward in their 
stage of change, meaning an increased motivation to quit smoking. In the control 
group stage transition occurred in 10.9% of the patients (n=16) (Chi2 = 1.6, df = 1, 
P = 0.215). 
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Table 3. Quit rates (point prevalence) specified to baseline motivation to stop smoking (Nijmegen, 
Maastricht, the Netherlands, 2001-2002) 
 
Stages of change and quit rates SMOCC 
n = 244 
Control 
n = 148 
Overall quit rate  16.0  8.8  
Preparers (n)a 63 26 
    Quit rate among preparers (%) 20.6 15.4 
Contemplators (n)1 78 42 
    Quit rate among contemplators  16.7 7.1 
Precontemplators (n)1 97 75 
    Quit rate among precontemplators  13.4 8.0 
SMOCC: Smoking cessation in patients with COPD (intervention group) 
a Due to missing the stage of motivation of some patients, the total sample is greater than the sum of the 
patients in the three categories. 
 
Discussion 
The protocol was successfully implemented and doubled the quit rate compared to 
usual care. Other studies on COPD found continuous abstinence rates at 6 
months between 33.3% and 15.7% versus 21.4% and 9.0%, respectively, 
favouring an intervention.20,39 However, these more intensive interventions 
compared to the SMOCC strategy took place in a more controlled 
environment,20,39 either with patients with severe lung disease20 or with motivated 
patients.39 The present study reports on a smoking cessation program in 
predominantly less severe patients with different motivational stages, reflecting 
real life effectiveness in general practice. 
 Looking at the differences in quit rates per motivational stage, the protocol 
seemed relatively most successful for less motivated patients. Although recently 
some critiques on stage-based interventions40 and the stages of change 
construct41,42 have been published, this might be an indicator of success for a 
stage-based approach in this population. Application of a stage-based protocol 
has been proven to be effective in other risk populations as well where smoking 
formed a direct threat (cancer patients15 and pregnant women16). However, the 
present study found no intervention effect on stage progression, replicating the 
results of Cornuz.43 This raises some doubts about the usefulness of a refined 
stages of change approach in the COPD-population, the more because the 
preparators and contemplators in this population do not differ much regarding their 
determinants of motivation.17 A simplified stages of change model (either 
motivated or not to stop smoking) may be as effective as the refined version.  
 The implementation method chosen was well appreciated by the professionals. 
Outreach visits, small-scale interactive training and delivering support materials 
effectively contribute to guideline implementation in daily practice, which is in line 
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with other findings.22,44,45 However, implementation on a national scale could 
benefit from a less cost- and time-consuming implementation strategy (e.g. 
personal contacts through telephone helpdesks, e-mail and Internet) and could 
complement a reduced number of outreach visits. This implementation strategy 
needs further exploration, especially in educational settings. 
 Some methodological considerations can be made. Firstly, the size of the effect 
on quit rate might be distorted by the fact that also relatively many patients in the 
control group quitted smoking (8.8%) compared to the 6.5% in the general 
smoking population.46 This may be due to the influence of the research setting (i.e. 
Hawthorne effect47) or the detection procedure. Self-selection at practice level 
possibly affected the quit rate too: 37% of the practices in the control group had 
experience with the application of the MIS, which is more than the estimated 28% 
of the Dutch general practitioners at that time.48 Secondly, although we have self-
reported compliance data of the GPs with the protocol, information on the exact 
performance during the interaction with the patient is not available. Other research 
methods like videotaping consultations would be needed for that. Thirdly, self-
report of smoking behaviour is not always reliable, especially populations in which 
smoking forms an increased risk (pregnant women, patients with cardiovascular 
diseases) perceive pressure to report non-smoking behaviour.49-51 However, we 
applied the Bogus Pipeline procedure24 (briefing the patients that self-reported 
post-treatment smoking status would be checked by biochemical analysis). This 
enhances the accuracy of self-reported measures of smoking,25 especially when 
subjects perceive a pressure to hide smoking behaviour.52 
 In spite of the shortcomings, we recommend large scale implementation of the 
smoking cessation counseling protocol in general practice. As the prevalence of 
COPD in the Netherlands has been estimated between the 1.4% of the females 
and 2.4% of the males53 and approximately one third of them is still smoking,17 the 
implementation of the protocol on national scale would mean a considerable 
increase of patients with COPD succeeding in smoking cessation. 
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Abstract 
Objective: To evaluate two counselling programs in general practice to help 
smokers with chronic obstructive pulmonary disease (COPD) to quit smoking. 
Methods: Cluster randomised controlled trial including 68 general practices (667 
patients) using a randomly assigned intervention program with counselling and 
advice about nicotine replacement therapy (and additional bupropion-SR in one of 
the programs) or usual care. Usual care consisted of periodic regular check-ups 
and COPD information. The main outcome measure was biochemically verified 
point prevalence at 12 months. 
Results: The two intervention groups were treated as one in the analysis because 
they were equally effective. The intervention resulted in a significantly self-reported 
higher success rate (14.5%) compared to usual care (7.4%); odds ratio = 2.1, 95% 
confidence interval = 1.1–4.1. Biochemically verified quit rates were 7.5% 
(intervention) and 3.4% (usual care); odds ratio = 2.3, 95% confidence interval = 
0.9–6.0. 
Conclusion: The program doubled the cessation rates (statistically nonsignificant). 
Too few participants used the additional bupropion-SR to prove its effectiveness. 
Practice implications: The protocols can be used for COPD patients in general 
practice, but expectations should be modest. If quitting is unsuccessful, a stepped 
care approach should be considered. 
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Introduction 
The main cause of chronic obstructive pulmonary disease (COPD) is smoking.1,2 
Smoking cessation does not reverse respiratory function loss, but it slows down 
lung function deterioration and contributes to greater life expectancy.3–8 Treatment 
guidelines name smoking cessation support as the most important intervention.1 
 Motivating COPD patients to abstain from smoking proved to be very complex.9–
12 Many COPD patients are treated in primary care, where various cessation aids 
can be used: simple advice to quit,13 pharmacological therapies [nicotine 
replacement therapy (NRT), antidepressants, and varenicline,14–16 minimal 
intervention (counselling),17 and proactive telephone counselling.18 Combinations 
of pharmacological and behavioural strategies are recommended for COPD 
smokers.19 We investigated the impact of a combined intervention (counselling + 
NRT) and additional bupropion-SR, specifically aimed at COPD smokers in 
different motivational stages who were treated in routine general practice. 
 
Methods 
Design 
Cluster randomised controlled trial, with two intervention arms and one control 
arm. General practices assigned an intervention received support for implementing 
a smoking cessation program consisting of a counseling strategy plus the 
recommendation of NRT (CN20); or a counseling strategy plus the 
recommendation of NRT as well as the prescription of bupropion-SR (CNB). Both 
strategies used the same counseling protocol. The control practices continued 
their usual care (UC). A convenience sample was recruited in nine Dutch districts 
from general practices using one of four widely used general practice electronic 
record systems (Figure 1). Power analysis (alpha = 0.05 and beta = 0.20) showed 
that each arm should contain at least 25 practices to find a 10% difference in 
cessation figures. 
 A software program using the prescription codes of Anatomical Therapeutic 
Chemical Classification System and diagnosis codes of the International 
Classification of Primary Care (ICPC) was used to select patients. The criteria 
were: age 35 years or more, diagnosis recorded as COPD (or relevant ICPC 
code), and at least three prescriptions of bronchodilators and/or anti-inflammatory 
medication in the preceding year. The general practitioners (GPs) had to confirm 
the diagnosis before inviting patients to participate. For detailed information, see 
Hilberink et al.20,21 
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Figure 1. Consort figure of the study 
 
 
 
CN: Counselling + nicotine replacement therapy; CNB: Counselling + nicotine replacement therapy +  
standard-release bupropion; SC^: smoking cessation 
 
Intervention and protocol 
The general practice team received a 4-h group training session about COPD and 
smoking cessation. An outreach visitor provided additional individual support at the 
practice location (three visits). The patient-directed intervention tailored to general 
3 Practices dropped out 
- 1 identification problems 
- 2 no patients invited 
2 Practices dropped out 
- 1 identification problems 
- 1 no patients invited 
1 Practice dropped out 
- 1 identification problems 
12-month follow-up: update to baseline data 
CN 
21 Practices 
252 Patients 
CNB 
25 Practices 
291 Patients 
Usual care 
22 Practices 
148 Patients 
CN 
21 Practices 
243 Patients 
CNB 
25 Practices 
276 Patients 
6 Patients dropped out 
- 1 deceased 
- 2 too ill 
- 3 lack of data 
9 Patients dropped out 
- 1 deceased 
- 1 quit smoking long ago 
- 1 other SC^ therapy 
- 6 lack of data 
15 Patients dropped out 
- 5 deceased 
- 2 too ill 
- 3 quit smoking long ago 
- 5 lack of data 
Randomisation 
75 Practices 1 Practice dropped out 
Usual care 
25 Practices 
CN 
23 Practices 
CNB 
26 Practices 
Patient identification procedure 
Baseline data 
Usual care 
22 Practices 
154 Patients 
SMOCC program 
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practice patients with COPD carried out in 2001–2002 was based on the minimal 
intervention strategy.17 The patient education tools consisted of a leaflet especially 
developed for COPD smokers and a videotape. Patients in the CNB program were 
also advised to use bupropion-SR. The patients paid for the pharmacological aids 
themselves. Table 1 summarizes the aspects of the intervention for the different 
motivational stages. The first visit to the GP took place within 1 month after 
baseline measurement. 
 
Table 1.  Aspects of the intervention. 
 
Intervention elements Preparers Contemplators Precontemplators 
The first appointment X X X 
Leaflet and videotape X X X 
Self-efficacy-enhancing information  X X  
Information about NRT (depending on nicotine 
dependency) 
X X  
New appointment in 2 weeks  X  
Planned quit day and follow-up visits X   
Proactive telephone calls X   
 
Outcomes 
The outcome measure was point prevalence abstinence after 12 months. Self-
reported quitters were invited to produce a urine sample at the practice location. 
The sample was biochemically verified by cotinine levels (measured by 
radioimmunoassay). Patients with no 12-month data, patients with more than 
50 ng/mL in their urine22 and patients not providing a sample were considered to 
smoke. 
 
Instruments 
The patients received three questionnaires: at baseline and 6-month and 12-
month follow-ups. We collected data about smoking, background characteristics, 
motivation to quit,23,24 nicotine dependence (FTND);25 attitude scales, self-efficacy 
expectations,26–29 COPD symptoms,30 and self-reported exposure to the 
intervention. 
 
Analyses 
Several bivariate techniques tested differences between the programs. Cohen’s h 
reflected the effect size.31 We used multilevel analyses to test treatment effects 
because of the study’s hierarchical structure, along with SPSS 14.0 and SAS V8.2 
(PROC MIXED and GLIMMIX MACRO). 
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Results 
Sample 
The participants were 753 COPD smokers, and there were 56 nonparticipants 
(Figure 1). No reasons for nonparticipation were obtained. Table 2 shows the 
baseline characteristics. Five hundred and thirty-nine participants (80.8%) returned 
the 12-month questionnaire (123 controls and 416 intervention participants).  
 
Table 2.  Baseline characteristics of the sample of 667 patientsa 
 
  Program 
Variable 
 
UC 
n = 148 
CN 
n = 243 
CNB 
n = 276 
Demographics  
Percentage of men  55.4 46.5 47.8 
Mean age in years (SD) 60.1 (11.5) 58.0 (12.2)e 60.7 (11.2) 
Percentage with partner  73.6 76.1 74.3 
Percentage with  partner who smokes  33.8 41.2 31.5 
Education in percentages    
     Primary level 48.0 47.7 47.1 
     Secondary level 38.5 41.6 41.7 
     Advanced level   7.4   7.4   6.2 
Percentage with job (voluntary or otherwise) 34.5 37.9 31.5 
Smoking  
Stages of change in percentages    
     Preparer (intention to quit within 1 month) 17.6 25.9 24.3 
     Contemplator (intention to quit within 6 months) 28.4 32.1 29.3 
     Precontemplator (no intention to quit within 6 months) 50.7 39.9 43.1 
Mean self-efficacy (SD) 19.5 (9.3) 21.5 (10.5) 21.2 (10.5) 
Mean nicotine dependenceb (SD)   4.3 (2.6)   4.4 (2.4)   4.6 (2.3) 
Mean number of cigarettes/shag per day  (SD) 16.8 (9.7) 16.9 (10.3) 16.9 (9.1) 
Percentages of participants who ever attempted to quit smoking  71.6 75.3 76.8 
Mean attitudes towards smoking (SD) 17.8 (4.6) 17.6 (4.7) 17.9 (4.3) 
Mean attitudes towards quitting (SD) 19.7 (9.1) 21.4 (9.4) 20.5 (9.3) 
Mean anticipated regret for smoking (SD) 11.5 (3.1)f 12.4 (3.0) 12.0 (3.0) 
Health    
Mean dyspnoeac,d (SD)   1.6 (1.2)   1.5 (1.2)   1.4 (1.2) 
Chronic coughingc in percentages 35.1 33.3 30.8 
Chronic sputumc in percentages 28.4 35.0 27.5 
Coughing or dyspnoea as reaction to tobacco smoke in 
percentages 
31.1 35.0 32.2 
a Nijmegen and Maastricht, The Netherlands, 2001– 2002. 
UC: Usual Care. 
CN:  Smoking cessation counselling + nicotine replacement therapy. 
CNB: Smoking cessation counselling + nicotine replacement therapy + sustained-release bupropion. 
SD: standard deviation. 
b Fagerström test of nicotine dependence.  
c Derived from the Medical Research Council.  
d Sumscore range: 0–3;  
e p = 0.028, mean age in CN program lower than in CNB program. 
f p = 0.022, mean score in usual care program lower than in CN program. 
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Table 3.  Use of nicotine replacement therapy and bupropion-SR and exposure to elementary parts 
of the protocol at the 6-month follow-upa 
 
 Program 
 
Variable 
CN 
n = 243 
CNB 
n = 276 
Pharmacological (n(%))   
NRT 32 (13.2) 21 (7.6) 
Bupropion-SR 12 (4.9) 46 (16.7)** 
Total NRT or bupropion-SR 44 (18.1) 53 (19.2)  
NRT and bupropion-SR   0 (0)   7 (2.5)* 
Support aids + follow-up (n (%))   
Leaflet 45 (18.5) 52 (18.8) 
Video  82 (33.7) 74 (26.8) 
Telephone counselling 58 (23.9) 71 (25.7) 
a Nijmegen and Maastricht, The Netherlands, 2001– 2002. 
Bupropion-SR: sustained-release bupropion. 
CN: Smoking cessation counseling + NRT. 
CNB: Smoking cessation counseling + NRT + bupropion-SR. 
NRT: Nicotine replacement therapy. 
*p < 0.01; **p < 0.001 
 
Dropout was associated with being assigned to the CNB program, and, at 
baseline, little motivation to quit and less positive attitude towards quitting (Chi2 = 
23.0, df = 5, p < 0.001, and R2 = 0.06). 
 
Comparison of the interventions 
More CNB participants than CN participants used bupropion-SR with or without 
NRT, although few of them used both (Table 3). The use of NRT and bupropion 
was low. The counselling activities were identical in both interventions. Smoking 
cessation rates, whether self-reported (14.4% CN versus 14.5% CNB) or 
biochemically verified [7.4% CN versus 7.6% CNB; odds ratio (OR) = 1.0, 95% 
confidence interval (CI) = 0.5–2.0; F = 0.01; p = 0.931], were similar (Table 4). 
 
Table 4. Quit rates at 12-month follow-up in the various study arms (%)a 
 
Quit rates UC 
n = 148 
CN 
n = 243 
CNB 
n = 276 
CN + CNB 
n = 519 
Self-report   7.4 14.4 14.5 14.5 
Biochemically verified   3.4   7.4   7.6   7.5 
a Nijmegen and Maastricht, The Netherlands, 2001– 2002. 
UC: Usual Care. 
CN:  Smoking cessation counselling + nicotine replacement therapy. 
CNB: Smoking cessation counselling + nicotine replacement therapy + standard-release bupropion. 
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Comparison of intervention and UC 
Self-reported smoking cessation rates differed [14.5% (intervention) versus 7.4% 
(UC); OR = 2.1, 95% CI = 1.1–4.1); p = 0.027]. After biochemical verification, 
these figures were 7.5% and 3.4%, respectively (OR = 2.3, 95% CI = 0.9.–6.0; F = 
3.02; p = 0.083) — a borderline significant effect with a small effect size (h = 0.18; 
Table 4). 
 
Discussion and conclusion 
Discussion 
The present study showed doubled quit rates favoring a smoking cessation 
protocol for COPD smokers over UC. After biochemical verification, these effects 
decreased to values of borderline significance. Thirty-one studies have shown that 
bupropion-SR is an effective single cessation aid.15 In our intervention, the addition 
of advice to use bupropion-SR did not increase successful quitting. Poor 
compliance with the recommendations may be an important issue: few participants 
reported using bupropion-SR or both NRT and bupropion-SR. Neither the 
prescription nor the use of bupropion-SR had extra benefit when embedded in a 
multifaceted protocol aimed at smoking cessation in general practice. 
 The success rate in the present study is lower than in other studies. Five factors 
that might help explain this: 
1.  Motivated and unmotivated COPD smokers were included; other studies 
included motivated participants only.4,8,32 Including smokers in different 
motivational stages better reflects the potential effectiveness in real-life 
settings. 
2.  The intervention was less intensive than in other studies due to the 
integration in routine care. Intensive counseling4,10,11 combined with 
pharmacotherapy4,8,32 in more controlled environments may result in better 
success rates, as studies of programs embedded in hospital care show.8,11,33 
3.  We did not monitor the exact protocol performance of the GP. The training of 
the GPs and their team might have had only a restricted influence on 
counseling behaviour. 
4.  The lower success rates after biochemical verification were partly caused by 
some participants’ noncompliance to the verification procedure. Reasons for 
noncompliance were related to poor health (unable to visit the practice) in 
some cases. 
5.  The differences between the quit rates were smaller than anticipated in the 
power analysis, showing a lack of power. 
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What can we learn from the present study? One can argue that the quit rates did 
not differ significantly, hence the program is not effective. This confirms clinical 
practice and other studies reporting that COPD patients are highly nicotine 
dependent and have great difficulty to give up smoking.9–11,34 But one can also 
claim that the intervention in a real-life, primary-care setting resulted in a quit rate 
twice that of the rate in UC. This might contribute to lowering the healthcare costs 
for these patients. From this viewpoint, the intervention can contribute to 
optimizing care for patients with COPD in general practice, in which smoking 
cessation plays a crucial role. However, a more intensive intervention might be 
more appropriate. 
 
Conclusion 
Both interventions resulted in similar small effects and might improve the treatment 
for COPD patients, but their effects are limited. We could not determine the 
effectiveness of the advice to use bupropion-SR. As not many patients used the 
pharmacological aids, the effectiveness of better compliance to the protocols 
(possibly encouraged by reimbursement of costs) is still to be studied. 
 
Practice implications 
General practice treats most of the patients with mild-to-moderate COPD and 
needs to incorporate effective strategies for smoking cessation in routine care. The 
protocols offer a tool, but success expectations should be modest and additional 
studies are needed to confirm its value in real-life practice. The protocols give 
directions for dealing with unmotivated or hesitant patients. For motivated patients, 
the protocols can be embedded in a stepped care approach, so that 
unsuccessfully counseled patients are subsequently referred to a more intensive 
smoking cessation program during routine follow-up. 
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Abstract 
Purpose: The present study reports on the biochemical validation of the self-
reported smoking status of patients with chronic obstructive pulmonary disease 
(COPD). The objective is to establish the proportion of overestimation of self-
reported success rates. 
Methods: A cross-sectional smoking-status validation study including 60 patients 
with COPD who reported that they had stopped smoking. In the analysis of urine 
samples, a cut-off point of 50 ng/mL of cotinine was used. 
Results: At the time of biochemical validation, 55 patients reported that they had 
quit smoking while five patients resumed smoking. Smoking status was 
biochemically confirmed for 43 patients (78%) and 12 patients (22%) were 
classified as smokers. The sensitivity of the self-report of smoking was 29% and 
the specificity was 100%. 
Conclusion: Many primary care patients with COPD do not provide valid 
information on their smoking status, which hamper adequate therapeutic 
interventions. Integration of biochemical validation in daily care could overcome 
this problem, but may harm the doctor–patient relationship. 
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Introduction 
Smoking cessation interventions provided in general practice have proven to be 
effective.1,2 The role of general practitioners (GPs) in supporting their patients who 
want to quit smoking is documented in international guidelines.3 Addressing the 
smoking status of patients can be difficult, but GPs are more likely to do so if their 
patient suffers from smoking-related complaints.4 The GPs’ advice and support 
encourages patients to quit smoking. How do physicians learn whether their 
support was successful? Are they able to rely on the patients’ self-reports? 
 Chronic obstructive pulmonary disease (COPD) is illustrative of a smoking-
related disease. This slowly progressive disease is characterized by airflow 
obstruction with related symptoms such as cough, sputum production, dyspnea, 
and wheeze and it is mainly caused by smoking.5–7 Among patients with COPD, 
smoking prevalence varies from 38%–52% in seven countries.8 Because smoking 
accounts for 80%–90% of COPD, one may assume that many patients find it 
difficult to quit smoking. Smoking cessation slows down the rate of deterioration of 
lung function, improves COPD prognosis, and may prolong life expectancy for 
these patients.9–12 Consequently, smoking cessation is the most important element 
of therapy for COPD,5 and it is necessary to measure the results of smoking 
cessation interventions during the therapeutic process.  
 The self-report of smoking cessation in community surveys among the general 
population is reasonably valid.13–16 For smokers specially at risk (e.g. coronary 
disease, COPD, pregnancy), the self-reported smoking status is less reliable.13,17–
20 Biochemical testing is recommended for specific populations where quitting is 
very desirable.21 Cotinine, the major proximate metabolite of nicotine, has been 
widely used as a biomarker of tobacco exposure. The relatively long half-life of 
cotinine (16–20 hours) enables detection for a few days after cessation of tobacco 
use. The sensitivity and specificity of cotinine are high, 97% and 99%–100%, 
respectively,22,23 and it is therefore the preferred substance to measure. 
 Although the rationale for biochemical validation of the smoking status of 
patients with increased health risks is evident, the Lung Health Study found little 
discrepancy between self-reports and cotinine measurement of patients with early-
staged COPD.24 Nevertheless, the patients who had received smoking cessation 
support misreported their smoking status more often than patients who had not 
(6% versus 1%). This may suggest that participation in a smoking cessation 
program increases the social desirability bias. Participation of COPD patients in an 
intensive smoking cessation program had even higher rates (52%) of misreporting 
after biochemical testing of their smoking status.20 Smoking cessation 
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interventions, as carried out in general practice during routine follow-up, are 
generally less intensive than these programs.20,24 The question is, then, how 
accurate are the self-reports of COPD patients if they have been subjected to a 
less intensive smoking cessation intervention in the patients’ own general 
practice? As smoking cessation support is recommended in routine general 
practice for patients with COPD, it is important for GPs to obtain valid information 
about their patients’ smoking status. This is necessary to use smoking cessation 
programs effectively and to adjust the medical therapy to their results. Since the 
literature is inconclusive about the extent of misreporting of the smoking status of 
COPD smokers in general practice, the present study examines the validity of self-
reported smoking status of COPD patients participating in a study testing a 
moderately intensive smoking cessation program in daily general practice. 
 
Methods and materials 
The present study is a validation study of self-reported smoking status assessed 
by urine cotinine analysis. The data were collected from all patients who reported 
that they had not smoked in the past 7 days. 
 
Subjects and procedure 
A software program using Anatomical Therapeutical Chemical (ATC) prescription 
codes and International Classification of Primary Care (ICPC) diagnosis codes 
selected potential patients with COPD from general practices. The criteria included 
age of 35 years or more and a diagnosis recorded as COPD, or as ICPC code 
R95/96, or at least three prescriptions of bronchodilators (ATC code R03a/bc), 
and/or at least two prescriptions of inhaled anti-inflammatory medication in the last 
year (ATC code R03). The GPs had to confirm the diagnosis of the selected 
patients. Patients were eligible to participate if they were: 1) currently smoking; 2) 
suffering from COPD according to the GP’s diagnosis; 3) not being treated by a 
chest physician; 4) in command of the Dutch language; and 5) not suffering from 
any serious physical or psychological co-morbidity. The participants consented to 
participate in an intervention study in general practice and were allocated to one of 
the three study groups (including a control group). The patient-directed 
intervention tailored to general practice patients with COPD was based on the 
minimal intervention strategy.2 GPs applied a stage-based protocol, providing 
information, smoking cessation counselling, and advised the use of 
pharmacological cessation aids (i.e. nicotine replacement therapy or bupropion-
SR). The patient education tools consisted of a leaflet especially developed for 
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COPD smokers and a videotape. The patients included in the present study self-
reported to have quit smoking during the 12-month follow-up. More information 
about patient inclusion and the smoking cessation program can be found 
elsewhere.25–27  
 Figure 1 shows that of the 667 enrolled patients, 86 patients said at the 12-
month follow-up that they were not smoking: however, 22 patients (26%) did not 
enter the present study (17 patients refused and five patients were too ill), three 
patients were excluded because of their current nicotine replacement therapy, and 
one patient was excluded due to missing data. Hence, our sample consisted of 60 
patients. The procedures followed were approved by the Committee on Human 
Experimentation, Maastricht University, The Netherlands. 
 
Measurement 
The participants were briefed at the beginning of the study (1 year prior to the 
assessment of their smoking status) about possible self-report crosschecks with 
biochemical validation. They received a baseline questionnaire (Q0) to complete at 
home to provide the baseline characteristics of the sample including their 
motivation to quit smoking,28 severity of nicotine dependence (Fagerström Test of 
Nicotine Dependence),29 and COPD symptoms (Medical Research Council).30 
Twelve months later, they received another questionnaire (Q1) regarding their 
smoking status (7-day point prevalence). The patients who reported that they had 
quit smoking were included in the validation study and received a letter in which 
they were asked to visit the general practice within a week to produce and hand 
over a urine sample to be sent to the researchers for analysis. If they were unable 
to visit the practice, a research assistant collected the sample during a home visit. 
Furthermore, they were asked to complete an additional short questionnaire at the 
exact time of the sample production (Q2), which included their current smoking 
behaviour and use of nicotine substitution. All questionnaires were self-
administered and were used for research only. The results of the biochemical 
validation of the self-reported smoking status were not communicated to the 
patients’ GPs. 
 The amount of urinary cotinine was measured by radioimmunoassay. 
Radioimmunoassay involves the use of antibodies to cotinine. The double-
antibody technique was used to separate free-labeled antigen from antibody-
bound antigen. A reaction mixture containing 0.1 mL 3H-cotinine, appropriately 
diluted antiserum and buffer (0.14 M NaCl, 0.01 M Tris-HCl, and 0.1% gelatin) was 
incubated at 37°C. 
66 | Chapter 5 
Figure 1. Flow of the biochemical validation study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Self-report  
b Biochemically verified  
c Including the 5 self-reported resumed smokers 
 
For inhibition experiments, 0.1 mL-aliquots containing known amounts of standard 
or dilution of the urine-samples were added in place of buffer. Goat anti-rabbit 
immunoglobulin was added and the mixture was incubated at 4°C overnight. To 
667 COPD smokers included in an intervention study 
Baseline measurement (questionnaire 0) 
Follow-up measurement (12 months) (questionnaire 1) 
Validation questionnaire (questionnaire 2) 
Biochemical validation (urine cotinine test) 
Application of a smoking cessation program in general practice 
(1-3 consultations + telephone counselling) 
OR usual care(questionnaire 2) 
55 Quitted smoking a 
  5 Resumed smoking a 
43 Quitted smoking b 17 Resumed smoking b,c 
581 Current smokers 86 Self-reported quitters  
26 Patients dropped out 
– 22 nonresponders 
–   3 using NRT 
–   1 lack of data 
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control for nonspecific binding, normal rabbit serum was used in place of immune 
serum. The precipitate was collected by centrifugation at 4,200 rpm for 45 minutes 
at 4°C, the supernatant decanted, and the walls of the tubes wiped dry. To count 
the 3H-cotinine, the precipitate was dissolved in 0.1 mL 0.1 N sodium hydroxide 
before adding 2.5 mL scintillation fluid. Eventually the rate of radioactivity was 
counted and the amount of cotinine could be calculated from the linear portion of 
the standard curve. The results were reported in nanograms per milliliter. 
 
Analyses 
The cut-off point for both smokers and nonsmokers was 50 ng/mL.21 We used the 
contingency coefficient (two-tailed test) to analyse the association of the self-
reported status and the biochemically confirmed smoking status. Moreover, the 
sensitivity and specificity of the self-report were calculated. Differences in cotinine 
levels were analysed by means of the Mann–Whitney U test (two-tailed). The data 
were analysed with SPSS software (v. 14.0; SPSS Inc., Chicago, IL). 
 
Results 
Table 1 shows the baseline characteristics (Q0) of the 60 participants. Seven 
patients were allocated to the control group. The sample included 59% men, and 
the participants had a mean age of almost 60 years. At baseline, 38% indicated 
they wanted to quit smoking within 1 month, 34% wanted to quit within 6 months, 
and 28% were not motivated to quit smoking. Thirty percent suffered from chronic 
sputum production and 35% from chronic coughing. 
 
Table 1. Characteristics of 60 self-reported quitters 
 
Variable Sample 
Men (%) 59 
Mean age (SD) 59.9 (11.0) 
Stages of change (%)  
  Preparer 38 
  Contemplator 34 
  Precontemplator 28 
Mean number of cigarettes per day (SD) 16.4 (8.2) 
Mean FTND (SD)   4.2 (2.4) 
Chronic sputum (%) 30 
Chronic coughing (%) 35 
Mean dyspnoea, range 0-3 (SD)   1.3 (1.1) 
Note: Percentages are rounded.  
Abbreviations: FTND: Fagerström Test of Nicotine Dependence, SD Standard deviation 
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Forty-three patients (72%) of the 60 patients were classified by the urine cotinine 
test as nonsmokers (median cotinine level 13.0 ng/mL, quartile range 6.0–22.0), 
and 17 patients (28%) were classified as smokers (median cotinine level 134.0 
ng/mL, quartile range 68.0–194.0) (z-6.00; P< 0.001). 
 During the time of the biochemical validation, 12 of the 17 patients, who were 
classified as smokers, reported that they did not smoke (11 had taken part in the 
smoking cessation intervention) and five said that they had smoked recently (three 
had attended the intervention). Thus, the self-reporting of 43 (78%) of the 55 
patients who claimed that they were not smoking at the time of taking the urine 
sample (Q2) corresponded with the classification by the cotinine level and 12 
(22%) patients did not correspond (see Table 2) (contingency coefficient 0.43; 
P < 0.001). The self-report had 29% sensitivity for detecting actual smoking, and a 
specificity of 100%. 
 
Table 2. Association between self-reported quit rates and biochemically validated quit rates 
 
Biochemical validation Self-report (questionnaire 2) 
 Not smoking Smoking 
Not smoking 43 0 
Smoking 12 5 
 
Discussion 
We found a misreport rate of 22%. For COPD patients both lower24 and higher20 
misreport rates have been described. It is important to bear in mind that the self-
reporting of smoking status was combined with providing a urine sample for 
biochemical validation. This combination might result in a lower misreport rate, 
because the patients are aware that their self-reports will be checked. If this is 
true, then the misreporting of 22% could be an underestimation. If the patients who 
refused to be tested (n=22) were still smoking, then the misreport rate could be as 
high as 42%. The real misreporting figures will probably lie somewhere between 
these figures. The low sensitivity of self-reports (29%), even in a situation where 
the report may be biochemically verified, shows their restricted value in clinical 
smoking cessation programs for high-risk populations. 
 There may be several explanations for the difference between self-reported and 
biochemically determined smoking status. First, the time elapsed between the two 
measurements (Q1 and Q2) might be a factor. One of the reasons for the great 
percentage of misreports might be that patients had relapsed to smoking after Q1. 
We tried to overcome this problem by reassessing the smoking status (Q2), which 
showed that some of the COPD patients had indeed resumed smoking. Second, 
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the results did not account for the influence of environmental tobacco smoke, 
which is known to influence cotinine levels.31 However, since our cut-off point was 
50 ng/mL this is not likely. Third, misreporting might be triggered by the fact that 
patients participated in a smoking cessation intervention.24 Of the 12 patients who 
misreported their smoking status, 11 participated in the intervention. Interestingly, 
while Monninkhof et al. report a misreport rate of 52% for COPD patients 
participating in an intensive smoking cessation intervention, they found a misreport 
rate of 13.6% at baseline (i.e. for patients not participating in a smoking cessation 
intervention).20 This suggests that although biochemical validation of self-reported 
smoking status of COPD patients is recommendable in any situation to obtain valid 
data, participation in an intensive smoking cessation program may increase these 
misreport rates.  
 Although the number of participating patients might limit the external validity of 
our results, our population is a reflection of the self-reported quitters with COPD 
from a large sample of patients treated in general practice. However, the small 
numbers of patients that misreported their smoking status hampered in-depth 
analyses of factors contributing to (in)valid self-reports. 
 Our results show that the self-reporting of quitting by COPD smokers is not 
always trustworthy. A general question remains how should medical professionals 
deal with patients who need ongoing medical attention for chronic smoking-related 
diseases and who may lie about their smoking behaviour? In our study we did not 
communicate the results of the biochemical validation to the GPs because they 
were used for research purposes, but some argue that biochemical validation 
should be integrated in the therapeutic process. 
 Clinical practice teaches that some physicians are reluctant to treat patients with 
COPD who persist in smoking. They argue that treating symptoms that are 
consciously caused by the patient’s persistence in an unhealthy lifestyle is a waste 
of valuable time and effort. In this case, biochemical validation might be a good 
instrument for assessing smoking and for increasing the pressure on the patient to 
quit smoking. Apart from the questions of which measurement is feasible in routine 
daily general practice and which measurement has good sensitivity and specificity 
(e.g. carbon monoxide or cotinine measures), this harsh approach might damage 
the relationship with the patient and it questions the ethical codes for health 
professionals. Misreporting one’s smoking behaviour, lying about it, social 
desirability bias; whatever we call it, it is probably a result of feeling ashamed or 
guilty, and therefore one might ask whether it is wise to apply biochemical 
validation tests as a sort of lie detector. Besides the ethical problem, Bize et al 
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found in their systematic review no sufficient evidence that providing this kind of 
biomedical feedback contributes to successful smoking cessation.32 Therefore, in 
spite of the importance of getting a reliable view of the patients’ smoking status in 
the context of therapeutic general practice interventions, we do not have a clear-
cut answer on how best to obtain this information in a real-life general practice 
setting. Ethical issues concerning the patient’s own responsibility and the 
effectiveness of biomedical feedback should be weighed against the professional 
need of getting reliable information about therapeutic patient outcomes. 
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Abstract 
For chronic obstructive pulmonary disease (COPD), smoking cessation is the main 
treatment goal. We examined compliance with a smoking cessation treatment 
protocol for COPD smokers by 47 general practitioners (GPs). Baseline and 
evaluation questionnaires were completed, and 34 of the GPs then took part in a 
semi-structured telephone interview. The main outcome measure was restarting of 
the protocol when a patient had relapsed during a quit attempt. Attitudes, social 
influences and perceived self-efficacy were assessed to understand compliance or 
non-compliance with the treatment protocol. The rates of self-reported compliance 
with seven out of nine aspects of the protocol were high (76% on average). Fifty-
three per cent of the GPs restarted the treatment protocol following patient’s 
relapse. A substantial percentage of the GPs reported being seriously 
disappointed by the effectiveness of the treatment protocol. A change of practice 
personnel or having unmotivated personnel hindered compliance with the 
treatment protocol. The majority of the GPs planned to continue using the protocol. 
Given that negative attitudes, a perceived lack of social support and lack of 
counselling self-confidence were associated with lower protocol compliance, less 
confident GPs and GPs who have negative attitudes towards the provision of 
smoking cessation support should delegate the counselling or refer their patients. 
It is also concluded that GPs should be given more realistic expectations about 
smoking cessation and, rather than drop support efforts when they experience a 
lack of time or lack of confidence for counselling smoking cessation, delegate 
these tasks to practice assistants or other personnel. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a progressive disease, which is 
mainly caused by smoking.1 Dutch general practice figures for mild-to-moderate 
COPD patients show a smoking prevalence of around 40% for the years 2009–
2011.2 
 Smoking cessation slows the rate of deterioration of lung function and can thus 
improve the prognosis and prolong life expectancy for COPD patients.3-6 Smoking 
cessation interventions have proven effective.7,8 Current general practice 
guidelines for the treatment of COPD recommend provision of smoking cessation 
support and cite this as the most important treatment intervention for COPD.1 
 To help patients quit smoking in the Netherlands, it is currently recommended 
that general practitioners (GPs) adopt a ‘minimal intervention strategy’ (MIS).9 A 
MIS involves the following: assessment of the severity of the nicotine dependence 
and motivation to quit smoking; reinforcement of a positive attitude towards 
smoking cessation and self-efficacy; setting a date to quit smoking; provision of a 
self-help manual; recommendation of nicotine substitution; and follow-up 
consultation.  
 Studies on the MIS show reduced adherence to the MIS at follow-up and 
infrequent adherence to the specific recommendations to follow-up during a 
patient’s cessation attempt.10 Barriers to successful implementation of a MIS are 
doubts about the effectiveness and a lack of social support for the use.11,12 Other 
reported barriers are a fear for to endangering the patient–doctor relationship, a 
lack of time and difficulties motivating patients.13,14 
 We adopted a MIS to encourage smoking cessation among COPD smokers: the 
smoking cessation for patients with COPD (SMOCC) protocol. To promote and 
stimulate its implementation, we developed an implementation program. The 
program involves education, training, tools, feedback and other materials for use 
by general practice professionals.15,16 To date, biochemical verification of the 
effects of the SMOCC protocol has shown only small effects.16,17 However, lack of 
actual compliance with specific aspects of the SMOCC protocol might be the 
cause of the small effects. To gain insight into the barriers to following specific 
aspects of the SMOCC protocol, we interviewed GPs who were included in the 
effectiveness trial. The GPs were asked about their compliance with specific 
aspects of the SMOCC protocol and adoption problems with special attention to 
compliance with this protocol. 
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Methods 
Study design 
We adopted a mixed methods approach to determine the compliance with the 
SMOCC protocol. We recruited general practices in nine districts in the 
Netherlands. General practices participating in the intervention group of the 
SMOCC trial were included in the present study (n=46; 63 GPs). GPs initially 
completed a baseline questionnaire and then a short evaluation questionnaire one 
year following inclusion of patients to determine the self-reported compliance of 
the GPs with the different aspects of the SMOCC protocol. Missing data were 
treated as non-compliance with the protocol. In a subsequent semistructured 
telephone interview, each GP was explicitly asked about their compliance with the 
protocol and any related concerns. The interview addressed several aspects of the 
SMOCC protocol and intended to reveal both facilitators of implementation and 
barriers to implementation. 
 A useful model for organising and understanding the detected facilitators and 
barriers is the social–psychological Attitude–Social influence–self-Efficacy model 
(ASE model).18 The ASE model has been successfully used to predict various 
health education behaviours on the part of such intermediaries as nurses12 and 
midwives.19 Assuming that these ASE constructs determine the 
intention/motivation to restart the SMOCC protocol, we adopted them as a 
framework for the analyses in this study. 
 
Multifaceted implementation and the SMOCC protocol 
The general practice team receives a four-hour group training on COPD, smoking 
and smoking cessation. Individual support is provided by an outreach visitor with 
counselling and feedback on performance during three practice location visits. 
Furthermore, the general practice team is given support materials, including 
software for identifying patients with COPD, information on COPD and smoking 
(cessation), patient letters and patient questionnaires to assess smoking status, 
the SMOCC protocol (summarized as a one page flow chart) and educational tools 
for use with patients. 
 The SMOCC protocol is aimed at the education and support of patients in 
general practice. Patients are invited for a number of check-ups in accordance with 
COPD treatment guidelines. The first check-up concerns the regular assessment 
of symptoms, health status and COPD treatment effectiveness; both actual 
smoking behaviour and motivational stage to stop smoking are also assessed.20 
Depending on the severity of nicotine dependence, patients are given information 
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about nicotine replacement therapy (NRT) and/or the use of bupropion-SR. The 
content and number of subsequent check-ups (one or two times in six months) 
and telephone consultations (three times for patients who actually quit) were 
tailored to the patient’s smoking and motivational status. Further details on the 
SMOCC protocol can be found in Hilberink et al.15,16 
 
Measurements 
Prior to implementation of the SMOCC protocol, baseline characteristics of the GP 
and the general practice were assessed as well as practice policy with regard to 
smoking cessation support and COPD using a short questionnaire. 
 One year following conduct of the SMOCC protocol, the GPs completed a 
questionnaire used to determine their compliance with the protocol. Compliance 
with the protocol was defined by nine items: (1) proactively inviting the patients for 
consultation; (2) assessing motivational stage to quit smoking; (3) tailoring 
counselling to patient’s motivational stage; (4) offering two additional consultations 
to patients motivated to stop smoking; (5) offering patient leaflet; (6) offering 
videotape on smoking cessation; (7) prescribing nicotine replacement; (8) offering 
telephone counselling; and (9) restarting the protocol in cases of patient relapse 
(1= not, 2 = sometimes, 3 = most of the time). 
 In the semi-structured telephone interview with the GPs, topics concerned with 
the nine steps in the SMOCC protocol were probed along with the extent of GP’s 
compliance with the protocol. 
 
Analyses 
To check for selective follow-up, bivariate analyses (t-tests and Chi2 tests) were 
performed: the characteristics of those GPs who completed the follow-up 
questionnaire were compared to the characteristics of those who did not. 
 The semi-structured telephone interviews were qualitatively analysed following 
transcription and categorisation by two authors of this article independently (SH 
and JJ). The ASE model was used to organise the coded outcomes. 
 Whether or not restarting the SMOCC protocol following relapse on the part of a 
patient was associated with particular GP characteristics and ASE variables was 
then tested using t-tests and Chi2 tests. Owing to the small number of GPs in the 
present study, we triangulated the quantitative and the qualitative data. 
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Results 
Sample 
Of the 63 GPs, 47 (from 39 practices) completed the follow-up questionnaire. 
Those GPs who did not do this were younger (41.9 years (SD=6.0)) than those 
who completed the questionnaire (46.6 years (SD=6.0)) (p=0.013). No other 
differences were detected between these groups, which suggests that selective 
dropout was not the case. In Table 1, the characteristics of the GPs are 
summarized.  
 Interviews were conducted with 37 of the GPs. Of these, two interviews were 
not properly recorded and one was with a GP who did not invite any patient for the 
study. Hence, the interview sample consisted of 34 GPs. 
 
Table 1. Characteristics of GPs (n=47) 
 
Variable GPs 
Age (mean (SD))     46.6 (6.0) 
Sex (female) (%)     23 
Working hours per week (mean (SD))     41.1 (11.1) 
Number of patients (mean (SD)) 4,498 (3,067) 
Prior use of the MIS (%)     47 
Smoking (%)     11 
MIS: minimal intervention strategy for smoking cessation 
 
GP compliance with the SMOCC protocol 
The majority of the GPs (70–83%) complied with six out of the nine aspects of the 
protocol. Less than a third advised patients to use pharmacotherapy to help them 
quit smoking. More than 50% of the GPs restarted the protocol after relapse 
following initial smoking cessation (Table 2). 
 
Table 2. Self-reported compliance of GPs with the SMOCC protocol: % usually or always applied 
(n=47) 
 
Aspects of the protocol Compliance rate (%) 
Assessed motivational stage 83 
Provided leaflet 79 
Number of 3 consultations for patients motivated to quit smoking 75 
Stage-based consultation 75 
Proactively invited patients for consultation 75 
Counselled via telephone  70 
Restarted the protocol following relapse 53 
Provided educational videotape 43 
Recommended nicotine replacement therapy 30 
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Table 3. Associations with restarting of the SMOCC protocol after by GPs following patient relapse 
(n=40) 
 
Variable GPs who restarted 
(n=25) 
GPs who did not 
restart (n=15) 
Practice characteristics1   
Having a personal set of patients (%)      84      47 
GP characteristics1   
Smoking (%)         -      20 
Task delegation (mean (SD))        1.8 (.98)          .93 (.68) 
Number of patients (mean (SD)) 3,496 (2,456) 5,766 (3,462) 
Attitudes2   
As GP, I have little influence over my patients’ smoking 
behaviour (mean (SD)) 
       2.9 (1.0)        3.9 (.83) 
If I pay attention to smoking behaviour, I’m bothering my 
patients (mean (SD)) 
       2.2 (1.1)        3.0 (1.3) 
If I pay attention to smoking behaviour, I’m patronizing 
my patients (mean (SD)) 
       2.0 (.98)        3.2 (.86) 
Social influence2   
Practice assistant (mean (SD))        4.6 (.58)        4.0 (.82) 
Regional general practice association (mean (SD))        3.9 (.88)        3.1 (1.2) 
National Union (mean (SD))        4.1 (.86)        3.3 (1.3) 
Self-efficacy2   
Do you feel capable of applying the protocol? (yes) (%)      88      60 
1 Associations with baseline variables 
2 Cross-sectional associations 
 
GPs who smoked restarted the SMOCC protocol less often than GPs who did not 
smoke (p=0.020) (Table 3). GPs who had their own personal set of patients 
restarted the protocol more often than those who did not (p=0.013). In addition, a 
greater degree of task delegation to practice assistants or nurses predicted 
restarting of the SMOCC protocol following relapse on the part of the patient 
(p=0.004). This was also the case for having less patients in the record file 
(p=0.020). 
 With regard to the attitudes of the GPs towards patient smoking behaviour, 
those GPs who restarted the SMOCC protocol were more convinced that they 
could influence patients’ smoking than those who did not restart the protocol 
(p=0.004); they were also more convinced that they would not annoy patients by 
addressing their smoking behaviour (p=0.035); and they were also less of the 
opinion that paying attention to patient’s smoking behaviour is patronizing the 
patient (p=0.001). 
 With regard to social influences, GPs who restarted the protocol reported 
greater support from their practice assistant(s) (p=0.020), from the regional 
general practice association (p=0.024) and from the national organisation of GPs 
(p=0.036). Finally, GPs who restarted the protocol felt more confident about being 
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able to counsel their patients effectively than GPs who did not restart the protocol 
(p=0.012). 
 
Experiences of GPs with the SMOCC protocol 
The interviews with 34 GPs provided insight into their experiences with the 
SMOCC protocol and, in particular, the determinants of their compliance with the 
protocol. Determinants could be classified as barriers or facilitators for restarting 
the treatment protocol after patient relapse and further categorised using the ASE 
model (Box 1). 
 
Box 1. Summary of barriers and facilitators for compliance by GPs with the SMOCC protocol 
(qualitative analyses) 
 
Barriers 
  Attitudes 
 Opposed to working with any kind of protocol 
 Requires too much effort for too little effect 
 Concerns about resistance from patient 
  Social influences 
 Unmotivated GP team 
 Changes in personnel 
 Practice routines, workload and lack of time 
  Self-efficacy 
 Too few patients to acquire necessary skills 
 
Facilitators 
  Attitudes 
 Providing smoking cessation support is seen to be natural part of tasks 
 Enjoyed participation in study 
 Sees SMOCC program materials as helpful  
  Social influences 
 Outreach visits and training are welcome 
 Assistance from the practice team 
  Self-efficacy 
 Gains experience with counselling skills during consultations with patients 
 Knowledge that increases in symptom severity are temporary after cessation 
 
Attitudes 
Some GP attitudes negatively affected compliance with the SMOCC protocol. 
Roughly, three categories of attitudes could be identified as barriers: (1) opposition 
to the use of any treatment protocol; (2) a perceived imbalance between the 
required effort and the expected effectiveness of the protocol; and (3) serious 
concerns about the resistance from the patients that may harm the doctor–patient 
relationship. The concerns about the unresponsiveness on the part of patients 
were perceived to be a major barrier to use the SMOCC protocol as the majority of 
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the GPs who were interviewed expressed disappointment with the effectiveness of 
use of the SMOCC protocol: 
… Apart from that, I spent much time in the study whilst the result was 
minimal. They only want to discuss it [quitting smoking] with me. 
Another GP observed that there was ‘... an enormous stream to struggle against’. 
Several other attitudes positively affected compliance and could thus be 
considered facilitators. First, GPs who thought that addressing smoking behaviour 
on the part of patients was one of their tasks also were positive about use of the 
SMOCC protocol. Second, some GPs reported enjoying participation in the 
SMOCC study, which encouraged the use of the protocol: 
Very pleasant, it is one of those times that I believe it was useful for us. 
Third, the adoption of the materials and especially the flow chart outlining the 
smoking cessation treatment protocol very clearly contributed to the application of 
the protocol: 
In any case, that card [flow chart], was useful to me. 
In the words of another GP: 
Those flaps [flow charts] or whatever you call it, that is convenient. 
And according to yet another GP: 
The information folder and the flow chart, they were really a support. 
 
Social influence 
The GPs we interviewed were asked about reliance on their practice nurses for 
support and indeed reported unmotivated nurses or the departure of a nurse to be 
perceived as barriers to protocol compliance: 
Yes, the change of the practice nurse, yes, that is hopeless. 
Elements of practice management also complicated compliance. Some GPs found 
it difficult to limit their consultation time but also noted: 
But that’s also up to myself. 
Others noted they had problems with working proactively: 
The strength of my practice is that it is considerable demand driven. 
Time pressure combined with heavy workloads also negatively affected 
compliance: 
It is usually the time that makes it impossible. 
The outreach visits and educational sessions as part of the implementation 
strategy were helpful. Several GPs mentioned appreciation of the training and that 
they experienced the outreach visits to be both supportive and stimulating. 
Your active approach got things done. 
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Nurses were also seen as important facilitators of protocol application. Several 
GPs acknowledged this when they said, for example: 
My nurse can monitor things perfectly. 
Another said: 
Nurses have to cooperate well with the GP ... And the nurse must have 
the ability to work independently. 
 
Self-efficacy 
Few barriers to protocol compliance concerned the GP’s perceived self-efficacy 
with regard to smoking cessation treatment. A few remarks were nevertheless 
made during the interviews about insufficient training and thus indicated a barrier 
to protocol compliance. 
I considered it a bit of a problem that the supply [of patients] was so 
small, that I did not really gain experience with it [the protocol]. 
Other GPs perceived the practice with the patients to be sufficient and thus as a 
facilitator of protocol compliance. They reported gaining confidence after practicing 
with the patients during the SMOCC protocol: 
After the SMOCC program I’m more successful in making patients quit 
smoking. 
The data from our study also showed the GPs to apply their skills in consultations 
with other patients: 
I noticed, like this morning when I had a man who wanted to quit, that 
this [smoking cessation counselling] does not encounter resistance [in 
the patient] anymore. 
Another GP observed:. 
... since I’ve joined the project, my contact with patients who want to quit 
smoking have been quite different. 
For some of the GPs, it took some time to learn to work with the protocol but, in 
the words of one of the GPs: 
... once you have mastered the structure, the rest comes naturally. 
And finally, one GP told us about how learning that smoking cessation can cause 
a temporary increase in coughing influenced his reaction to the reporting of such 
symptoms: 
... I came upon this later in my practice and then I could positively 
approach it ’cause I knew it would disappear. 
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Discussion 
In the preceding, both barriers to and facilitators of successful implementation of a 
smoking cessation treatment protocol for COPD patients were identified. The 
majority of the GPs in our study planned to continue using the smoking cessation 
treatment protocol. Barriers to compliance nevertheless existed in the form of 
resistance to working with any kind of protocol, changes of practice personnel and 
seeing too few patients to acquire the necessary counselling skills. Clear 
facilitators of protocol compliance were feeling better equipped to apply the 
protocol with the aid of the SMOCC program materials and assistance from the 
practice team. GPs who smoked did not restart the treatment protocol, which 
raises the question of whether they should perhaps delegate smoking cessation 
counselling to someone else. 
 Restarting the SMOCC protocol when patients relapsed is one of the essential 
aspects of the protocol. In our study, slightly more than 50% of the GPs said that 
they complied with this recommendation. Using the ASE model, we were able to 
detect critical differences in the attitudes, social influences and self-efficacy of the 
GP for compliance with the SMOCC protocol. Their attitudes contributed to 
restarting the protocol when the GPs perceived themselves as medical advisors 
with the legitimate task of intervening in the lifestyles of patients. Restarting the 
protocol was also facilitated by social support from professional organisations, the 
help of practice assistants/nurses and confidence in one’s own counselling 
capacities. This confidence can be enhanced via daily practice. Counselling for 
smoking cessation might become a routine for the management of various chronic 
diseases if a shift in culture occurs towards more secondary and tertiary preventive 
activities during daily primary care. Support along these lines from professional 
organisations and the incorporation of this topic with practical exercises into the 
training of professionals would be helpful. 
 At first glance, the compliance of the GPs with the several aspects of the 
SMOCC protocol appeared to be good, which suggested that patients are indeed 
exposed to the central aspects of the protocol (e.g. proactively inviting patients, 
assessing motivation to quit smoking and stage-based counselling). However, the 
recommendation of NRT was low, which is in keeping with the low use of NRT by 
the smokers in the previous SMOCC trial.16 Although we do not have an 
explanation for why more than two-thirds of the GPs did not follow this 
recommendation, such non-compliance may have influenced the effectiveness of 
the SMOCC protocol. The literature shows approximately doubled quit rates when 
NRT is used as opposed to a placebo.21 The structural recommendation of NRT to 
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support quit attempts can thus be expected to yield better protocol effects and 
should thus be advised. 
 While 50% of the GPs restarted the protocol when the patient had relapsed, 
ideally 50% of the GPs should have followed a stepped-care approach with 
referral of patients who had relapsed for more intensive cessation treatment and 
50% of the GPs should have given the protocol another try. The associations 
found with not restarting the protocol, however, suggest that GPs who currently 
smoke, GPs delegating fewer tasks to their co-workers, being less optimistic about 
successful smoking cessation, perceiving less social support and feeling less 
confident about their ability to counsel predisposed them to not comply with the 
protocol further and therefore not restart it. To optimise smoking cessation 
treatment for COPD smokers, it is thus advisable that those GPs who feel 
uncertain about the use or continued use of the smoking cessation treatment 
protocol should be encouraged to refer their patients for smoking cessation 
treatment. 
 
Study strengths and limitations 
One possible limitation on this study is that compliance with the treatment protocol 
was determined on the basis of self-report data. We were nevertheless able to 
assess self-perceived compliance in such a manner and also gain insight into the 
problems encountered by the GPs. Research has shown the reliability of self-
reported performance to be unclear,22 which means that the obtained figures may 
be overly positive, but the responses of the GPs nevertheless represent their 
experienced reality and therefore provide valuable information on the motivational 
aspects of applying a smoking cessation treatment protocol. The use of more 
objective observation/measurement methods, such as audiovisual recording of 
counselling sessions, is nevertheless needed to verify our findings. Because the 
present study took place in a daily clinical context, the use of such methods was 
not possible. 
 Another possible limitation is the small number of GPs who participated in this 
study. The external validity of our findings is thus limited. However, the 
triangulation with qualitative interviews provided an in-depth understanding of the 
perceived barriers and facilitators for compliance with the SMOCC protocol. 
 
Practice implications 
The strategy adopted for implementation of the SMOCC protocol stimulated 
application of the smoking cessation treatment protocol by the GPs in our study. 
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The qualitative interview data also give us clues for the further fine-tuning of the 
support protocol. First, GPs should be given a realistic picture of what cessation 
figures can be expected. Major lifestyle changes can only be attained using a 
series of short advice and support sessions in a minority of patients. Second, lack 
of time for protocol compliance was often mentioned as a problem, but this 
‘reported problem’ may conceal a negative attitude towards health counselling by 
the GP as part of chronic disease management and medical intervention. Health 
counselling as a medical intervention for the treatment of smoking as an addictive 
disease, which contributes to several other chronic diseases, should thus be part 
of the training of the general practice health professional and thus perceived as 
one of the health professional’s tasks. Health counselling and the prescription of 
smoking cessation medication should be reimbursed by health insurance 
companies as this will help GPs find the time to stimulate smoking cessation and 
support the efforts of patients who smoke. An experiment in the Netherlands with 
the reimbursement of smoking cessation support showed 22% of patients in the 
experimental group to have stopped smoking and only 8% in the control group 
after two years.23 Third, for refinement of the SMOCC protocol, greater attention 
should be paid to the support services available in the general practice. The 
smoking cessation treatment protocol relies on a team approach that thus involves 
practice assistants and nurses in addition to the GPs. For large-scale 
implementation of the SMOCC program, the working conditions of the practice 
nurses should be checked. Greater availability of practice nurses for more than 
just telephone follow-up would allow more of the tasks in the smoking cessation 
treatment protocol to be delegated or at least partially delegated and for referral of 
patients to someone else when the GP feels uncertain about the provision of 
smoking cessation support. Finally, more experience with smoking cessation 
counselling and possibly counselling, in general, is needed to increase the self-
efficacy of health professionals within this domain. The recommendation of 
pharmacological cessation aids as part of counselling for smoking cessation 
should be stressed more. In the end, embedding smoking cessation counselling in 
the basic and continuing education of medical professionals should improve the 
care for COPD patients. 
 
86 | Chapter 6 
References 
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, 
Management and Prevention of COPD. GOLD, 2011. 
2. Smeele IJM, et al. Implementation of integrated care in COPD. Huisarts Wet 2012;55(5):194–98. 
3. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, 
Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic 
bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505. 
4. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung 
function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J 
Respir Crit Care Med 2000; 161:381-90. 
5. Hersh CP, DeMeo DL, Al-Ansari E, Carey VJ, Reilly JJ, Ginns LC, Silverman EK. Predictors of 
survival in severe, early onset COPD. Chest 2004;126:1442-51. 
6. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on 
respiratory symptoms, lung function, hyperresponsiveness and inflammation. Eur Respir J 2004; 
23:464-76. 
7. van der Meer RM, Wagena EJ, Ostelo RW, Jacobs JE, van Schayck CP. Smoking cessation for 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; (1): CD002999. 
8. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database 
Syst Rev 2008; (2): CD000165. 
9. Partnership Stop met Roken, 2009. Zorgmodule Stoppen met Roken. Partnership Stop met Roken. 
10. Pieterse ME, Seydel ER, de Vries H. Over roken gesproken: Implementatie van de Minimale 
Interventie Strategie in de Nederlandse huisartspraktijk. Enschede: Universiteit Twente, 1997. 
11. Bakker MJ. Pregnancy, a window of opportunity to quit smoking. The development, implementation 
and evaluation of a minimal intervention strategy for pregnant women and their partners. Thesis. 
Maastricht: Maastricht University, 2001. 
12. Bolman C, de Vries H, Mesters I. Factors determining cardiac nurses' intentions to continue using a 
smoking cessation protocol. Heart Lung 2002;1:15-24. 
13. Drossaert CHC, Pieterse ME, Seydel ER, Drenthen AJM. Programmatische toepassing van de 
Minimale Interventie Strategie (MIS) stoppen met roken in een experimentele setting: evaluatie onder 
huisartsen en onder patiënten. Enschede: Universiteit Twente, 1999. 
14. Stead M, et al. Factors influencing European GPs’ engagement in smoking cessation: a multi-country 
literature review. Br J Gen Pract 2009;59(566):682–90. 
15. Hilberink SR, et al. Smoking cessation in patients with COPD in daily general practice (SMOCC): six 
months’ results. Prev Med 2005; 41 (5–6): 822–27. 
16. Hilberink SR, et al. General practice counseling for patients with chronic obstructive pulmonary 
disease to quit smoking: impact after 1 year of two complex interventions. Pat Educ Couns 2011; 
83(1): 120–24. 
17. Hilberink SR, et al. Validation of smoking cessation self-reported by patients with chronic obstructive 
pulmonary disease. Int J Gen Med 2011; 4: 85–90. 
18. de Vries H, Mudde AN. Predicting stage transitions for smoking cessation applying the Attitude-
Social influence-Efficacy model. Psychol Health 1998;13:369-85. 
19. Segaar D, Bolman C, Willemsen M, de Vries H. Identifying determinants of protocol adoption by 
midwives: a comprehensive approach. Health Educ Res 2007; 22:14-26. 
20. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: Toward an 
integrative model of change. J Consult Clin Psychol 1983; 51:390-5. 
21. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking 
cessation. Cochrane Database Syst Rev 2008;(1): CD000146. 
22. Eccles MP, et al. Do self-reported intentions predict clinicians’ behaviour: a systematic review. 
Implement Sci 2006; 1: 28. 
23. Kaper J, et al. A randomized controlled trial to assess the effects of reimbursing the costs of smoking 
cessation therapy on sustained abstinence. Addiction 2006;101(11): 1656–61. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
 
Feasibility of a recruitment and inclusion procedure to include 
COPD smokers for a smoking cessation program 
 
 
 
Sander R. Hilberink 
Johanna E. Jacobs 
Irma T.H.M. Maassen 
Reinier P. Akkermans 
Richard P.T.M. Grol 
 
 
 
 
 
 
 
 
Submitted. 
 
88 | Chapter 7 
Abstract 
Background: In the Netherlands about one third of the patients with Chronic 
Obstructive Pulmonary Disease (COPD) still smoke. Provision of smoking 
cessation support is the most important therapeutic intervention. To encourage 
general practices to support COPD smokers to quit smoking, a procedure to recruit 
smoking patients with COPD and include them in a stop smoking program was 
implemented.  
Methods: The feasibility of the recruitment and inclusion procedure was tested 
among 152 general practices. The recruitment procedure consisted of assistance 
with the retrieving COPD patients from electronic patient records by means of a 
software program, a short questionnaire to assess their smoking status and an 
invitation to participate in a smoking cessation program. Patient and practice 
characteristics possibly influencing the numbers of recruited smoking patients with 
COPD willing to participate were analysed using cross-sectional analyses.  
Results: A total of 9,786 patients with COPD were retrieved. Of them, 926 actually 
smoking patients responded (9.5%) of which 366 were positive to participate in the 
smoking cessation program. Being motivated to quit smoking within 6 months and 
having tried quitting before positively influenced patient participation. Other patient 
characteristics nor practice variables could explain differences in participation. 
Experienced barriers for the recruitment of smoking patients were difficulties to 
perform electronic patient record extraction programs, the priority of the practices 
to adapt to changes in insurance legislation, and the detached mail approach of 
the patients.  
Conclusion: Improvement of electronic recording seems a prerequisite to detect 
COPD smokers as well as the delivery of more support to the practices. A 
bottleneck proved to be the approach of patients by mail to provide their smoking 
status and quit motivation. A more personal and gradual approach embedded in 
daily consultations is needed to recruit less motivated patients with COPD for a 
smoking cessation program. 
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Introduction 
The prevalence of chronic obstructive pulmonary disease (COPD) in Dutch 
general practice is about 20 per 1,000 patients.1-3 The yearly smoking related 
COPD-mortality is estimated at 0.33 per 1,000 inhabitants.4 Smoking cessation, 
even when COPD has developed, improves the prognosis and lung function.5-6 
Patients with COPD who definitively stopped smoking can reach a normal 
physiological lung function decline.6,7 Despite suffering from severe airway 
complaints, many patients with COPD still smoke. In recent studies the percentage 
of COPD smokers in primary care ranged from 33% to 40%.3,8,9 Patients reported 
that they are not aware of the smoking cessation support they can get.10 
 According to national guidelines in the Netherlands patients with COPD should 
be monitored at least once a year.11,12 In the control visits smoking cessation 
support for those still smoking is the most important therapeutic intervention. 
Nurses, practice assistants or facilitating services can perform parts of the control 
visits. The guidelines give only minor directions concerning the strategies to 
achieve non-smoking, nor do they state COPD-specific characteristics, e.g. 
symptom-related motivation, which can be used as leads to provide patient 
support. A controlled study demonstrated that a smoking cessation protocol 
(SMOCC) specifically targeted at patients with COPD in general practice doubles 
the smoking cessation rates at 6 and 12 months.13,14 
 A premise for offering effective smoking cessation support for COPD smokers is 
knowing how the target group can be best approached and involved in a smoking 
cessation program. Studies in general practice have shown difficulties in including 
sufficient participants.15-17 Recruitment appears to be more successful if it 
concerns prevalent cases instead of incident cases and if potential participants are 
invited by means of personalized letters.15 The previous SMOCC study applied a 
recruitment procedure including a software program to assist practices to detect 
patients with COPD and a short questionnaire to assess their smoking status sent 
by the practices. This procedure was intensively supported by the researchers. 
 In the present study this recruitment and inclusion procedure was applied to 
invite COPD smokers to take part in a smoking cessation program in their general 
practice. However for the large-scale implementation the support of the 
researchers was minimised. The feasibility of the recruitment and inclusion 
procedure, and practice and patient characteristics that affected smokers' 
willingness to participate in the smoking cessation program, were explored. Insight 
in these characteristics might give clues to better organise recruitment procedures 
for COPD smokers and to include them in smoking cessation programs. 
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Methods 
Design 
The present feasibility study was conducted in 152 general practices in the 
Netherlands. The general practices were recruited by direct mailing and a call in a 
general practice magazine. Quantitative descriptive methods supplemented by 
narrative experiences of the researchers were used to perform the process 
analyses of the detection and recruitment of patients.  
 
Intervention 
Practices received low-intensity support for the recruitment and inclusion of 
smoking patients with COPD. The support consisted of the delivery of queries for 
the electronic patient record system and of a form to record exclusion criteria, a 
short preprinted patient questionnaire to assess the smoking status and the quit 
motivation of the detected patient with COPD to be sent to the patient by the 
practice professionals themselves with an accompanying letter.  
 To minimise the influence of intervening factors the general practices received 
electronic detection queries tuned to the specific electronic patient record system 
they used. 
 The queries for patient detection were based on the following criteria: age > 40 
years and being diagnosed as having COPD or having an ICPC-code R95/96 or 
prescription of at least three times of bronchodilators in the past year (ATC code 
R03a/bc), and/or prescription of at least two times of anti-inflammatory medication 
in the past year (ATC code R03). As providing smoking cessation support was the 
main goal, the inclusion criteria for COPD were not set very limiting and strictly. 
Patients mainly treated by a chest physician or having serious physical or mental 
(co-)morbidities were excluded, as well as patients not being in command of the 
Dutch language. Patients’ own general practitioners had to make the exclusion 
decisions.  
 The retrieved patients with COPD from the electronic patient records received a 
short pre-structured questionnaire to assess their smoking status as well as forms 
to participate in a smoking cessation program. The questionnaires and forms were 
sent to the patients by the practices accompanied by a personal letter explaining 
the purposes of the project. The questionnaires and forms had to be returned to 
the practices which sent them to the researchers. Practices were asked to send 
reminders to non-responding patients. This procedure was approved of by the 
Committee of Research on Humans of the Radboud University Nijmegen Medical 
Centre. 
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Measures and instruments 
The research question in this study focuses on the patient and practice factors 
influencing the recruitment and inclusion of smoking patients with COPD. The 
main dependent variable was the number of included smoking patients with 
COPD. 
 Practice measures, derived from the recruitment questionnaire practices 
completed when entering the project were practice size (number of registered 
patients), number and type of practice professionals (GPs, practice nurses), 
experience with providing smoking cessation support (having formerly used a 
minimal intervention strategy to support smoking cessation yes/no or having 
formerly used an other cessation program yes/no).  
 Patient measures, derived from the pre-structured detection short questionnaire 
were age, sex, amount of smoking (number of cigarettes/shags per day/week, 
number of pipes or cigars per week), nicotine addiction (smoking within 30 minutes 
after wakening: yes/no), intention to quit smoking (yes (< 1 month, < 6 months, > 6 
months, no), former quit attempts (no/yes, number of attempts), physical and 
mental complaints due to respiratory illness (RIQ-MON10-A), physical and social 
restraints due to respiratory illness (RIQ-MON10-B).18 
 Three researchers (JJ, SH, IM) documented and categorised their experiences 
with the recruitment procedure (duration, barriers and facilitators). Only consensus 
about the main findings is presented.  
 
Analyses 
Explorative cross-sectional descriptive analyses were performed (Chi2, T-tests) to 
compare non-participating and participating patients. A multivariate multilevel 
descriptive analysis (GLIMMIX Procedure) was performed to detect significant 
influences of participation. We considered p < 0.05 as limit for statistical 
significance. 
 
Results 
Recruitment and characteristics of practices and patients 
The convenience sample of 152 practices had a mean of 3,655,40 (SD 1,702.40) 
patients per practice (Range 1,200 - 9,000) and the mean number of GPs and 
nurses was 2.3 (SD 2.8) (Range 1 - 22) and 1.0 (SD 0.6) (Range 0 - 4) 
respectively. Almost all participating GPs and practice nurses admitted that 
providing smoking cessation is their task but 22% of the GPs and 13% of the 
nurses stated that it is difficult to integrate this in their normal routines. A minority 
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of practices had a protocolised collaboration for COPD with other disciplines 
(Range 22-48%), but little cooperation regarding smoking cessation counseling 
(14%). In 70.3% of the practices the professionals had already used a minimal 
intervention strategy or another cessation program to support smoking cessation. 
 In the practices 11,588 patients with COPD were retrieved of which 1,802 
(15.5%) did not meet the inclusion criteria according to the clinical judgement of 
the GPs. From the retrieved patients 926 COPD smokers (9.46%) adhered to the 
preset assessment procedure (questionnaire + letter). Of these 366 patients 
(39.5%) were willing to be included in a smoking cessation program (Figure 1). 
 On average only 17% of the retrieved smoking patients with COPD had never 
attempted to quit smoking and about 34% indicated that they were motivated to 
quit smoking within 6 months. About 18% reported physical and mental problems 
because of the respiratory disease (RIQ-MON10 > 2.5), however only 4.3% 
patients experienced physical and social restraints (RIQ-MON10 > 3.5). 
 
Figure 1. Flowchart of participants 
 
 
152 general practices, 
11,588 COPD patients 
1,802 patients not eligible according to 
the inclusion criteria  
9,786 COPD patients 
366 COPD smokers willing 
to participate in a smoking 
cessation program 
560 COPD smokers not 
interested to participate in a 
smoking cessation program 
926 COPD smokers 
reached 
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Analyses of factors influencing participation of smoking patients with COPD 
We compared the characteristics of the smoking patients willing or not willing to be 
included in the smoking cessation program (Table 1). The cross-sectional 
exploration of possible determinants of non-participation showed that inclusion in 
the smoking cessation program was associated with: greater motivation to quit 
smoking (Odds Ratio (OR) 95% Confidence Interval (95%CI)): being a pre-
contemplator 1.7 (1.2-2.4); being a contemplator 2.8 (1.9-4.1); being a preparer 
1.6 (1.0-2.5), and having performed former quit attempts 2.2 (1.5-3.3). Perceiving 
more disease-specific physical and mental problems was borderline significant; 
sex, age, amount of cigarette consumption and being restraint from the COPD did 
not affect inclusion. 
 
Table 1. Characteristics of recruited and included smoking patient with COPD (n=926) 
 
Variables No inclusion 
n = 560 
Inclusion 
n = 366 
P 
Age (mean, SD) 63.9 11.7 62.8 10.4 .158 
Sex, % male 52.6  49.5  .350 
RiQ-MON 10 physical and mental problems (mean, SD)  1.8   0.7   1.9   0.4 .046 
RIQ-MON10 physical and social restraints (mean, SD)  1.7   0.9   1.8   0.8 .206 
Number of cigarettes/shags a day (mean, SD) 13.0   8.4 14.0   9.0 .108 
Nicotine addiction, % first smoke < 30 minutes after 
awakening   
51.9  56.1  .218 
% Motivation to quit       
   < 1 month 12.6  12.7  <.001 
   < 6 months 16.4  29.2   
   > 6 months 30.6  32.4   
   No 40.4  25.7   
% ever attempted to quit smoking 78.5  89.0  <.001 
 
Inclusion was not affected by professional influences as the professionals treating 
the patients who wanted to be involved had not used more often smoking 
cessation protocols in the past than those treating the patients who did not want 
(Table 2). Nor did the number of practice professionals providing care to COPD 
patients differ significantly. 
 The multilevel multivariate procedure combining patient and practice factors 
revealed the same result; only two patient factors influenced inclusion, the 
motivation to quit within quit within 6 months (OR 2.4, 95% CI 1.6-3.6) or after 6 
months (OR 1.4, 95% CI 1.0-2.1) and having performed former quit attempts (OR 
= 1.9, 95% CI = 1.2-2.9). 
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Table 2.  Characteristics of the general practice teams in the patient sample 
 
Variables No inclusion 
n = 560 
Inclusion 
n = 366 
P 
Experience with the Minimal Intervention Strategy for 
smoking cessation % 
     85.6       81.9  .214 
Experience with other cessation programs %      37.8       37.2  .865 
Having used a cessation protocol  %      61.6       60.4  .709 
Number of patients in the practice (mean, SD) 3,710.8 1,765.2 3,574.4 1,605.5 .280 
Number of practice nurses in the practice (mean, SD)        1.0       0.7        1.0        0.6 .636 
Number of GPs in the practice (mean, SD)        2.3        2.8        2.2        2.8 .518 
 
Qualitative findings of the researchers 
• Many practices could not retrieve lists of their patients with COPD from the 
electronic patient records with the help of the delivered queries and it proved to 
be necessary to deliver much more personal support at the practice location to 
several practices.  
• Detection of smoking patients by the practices with the provided short smoking 
status assessment questionnaires to be sent to the patients with COPD was a 
bottleneck too, partly because the intervention coincided with the time-
consuming implementation of a new national health insurance system. The 
efforts to send the questionnaires and reminders to non-responding patients got 
low priority in the practices which were already subjected to a large 
administrative burden. 
 
Discussion 
Although a huge number of patients with COPD were retrieved, the number of 
smoking patients was less than half of the expected number. In total only 9.5% 
smoking patients in the COPD population were reached whereas about 33-40% 
was to be expected.3,8 Furthermore the inclusion of smoking patients in the stop 
smoking program was even less.  
 Finding more inclusion from patients with higher motivation to stop smoking and 
having had more quit attempts before was not surprising. Many studies are only 
dealing with motivated patients,7,19-22 but the real challenge is to reach the patients 
in various stages of quit motivation. Even more so for patients with COPD, a 
disease for which smoking cessation is the major therapy. Compared to previous 
research13,14 the recruitment procedure was less personal and less embedded in 
the normal treatment control regime. In the previous procedures the smoking 
status assessment form was sent to the patients just before a regular control visit 
and had to be taken to the practice whereas in the present project the forms were 
sent to the whole detected population at the same time and had to be sent back by 
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mail to the practice. Moreover, the smoking cessation program was to be delivered 
to the patients during regular control visits and the time to the appointment date 
might vary a lot for the patients. What also might have influenced the response 
figures of the patients was the invitation not only to consent to a smoking cessation 
program but to participate in a study project as well and to complete 
questionnaires and informed consent forms with no direct link to the appointments 
in the practice. The Lasagna study15 revealed similar problems concerning 
recruitment and inclusion, although sending letters by mail to patients was seen as 
one of the more successful strategies.  
 The analyzed practice factors like size, number of professionals or experience 
with providing smoking cessation treatment showed no influence on inclusion in a 
smoking cessation program. The practice professionals having volunteered to 
participate in the project were interested in the subject of smoking cessation 
support for patients with COPD but were confronted with major obstacles during 
the course of the recruitment procedures. The most important barrier was the 
inability to retrieve their smoking patients with COPD using a combination of 
queries from the electronic patient records and the logistical problems to send a 
short questionnaire to the patients. It seems that good recordkeeping is a 
prerequisite to start and monitor the provision of lifestyle interventions during 
regular care, which is in line with previous research.23  
 The recruitment and inclusion procedure was furthermore hampered by the 
requested time investment in the project above the administrative workload of a 
change in health insurance regulations. This lead to an unforeseen and 
understandable change in priorities of the practices during the course of the 
project. Keeping the practice professionals enthusiastic about the project 
presumably requires the delivery of more or more timely incentives or support than 
was planned in the intervention. To get better recruitment rates redrafting the 
large-scale implementation of the recruitment procedure in general practice would 
probably benefit from more gradual inclusion of practices with more support at the 
start and a larger time frame of the whole project or putting in more (costly) 
support personnel in the initial phase.  
 
Conclusions 
We studied the recruitment and inclusion of COPD smokers to participate in a 
smoking cessation program in general practice. In spite of the delivery of software 
program-based queries the practices had difficulties retrieving COPD patient from 
their electronic patient records and needed more help to do so.  
96 | Chapter 7 
The procedure of the practices to assess the smoking status of the patients and 
their quit motivation via mailed letters and short questionnaires was only partly 
successful as less than half of the expected patients sent back the assessment 
form. The patients reached and included in a smoking cessation program were 
more motivated to quit and had more often attempted to quit smoking than those 
not included. Improvement of up to date electronic recording of the smoking status 
of patients seems needed to get the smoking cessation protocol implemented in 
daily general practice. However, despite the practice difficulties with the 
recruitment and inclusion procedure, our data suggest that the inclusion of 
smoking patients with COPD in a smoking cessation program is most of all 
affected by the smoker's motivation to quit and their longer history with quit 
attempts. The recruitment procedure of this study is suitable for a quick 
recruitment and inclusion of the more motivated patients in a smoking cessation 
program. An adaptation of the procedure is needed to reach the less motivated 
patients. Linking the recruitment procedure to daily routines (e.g. consultations) 
might be a better strategy to include these COPD smokers in a smoking cessation 
program. 
 
Feasibility of a recruitment and inclusion procedure | 97 
References 
1.  Boezen HM, Postma DS, Smit HA, Poos MJJC. Hoe vaak komt COPD voor en hoeveel mensen 
sterven eraan? In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. 
Bilthoven: RIVM, <http://www.nationaalkompas.nl> Nationaal Kompas Volksgezondheid\ Gezondheid 
en ziekte\Ziekten en aandoeningen \Ademhalingswegen\COPD, 17 mei 2010.  
2. Tabak C, Smit HA. De morbiditeit van astma en COPD in Nederland; leemtes in kennis opgevuld 
door aanvullende analyses en actualisering van beschikbare gegevensbronnen. Bilthoven: RIVM, 
2002.  
3. Smeele I, Meulenpas M, Meulemans M, Reus I, Klomp M. Eerste ervaringen met COPD-ketenzorg. 
Huisarts Wet 2012; 55:194-8. 
4. RIVM. Nationale Atlas Volksgezondheid, Volksgezondheid Toekomst Verkenning. Bilthoven: RIVM, 
www.zorgatlas.nl, versie 4.7, 22 maart 2012. 
5. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung 
function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J 
Respir Crit Care Med 2000;161:381-90. 
6. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in 
current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from 
the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-64. 
7. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, 
Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic 
bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505. 
8. Hilberink SR, Jacobs JE, Schlösser M, Grol RPTM, et al. Characteristics of patients with COPD in 
three motivational stages related to smoking cessation. Patient Educ Couns 2006;61:449-57. 
9. Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of 
chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a 
follow-up in middle-aged rural men. Chest 2006;130:1129-37. 
10. Henselmans I, de Witt LJ, Hilberink SR, Jacobs JE. Professionele behandeling van tabaksverslaving: 
het cliëntenperspectief. Nijmegen: Centre for Quality of Care Research (WOK), 2003. 
11. Smeele IJM, van Weel C, van Schayck CP, van der Molen T, Thoonen B, Schermer T, Sachs APE, 
Muris JWM, et al. NHG-Standaard COPD (Tweede herziening). Huisarts Wet 2007;50:362-79. 
12. Long Alliantie Nederland (LAN). Zorgstandaard COPD, 2009.  
13. Hilberink SR, Jacobs JE, Bottema BJAM, de Vries H, Grol RPTM. Smoking cessation of patients with 
COPD in daily general practice (SMOCC): Six months’ results. Prev Med 2005;41:822-7. 
14. Hilberink SR, Jacobs JE, Breteler MHM, de Vries H. Grol RPTM. General practice counseling for 
patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two 
complex interventions. Patient Educ Couns 2011;83:120-4. 
15. van der Wouden JC, Blankenstein AH, Huibers MJ, van der Windt DA, Stalman WA, Verhagen AP. 
Survey among 78 studies showed that Lasagna's law holds in Dutch primary care research. J Clin 
Epidemiol 2007;60:819-24. 
16. Spilker B, Cramer JA. Patient recruitment in clinical trials. New York: Raven Press, 1991. 
17. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, Entwistle V, Garcia J, 
Roberts I, Grant A, Grant A; STEPS group. Recruitment to randomised trials: strategies for trial 
enrollment and participation study. The STEPS study. Health Technol Assess 2007;11: iii, ix-105. 
18. Jacobs JE, Maillé AR, Akkermans RP, van Weel C, Grol RP. Assessing the quality of life of adults 
with chronic respiratory diseases in routine primary care: construction and first validation of the 10-
Item Respiratory Illness Questionnaire-monitoring 10 (RIQ-MON10). Qual Life Res 2004;13:1117-27. 
19. Tönnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD 
using nicotine sublingual tablets and behavioral support. Chest 2006;130:334-42. 
20. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, 
Jamerson B. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-
blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-5. 
21. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking 
cessation in mild-to-moderate COPD: a randomized controlled trial. Chest 2011;139:591-9. 
22. van Schayck CP, Kaper J, Wagena EJ, Wouters EF, Severens JL. The cost-effectiveness of 
antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. 
Addiction 2009;104:2110-7. 
23. Mitchell E, Sullivan F. A descriptive feast but an evaluative famine: systematic review of published 
articles on primary care computing during 1980-97. BMJ 2001;322:279-82. 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
 
 
General discussion 
 
 
100 | Chapter 8 
This thesis reports on a smoking cessation program for patients with chronic 
obstructive pulmonary disease (COPD) treated in general practice. The program 
consisted of 1) a smoking cessation protocol, named the SMOking Cessation for 
patients with COPD (SMOCC) (appendix), and 2) an implementation strategy 
using a multifaceted approach aimed at the general practice team.  
 The SMOCC protocol can be seen as integral of the stepped-care approach to 
support smoking cessation.1 The first steps are included in the SMOCC protocol. 
First all smokers are advised to quit, tailored to the personal situation (i.e, having 
COPD) and the patient’s motivation to quit is assessed, embedded in routine care. 
Patients who are not willing to quit smoking get information but no further smoking 
cessation treatment at this time. In the second step attempts are made to influence 
the patient's motivation to quit smoking, using motivational interviewing strategies. 
Smokers who do not respond to this intervention do not receive further smoking 
cessation treatment for now. The third step is the application of a combination of 
pharmacotherapy and low intensity cessation counselling (with a maximum of 
three practice visits and three times telephonic follow-up). The SMOCC protocol is 
aimed at embedding the counseling in normal primary care and does not include 
intensive treatment which should be delivered elsewhere. 
 The implementation strategy consisted of a group training, outreach visits to the 
general practice, an information folder about COPD and smoking cessation, and 
support with the detection of COPD smokers. Furthermore, practice teams 
received one-paged coloured protocol summaries to assist the counselling 
activities. 
 
First, an investigation of patients’ smoking cessation motivation revealed that more 
than 50% of the COPD patients who smoke and are treated in general practice are 
amenable to smoking cessation counselling. Suffering from more COPD 
symptoms was related to a greater motivation to quit. Second, the results of the 
SMOCC trial are presented. Based on self-reports, patients taking part in the 
protocol more frequently attempted to quit smoking and actually succeeded in their 
attempt to refrain from smoking. However, when self-reports were biochemically 
verified the quit rates appeared to be less impressive. Although the quit rate in the 
intervention group was twice as high as that in the control group, patients in the 
intervention group were not more successful in quitting smoking compared to 
patients in the control condition (moreover, the effect size was small). An attempt 
to large-scale implement the SMOCC protocol revealed barriers to the smokers’ 
recruitment and inclusion. Finally, the results allow us to conclude that the smoking 
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cessation protocol might be effective for motivated patients and that it should be 
regarded as fitting in a stepped-care approach. which is recommended by the 
national guideline smoking cessation.1 
 
Relevant characteristics of patients with COPD 
We investigated the motivation of patients with COPD to stop smoking and 
explored whether these patients (at different motivational stages) could be 
identified on the basis of health indicators, attitudes, social influences, self-efficacy 
beliefs, and action plans. The rationale was that this might provide clues for 
tailoring the care for these patients to improve smoking cessation support. 
 In the smoking cessation literature, smokers are often categorised according to 
their stages of change, i.e. the phase in which they are motivated to quit.2 In the 
present study we distinguished three groups: preparers (plan to quit within one 
month), contemplators (plan to quit within six months) and precontemplators (not 
planning to quit within six months). We found that about one in four COPD patients 
was motivated to quit smoking within one month. In the Dutch population at that 
time, our group of smokers in preparation (22.5%) was larger than the group of 
preparers in Dutch smokers (± 7%).3 Other studies on risk populations also 
reported higher percentages of smokers willing to quit than in the general 
population.4,5 One explanation is that patients with a smoking-related disease may 
find themselves in a vulnerable health situation in which smoking plays a causal 
role. The positive relationship found in our study between the COPD symptoms 
and motivation to quit smoking supports this view.  
 Although originally the Transtheoretical Model consists of five categories, this 
three-category approach is often used in Dutch clinical guidelines.1 The three 
groups can be distinguished based on smokers’ attitudes, social support and self-
efficacy. During the shift in motivation these three factors increase according a so-
called Ø pattern,6 showing that transitions from an unmotivated to a motivated 
phase are best predicted by attitudes, while transitions from motivation to action 
are best predicted by self-efficacy. Evidence of these patterns was found cross-
sectionally, longitudinally and experimentally.6-8 In case of smokers with COPD, 
our data suggest that this pattern differs. Preparers and contemplators were more 
similar to each other, compared to these two groups of smokers in the general 
population, regarding the degree of social support and readiness to take action, 
whereas contemplators experienced higher self-efficacy expectations than 
precontemplators. Based on our findings, a more simplified model to assess the 
motivational stage of change seems relevant, by making a distinction between 
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persons who are motivated to quit (preparers and contemplators) and unmotivated 
to quit (precontemplators). Such a simplified model might also be useful in general 
practice to tailor the smoking cessation support for COPD smokers. Kraft et al.9 
argue that the cut-off points of 6 months and 1 month before starting with quitting 
lack a theoretical basis. The more simplified model recommends to focus on 
increasing the motivation to quit of smokers with smoking-related health 
complaints. The general practitioner (GP), or practice assistant, is advised to 
collaborate with other professionals to ensure an intensive investment of time to 
support their patients; such contacts appear to be cost-effective.1 
 
Motivation and physical COPD characteristics 
The association between readiness to quit smoking and suffering from symptoms 
caused by smoking has often been reported10-13 and the present study confirms 
this: more highly motivated patients suffered from more severe COPD symptoms 
and had more regrets about smoking because of their COPD symptoms. The 
negative health effects of smoking might serve as an extra motivator to quit. 
However, it is less clear how to use health symptoms to effectively influence 
motivation and successful quitting. 
 Although performing spirometry was found to increase the intention to quit 
smoking among COPD smokers 4 weeks after testing, this effect faded after 3 
months; however, spirometry appeared to be effective based on smoking 
cessation rates at 3-months follow-up.14 Spirometry in combination with advice can 
be effective in increasing smoking cessation rates among COPD smokers,15,16 but 
the contribution of spirometry together with counselling is not conclusive.17 Also, 
the combination of feedback of spirometry results, counselling and nortriptyline 
had no effect on smoking status, although it did influence risk perceptions and self-
efficacy.18 Thus, it seems that ‘hard symptom feedback’ as provided by lung 
function tests is not sufficient to support successful quitting. Nevertheless, in line 
with the results of Sundblad et al.,14 COPD patients report that measuring lung 
function can increase their motivation to quit.19 Risser and Belcher20 added the 
personal effects of smoking (e.g. lung symptoms, spirometry values) to patient 
education on health risks of smoking, and found a positive impact of this 
motivational intervention on success rates. There is evidence that worrying about 
one’s health due to smoking predicts a quit attempt when the smoker’s self-
efficacy and awareness of the damaging effects of smoking are high.21 Thus, 
addressing smoking-related symptoms (including lung function) only seems to 
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contribute if it fits into a motivational context, after taking a person’s attitude and 
perceived competence into account.  
 The SMOCC protocol provides such motivational context with a stage-based 
approach, built on the rationale of the ASE model.22 This implies that the patient's 
motivational stage should be assessed before the GP makes use of any 
information about smoking-related health complaints. 
Whatever the case, the GP needs information on COPD severity to optimise the 
treatment during a quit attempt. The Lung Health Study found that suffering from 
fewer respiratory complaints was associated with successful smoking cessation in 
COPD patients.23 Increased coughing is a short-term effect of smoking 
cessation24,25 and is considered to be a nicotine withdrawal symptom.26 In a clinical 
guideline for treatment of COPD, the worsening of coughing during the first weeks 
after quitting is identified as an extra barrier for COPD patients to quit.27 The 
underlying mechanism could be an increased cough reflex sensitivity after 
withdrawal from exposure to tobacco smoke.28 Although one study found a 
decrease in COPD symptoms 30 days after smoking cessation,29 physician’s 
might consider prescribing extra symptom medication to support the patient in their 
quit attempt. In our trial, use of symptom relief medication was not recommended 
during a quit attempt. We advise to prepare patients that an increase in symptoms 
after quitting might occur and to investigate the effects of symptom relief 
medications in the few first weeks of the quit attempt. 
 
Effectiveness of the SMOCC protocol 
In our stop-smoking program, the 6-month follow-up showed a self-reported point 
prevalence rate of 16% vs. 8.8% in the control group. However, at one-year follow-
up our expectations about the effectiveness of the program were reduced; this was 
because the self-reported quit rates before biochemical verification (14.5% vs. 
7.4%) decreased to a non-significant difference (7.5% vs. 3.4%) after biochemical 
verification at one-year follow-up. Some remarks are relevant in this respect. 
 Compared to other studies on smoking cessation in COPD patients, the success 
rate in the present study is relatively low. This might be explained by several 
factors, of which two important ones are discussed here. First, we included both 
motivated and unmotivated COPD smokers whereas other studies included only 
motivated patients – resulting in abstinence rates of 15.7-34.7%.30-34 Although we 
found a success rate of 20.6% among preparers after six months based on self-
report, the earlier studies used biochemical validated quit rates. This suggests that 
our percentage may be an overestimation. Nevertheless, including only highly 
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motivated smokers in a study may lead to biased conclusions regarding the 
effectiveness of a program. Including smokers at different motivational stages will 
better reflect the potential effectiveness in a real-life setting such as general 
practice. Second, compared with other RCTs on smoking cessation in COPD 
smokers, our protocol was embedded in the routine healthcare delivery in the 
patients’ own general practice and therefore less intensive compared to other 
settings. For example, some smoking cessation studies including patients with 
COPD were embedded in hospital care,31,35,36 and some offered intensive 
counselling35,37 combined with pharmacotherapy.30-34 Increasing the treatment 
intensity correlates with increasing success rates.38 These smoking cessation 
protocols were offered in more controlled environments than in routine general 
practice, which probably contributed to their greater success. As Willemse et al.39 
argued, exposure to an intensive research setting may be an extra motivator for 
patients with COPD to quit smoking.  
 Both bupropion-SR and nicotine replacement therapy are effective single 
cessation aids,40,41 but the use of antidepressants in COPD smokers is not always 
effective.34 According to the literature, a combination of behavioural counselling 
and pharmacological therapy aimed at smoking cessation in COPD smokers is 
more effective than each strategy separately.42,43 However, in our smoking 
cessation protocol, addition of the advice to use bupropion-SR to counselling and 
the advice to use NRT did not increase successful quitting; this is in line with 
studies showing that bupropion-SR does not have a surplus value over the use of 
nicotine replacement therapy (NRT).40 This might be explained by low compliance 
with the recommendations: only a minority (19.2%) of the patients reported to have 
used bupropion-SR of which 2.5% used both NRT and bupropion-SR. The 
additional costs for the patients and the occurrence of adverse events may have 
contributed to this suboptimal use. In the general population, reimbursement of 
smoking cessation support contributes to higher quit rates and turns out to be 
cost-effective on the long term.44,45 The Dutch healthcare system introduced the 
reimbursement of smoking cessation therapies in January 2011. In 2011 the 
number of applicants for telephone counselling for smoking cessation increased 
with factor ten, which might be an indicator for larger quitting activity nationwide.46 
Although it is difficult to prove a causal relationship, the prevalence of smokers in 
the Dutch population decreased thereafter to the lowest figure ever, i.e. 25%.47 
The reimbursement system was withdrawn due to a change in policy in 2012, but 
was re-introduced in 2013 for pharmacotherapy combined with counselling. For 
COPD smokers, who are overrepresented in the lower socioeconomic class,48 
General discussion | 105 
reimbursement might partly overcome the suboptimal use of pharmacological 
cessation aids due to financial reasons. Taking into account the costs of the 
chronic and deteriorating nature of COPD, and the benefits of smoking cessation, 
reimbursement of smoking cessation therapies not only has a financial rationale 
but is also an investment in public health. 
 The present thesis does not report on the cost-effectiveness of the SMOCC 
protocol. One might argue that performing such an analysis is not even logical 
because the protocol did not significantly lower the smoking prevalence among the 
participants. However, insight into the program’s costs compared with its results 
might help in the decision-making process as to whether to offer this protocol to 
specific individuals. Moreover, cost-effectiveness analyses have been published 
about smoking cessation therapies for COPD smokers.34 In general, minimal 
counselling strategies in COPD smokers yield low success rates (average 2.6%) 
compared to intensive counselling (average 6.0%) and pharmacotherapy (average 
12.3%).49 These authors calculated that the cost per quality-adjusted life-year was 
below the threshold of € 20,000 (€ 16,900), but made no significant contribution to 
usual care. Better use of pharmacological agents, which was an integral part of 
our protocol, might substantially increase the (cost-)effectiveness of the SMOCC 
protocol in general practice. 
 To conclude, the smoking cessation protocol yielded low success rates. Our 
hypothesis is, that although half of the patients seemed motivated to quit smoking, 
the intensity of the smoking cessation support was too low to help a substantial 
proportion of these patients to counteract their addiction. The SMOCC protocol is a 
tool for dealing with patients in various motivational stages. In cases where 
counselling according to the SMOCC protocol does not lead to quit attempts and 
smoking cessation, the protocol can nevertheless be considered as a useful 
COPD-tailored step; afterwards, based on a stepped-care approach, the patients 
can be referred to more intensive and specialised smoking cessation services. 
 
Feasibility of the implementation program and the SMOCC protocol 
Effectiveness of the SMOCC protocol is dependent on the feasibility and 
effectiveness of the implementation program. The implementation strategy of the 
first two trials appears to be well chosen. The group training and support visits to 
the general practice took place as planned; all elements were well adhered to and 
highly appreciated. Also, the support materials provided were positively evaluated 
by the GPs. Self-reported compliance to the smoking cessation protocol by the 
general practices was moderate to good, ranging from 70-80% of the several 
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components embedded in the protocol. Based on these data the implementation 
strategy can be considered successful; however, the self-reported behaviour of 
professionals is not always reliable and may be liable to positive overestimation.50 
Assessment of patients’ motivational stage, offering the patient leaflet, tailoring the 
consultation to the motivational stage, and scheduling three visits for motivated 
patients were components of the protocol that were most complied with. Although 
we have self-reported data on compliance of the GPs with the protocol, 
information on the actual performance during the interaction with the patient is not 
available. However, the self-reports of the professionals can be considered as 
providing circumstantial evidence in favour of the effectiveness of the 
implementation strategy. This is in line with other findings stating that outreach 
visits,51,52 small-scale interactive training53,54 and delivering support materials55,56 
all effectively contribute to guideline implementation in daily practice.  
 The large-scale implementation of the recruitment and inclusion procedure that 
was applied in the SMOCC program encountered some problems. The 152 
general practices retrieved only 9.5% smokers of the identified COPD population 
from the electronic patient records whereas 33-40% was to be expected.57,58 The 
most important barrier was the inability to retrieve their smoking patients with 
COPD from the electronic patient records using a combination of queries and the 
logistical problems to send a short questionnaire to the patients. Good 
recordkeeping seems to be an important factor to start and monitor the provision of 
lifestyle interventions during regular care, which is in line with previous research.59 
Moreover, a small minority of COPD smokers were willing to be included in a stop 
smoking program. Having no intention to quit smoking and never having attempted 
to quit distinguished those who were not willing to be included in a smoking 
cessation program from those who were. Despite the practice difficulties with the 
recruitment procedure, inclusion of smoking patients with COPD in a smoking 
cessation program appears to be most of all affected by the smoker’s motivation to 
quit and their longer history with quit attempts. The recruitment and inclusion 
procedure seems to reach more motivated COPS smokers for a smoking 
cessation program. To recruit less motivated patients, the procedure should be 
more integrated in daily practice (e.g. consultations). 
 
Methodological considerations 
Evaluation of the effectiveness of the SMOCC protocol also requires some 
consideration. First, the biochemically verified quit rates decreased because 22 
patients who self-reported to have stopped smoking did not comply with the 
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verification procedure and, subsequently, were considered to be smokers. 
Nevertheless, we found a misreport of 22% in the remaining self-reported quitters, 
suggesting that about one in five patients reported that they did not smoke 
whereas their cotinine level indicated otherwise. Both higher and lower misreport 
rates have been reported for COPD patients.60,61 Participating in a smoking 
cessation study might have increased the number of misreports. For example, one 
study found that 13.6% of COPD patients gave false self-reports on their smoking 
status prior to the start of an intensive smoking cessation intervention; after the 
intervention this percentage was as high as 52%.60 This increased percentage of 
misreport following an intervention is a serious problem for healthcare providers 
providing smoking cessation support which is a key element in the effective 
treatment of COPD. Some physicians are reluctant to treat patients with COPD 
who persist in smoking. Treating symptoms that are knowingly caused by the 
patient’s persistence in an unhealthy lifestyle may be seen by some physicians as 
a loss of valuable time, effort and resources.62 The use of biochemical verification 
procedures can be seen as an aid to end unreliable self-reports and a contribution 
to effective smoking cessation support. However, this ‘harsh’ approach might 
damage the relationship with the patient and questions the ethical codes for health 
professionals. Nowadays, trends in guideline setting are increasingly based on 
principles of patients’ own responsibility and self-management, and compulsive 
elements in the treatment protocol would not be in line with these principles. In 
their systematic review Bize et al.63 found insufficient evidence that providing this 
kind of biomedical feedback contributed to successful smoking cessation. 
Therefore, addressing a patient’s responsibility and increasing one’s self-efficacy 
might be a better strategy than biochemical testing to encourage smoking 
cessation. 
 Prior to enrolment in the study, the power analysis indicated that we needed to 
include 25 practices with a minimum of 150 patients in each in order to detect a 
10% difference in quit rates. However, the assumption that the results of the 
protocol exceeded those of usual care by 10% proved to be overoptimistic and 
resulted in a lack of power. As discussed, it resulted in a doubled quit rate 
compared to the control condition, indicating that some patients may indeed 
benefit from the SMOCC approach. Therefore, a larger sample size than ours was 
needed to demonstrate statistical significance. Despite our underpowered sample 
our calculations reveal a small effect size, implying that when implemented 
nationwide public health effects may be significant (impact = reach x effect).64 
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However, attempts to recruit more practices and more patients in a follow-up study 
did not result in increased numbers of included patients.  
 
Implications for the future 
This study has considerable value for both clinical practice and future research. 
Given the lack of tailored methods for smoking COPD patients and the finding that 
our intervention almost doubled success rates, the current intervention for smoking 
COPD patients can have a place in general practice. Smoking cessation is the 
core element in the treatment of COPD and clinical guidelines emphasise the 
importance of providing support for smoking cessation. In the Netherlands about 
55-60% of patients with mild-to-moderate COPD are treated in general practice.58 
Therefore, general practice is the main healthcare facility for these patients to 
arrange and provide smoking cessation support. This support can be delivered by 
the practice nurse, who is experienced with advise and coaching in other life-style 
interventions for chronic diseases and who performs other COPD-related tasks 
such as spirometry. A recent development in the Netherlands is the founding of a 
quality register for health care professionals delivering smoking cessation 
treatment to ensure evidence-based treatment. In future to get reimbursement for 
the delivery of smoking cessation treatment a general practice should have at 
least one employee who is registered as trained smoking cessation treatment 
provider. If smoking cessation support provision remains too demanding for the 
general practice team in spite of having trained and registered general 
practitioners and/or practice nurses, the SMOCC protocol can easily be 
incorporated in a stepped-care approach in which patients can be referred to more 
specialised services. In addition, more research is needed to assess how to 
optimise and improve the current intervention, e.g. including elements of 
computer-tailored approaches which are generally successful.7,65 
 Recording smoking status and the provision of smoking cessation support is 
part of the quality indicators to assess adequate treatment of COPD.66 
Implementation of the protocol may help the professionals in general practice to 
meet these quality targets. Elements of the protocol, such as repeated recording of 
patients’ smoking status and their motivation to quit, is a prerequisite for adequate 
smoking cessation counselling and treatment in the stepped-care approach in both 
primary and specialised care. The SMOCC protocol can be considered as a more 
tailored form of the protocolised smoking cessation module1 which is to be 
incorporated in a common electronic patient record accessible to all healthcare 
professionals involved in the treatment of patients with COPD. Incorporation of the 
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SMOCC protocol in the module may lead to an improvement in the quality of care 
for these patients. 
 
Future research may focus on the following aspects. 
1. The organisation of the Dutch general practice has changed in the last decade. 
Whereas when our study started only about 6% of the Dutch general practices 
had a practice nurse, nowadays this proportion has increased to 75%.67 Practice 
nurses perform delegated tasks, mainly providing protocolised care for patients 
with a chronic condition including lifestyle interventions such as dietary advice, 
stimulation of physical exercise, and smoking cessation counselling. Patients 
appear to be satisfied with the communication with these practice nurses, 
however evidence on the effectiveness needs still to be demonstrated.68 
Nowadays, practice nurses have more time for patient education and 
counselling during a regular consultation. More research is needed to establish 
whether the SMOCC protocol would be more successful among COPD smokers 
in the current structure of general practices with use of the practice nurse. 
2. In addition, research is needed to reveal which COPD smokers respond to this 
type of protocol, and which patients should be directly referred to a more 
intensive individual or group intervention. Also, studies on the collaborative 
efforts between general practice and more specialised care are needed. 
3. Pharmacological cessation aids are effective in supporting smoking cessation, 
also for COPD smokers. Pharmacological agents used in this respect are the 
various forms of nicotine replacement therapy (NRT), including bupropion, 
nortryptiline and varenicline. Varenicline is a relatively new agent which 
outperforms placebo and bupropion.69 In a trial with motivated patients with 
mild-to-moderate COPD,33 varenicline outperformed placebo and appeared to 
be safe. Although recent findings suggest lower success rates in clinical 
settings,70 one study on COPD replicated the effectiveness of varenicline.71 As 
adherence to pharmacotherapy is essential, but was very low in our trial, 
efficacy trials should be followed by studies measuring adherence and effects of 
pharmacotherapy in real-life settings. Recently, concerns have been raised 
about serious adverse events in patients with underlying comorbidities.69 Thus, 
although two trials support the effectiveness and safety for COPD smokers, 
clinicians should be careful when prescribing varenicline for this patient group. 
4. Quitting smoking requires considerable effort, but maintaining the quit attempt 
and adopting a more healthy lifestyle is even harder to accomplish. Many COPD 
smokers have tried to quit at least once, but failed. To understand and prevent 
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relapse in these patients more research is needed. Studies should aim to 
elucidate at the determinants of relapse and then develop appropriate 
interventions. Symptoms such as increased coughing should be included in 
these analyses, and the prescription of extra bronchodilator medication should 
be tested as possible relapse prevention. A Cochrane review concluded that 
both counselling and pharmacotherapy yielded very limited effects with regard 
to relapse prevention.72 Therefore, more research on relapse prevention in 
general and for COPD patients in particular is needed. 
5. Since computer-tailored programs can result in significant effects,7,65 a 
challenge for the future might be to translate the current strategy into interactive 
eHealth approaches that may facilitate self-management of smoking in COPD 
patients. Since relapse is a considerable problem, these programs might also 
benefit from intensive computer-tailored programs to prevent relapse and 
resulting in continued abstinence rates of over 40% after 12 months.73  
6. Finally, as noted above, effectiveness does not necessarily imply public health 
impact.64 Public health impact is defined by effectiveness multiplied by 
implementation. This implies that not only is an effective protocol needed, but 
also favourable conditions for national implementation. Therefore, we also need 
to evaluate the best conditions for large-scale implementation of the current 
protocol, as well as for improved implementation strategies. 
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Summary 
 
Chronic obstructive pulmonary disease (COPD) is a chronic condition with a 
prevalence of 1.55% in women and 1.83% in men in the Netherlands. Smoking 
can be regarded as the most important single risk factor for developing COPD. 
Approximately 276,100 patients suffer from this condition in the Netherlands and 
5,984 patients died with COPD as primary cause of death in 2010; about 70% of 
the COPD-related mortality is accounted for by smoking. Considering the 
importance of smoking cessation to slow down the progression of the condition, 
international and national treatment guidelines stress smoking cessation support 
for these patients. 
 
Chapter 1 outlines the more detailed background of our study and its aims. The 
study was focussed on developing and evaluating a smoking cessation support 
strategy for general practice as the majority of the patients with COPD are treated 
in primary care. Since COPD smokers find it difficult to quit smoking, we 
developed the SMOCC protocol (SMOking Cessation in COPD) tailored to these 
patients and their motivation to quit smoking. A multifaceted strategy using 
professional group education and outreach visits was designed to implement the 
protocol in general practices and was tested in a randomised controlled trial. 
Practices in the intervention arm received a four-hour group training on COPD, 
smoking and smoking cessation. In addition each practice received support by an 
outreach visitor delivering counselling and feedback about performance in the 
practice (three visits). The general practice also received patient information 
materials (a video on smoking cessation, a designed leaflet about COPD and 
smoking cessation) and a stage-based smoking cessation protocol. The protocol 
described the several counselling steps depending on the motivational stage of the 
patient. Patients motivated to quit were advised to set a quit date and to use 
nicotine replacement therapy. A second consult was then scheduled. If the patient 
attempted to quit smoking, the practice assistant provided telephone counselling 
up to three times. Practices in the control arm delivered usual care. 
 
In chapter 2, differences between COPD smokers in three different motivational 
stages related to smoking cessation are explored. In a cross-sectional study with 
633 COPD smokers from 67 general practices, motivational stage is analysed in 
relation to health indicators, demographics, attitudes, social support, self-efficacy, 
nicotine dependence and action plans. COPD smokers were classified according 
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to their motivation to quit smoking: prepares (willing to quit within 1 month), 
contemplators (willing to quit within 6 months) and precontemplators (not willing to 
quit within 6 months). More than 50% of the COPD smokers were amendable to 
smoking cessation support (e.g. they were either contemplators or preparers). 
However, contemplators and preparers did not differ as much as previous studies 
reported. Consistent with the literature, COPD smokers in the precontemplation 
stage perceived fewer benefits from smoking cessation than smokers in the 
contemplation and preparation stage, and preparers showed significantly higher 
levels of self-efficacy than the less motivated patients. Contrary to what might be 
expected, contemplators and preparers did not differ concerning their social 
support, while contemplators experienced greater self-efficacy compared to 
precontemplators. Similarly, precontemplators showed less regret from smoking 
despite the symptoms compared to contemplators and preparers. Based on the 
found similarities among contemplators and preparers with COPD, it would be 
advantageous to tailor smoking cessation support to two distinct groups 
(unmotivated smokers and smokers motivated to quit). Advantages of quitting 
should be discussed with unmotivated smokers, and the smokers motivated to quit 
should be supported to increase their self-efficacy and action planning.  
 
The effectiveness of the SMOCC protocol was tested in a two-armed randomised 
controlled trial (43 general practices, 392 smoking patients with COPD). In 
chapter 3 we present the six months’ self-reported quit rates. General 
practitioners self-reported 70-80% compliance with the different aspects of the 
protocol. Significantly more smokers in the experimental group made a quit 
attempt (44.9% versus 36.5%) and actually quitted smoking than in the control 
group (16.0% versus 8.8%). We found no differences in quit rates between 
precontemplators, contemplators and preparers, which might be an indicator of 
success for a stage-based approach in this population. As the SMOCC protocol 
was complied well by the general practitioners and doubled the self-reported six 
months’ quit rates after six months it seems a valuable contribution to the care for 
COPD patients.  
 
In chapter 4 a second effectiveness study is presented on both self-reported and 
biochemically verified quit rates after twelve months. In this study 68 general 
practices with 667 COPD smokers were included. Originally this study was 
composed of three study arms, one usual care arm and two intervention arms. The 
two intervention arms were similar, except that one arm was instructed to advise 
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nicotine replacement therapy and the other arm was instructed to advise nicotine 
replacement therapy as well as bupropion-SR to the patients motivated to quit. 
Since both arms performed equally, the two intervention arms were taken together 
in the analyses. The intervention resulted in a significantly higher self-reported 
success rate (14.5%) compared to usual care (7.4%). However, biochemically 
verified quit rates decreased the effectiveness, showing quit rates of 7.5% 
(intervention) and 3.4% (usual care). The effect size was considered to be small 
(Cohen’s h = 0.18). Overall the use of nicotine replacement therapy and 
bupropion-SR was low, about a quarter received telephone counselling. The 
smoking cessation protocol can be used for COPD smokers in general practice, 
but expectations should be modest.  
 
Chapter 5 focuses on the biochemical verification of the self-reported smoking 
cessation rates of the patients at twelve months follow-up. The cross-sectional 
study included 60 patients. Smoking status was verified by means of urine 
analyses, levels of 50 ng/mL of cotinine or higher indicated that the patient was 
currently smoking. At the time of biochemical verification, 55 patients reported that 
they had quit smoking while five patients resumed smoking. The self-reported quit 
status was biochemically confirmed for 43 patients (78%) and 12 patients (22%) 
were classified as smokers. The sensitivity of the self-report of smoking was 29% 
and the specificity was 100%. Many primary care patients with COPD do not 
provide valid information on their smoking status, which hamper adequate 
therapeutic interventions. Integration of biochemical verification in daily care could 
overcome this problem, but may harm the doctor–patient relationship. 
 
Chapter 6 explores associations with reapplying the SMOCC protocol and 
qualitatively examines the facilitators and barriers to reapply the protocol reported 
by 43 general practitioners (GPs). GPs filled-out baseline and evaluation 
questionnaires and took part in a semi-structured telephone interview. We 
assessed attitudes (A), social influences (S) and self-efficacy (E) in order to 
understand the compliance with the protocol. Apart from advising nicotine 
replacement (30%) and providing an educational videotape (43%), the self-
reported compliance rates with the motivational treatment protocol components 
were high (76% on average). Fifty-three percent reapplied the protocol after the 
patients resumed smoking. A part of the GPs were seriously disappointed by the 
effectiveness of the treatment protocol, which was associated with negative 
attitude and lower perceived social support and self-efficacy. The change of a 
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practice assistant or having an unmotivated co-worker were found to hinder good 
application of the treatment protocol. Negative attitudes, a lack of social support 
and being less confident determined lower protocol compliance. GPs need to 
obtain realistic expectations concerning smoking cessation methods, and may 
need to delegate smoking cessation support to assistants when confronted by lack 
of time and/or confidence to provide this type of counselling or to refer the patient 
to other healthcare facility. 
 
Chapter 7 presents the feasibility of a recruitment procedure of COPD smokers in 
152 general practices. The recruitment and inclusion procedure consisted of 
assistance with retrieving COPD patients from electronic patient records by means 
of a software program, a short questionnaire to assess their smoking status and an 
invitation to participate in a smoking cessation program. A total of 9,786 patients 
with COPD were detected, of which 926 current smokers responded (9.5%). Of 
them, 366 were positive to be included in a smoking cessation program. Being 
motivated to quit smoking within 6 months and having tried quitting before were 
associated with inclusion. Other patient characteristics nor practice variables could 
explain differences in inclusion. Barriers to recruit COPD smokers were both 
difficulties with retrieving patients with COPD from the electronic patient records 
and assessing their smoking status by means of a short questionnaire sent by the 
general practice. A more personal and gradual approach embedded in daily 
practice seems to be needed to include patients with COPD in a smoking 
cessation program.  
 
Chapter 8 provides the general discussion on the present study. In drawing the 
main conclusions, also some methodological comments and directives for the care 
for COPD patients as well as for future research are made. Given the lack of 
tailored interventions for COPD smokers and the finding that our intervention 
doubled success rates, implementation of the SMOCC protocol is recommendable. 
In the Netherlands approximately 55 to 60% of the patients with mild-to-moderate 
COPD are treated in general practice. In line with smoking cessation guidelines for 
general practice the SMOCC protocol provides a tool tailored to COPD smokers. 
The protocol can easily be incorporated in a stepped-care approach and, if not 
successful, patients can be referred to more specialised services. At the same 
time, more research is needed to assess how to optimize and improve the current 
intervention, for instance by including elements of computer tailored approaches 
that have shown to be successful. Implementation of the protocol could help the 
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professionals in general practice to meet these quality targets. Elements of the 
protocol such as repeated recording of patients’ smoking status and their 
motivation to quit is a prerequisite for adequate smoking cessation counselling and 
treatment in the stepped care approach by primary as well as specialised care.  
 
Recommendations for actual practice 
The organization of the Dutch general practice has changed in the past decade. 
While at the time of study only three of the included practices had a practice nurse 
besides a receptionist or practice assistant, nowadays many Dutch practices have 
a practice nurse. Practice nurses perform delegated tasks, mainly providing 
protocolised care for patients with chronic condition, including lifestyle 
interventions such as smoking cessation counselling. Practice nurses have more 
time for patient education and counselling during a regular consultation. Probably 
the protocol would fit better in the present structure of general practice than at the 
time of the experiment.  
 Recording smoking status and the provision of smoking cessation support is 
part of the quality indicators to assess adequate treatment of COPD. 
Implementation of the protocol could help the professionals in general practice to 
meet these quality targets. The SMOCC protocol can be considered as a more 
tailored format of the protocolised smoking cessation module which is to be 
incorporated in a common electronic patient record (EPR) accessible to all 
healthcare professionals involved in the treatment of the patients with COPD. 
Incorporation of the SMOCC protocol in the module may be an improvement of the 
quality of care for these patients. 
 Since computer tailored programs have shown to be able to result in significant 
effects in lifestyle changes, a challenge for the future may be to translate the 
current strategy into interactive e-health approaches that may facilitate self-
management of smoking cessation in COPD patients. Since relapse is a significant 
problem, these programs may also benefit from the outline of recent intensive 
computer tailored programs to prevent relapse resulting in continued abstinence 
rates of more than 40% after twelve months. Making smoking cessation an 
indicator for good quality of care provision might encourage practices to include 
smoking cessation support in their routines. 
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Future research 
Pharmacological agents that are used for smoking cessation are various forms of 
nicotine replacement therapy, bupropion-SR, nortryptiline and varenicline, to name 
the most important ones. Varenicline is a relatively new agent, which outperforms 
placebo and nicotine replacement therapy. As adherence to pharmacotherapy is 
essential but was very low in our sample, efficacy trials should be followed by 
effectiveness trials measuring adherence and effects of pharmacotherapy in real 
life settings. Although varenicline has been associated with serious adverse event, 
trials with COPD smokers suggested the safety of this agent. 
 Quitting smoking is one effort, but persisting the quit attempt and adopting a 
more healthy lifestyle is even harder to accomplish. Many COPD smokers have 
tried to quit at least once, but failed. To understand and to prevent relapse in these 
patients we need more research. Studies should aim at the determinants of 
relapse and consequently build interventions. Symptoms like increased coughing 
should be included in these analyses, and the prescription of extra bronchodilator 
medication should be tested as relapse prevention.  
 Finally, as already noted above, effectiveness does not imply public health 
impact. This implies that not only an effective program is needed, but also 
favourable conditions for a national implementation. Research is therefore needed 
to also assess the best conditions for large scale implementation of the current 
program as well as for even better programs that may follow our first smoking 
cessation program for smoking COPD patients. 
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Samenvatting 
 
Chronisch obstructief longlijden (COPD) is een chronische aandoening met een 
prevalentie van 1,55% bij vrouwen en 1,83% bij mannen in Nederland. Roken is 
de meest belangrijke risicofactor voor het ontwikkelen van COPD. In Nederland 
zijn ongeveer 276.100 patiënten met deze aandoening; in 2010 overleden 5.984 
patiënten met COPD als primaire doodsoorzaak. Ongeveer 70% van de COPD-
gerelateerde sterfte is toe te schrijven aan roken. Omdat stoppen met roken de 
progressie van COPD vertraagt, benadrukken internationale en nationale 
richtlijnen voor de behandeling van COPD het belang van stoppen met roken 
ondersteuning voor deze patiënten. 
 
Hoofdstuk 1 schetst de achtergrond van het onderzoek. Het onderzoek was 
gericht op het ontwikkelen en evalueren van een stoppen met roken protocol voor 
de huisartspraktijk omdat de meerderheid van patiënten met COPD wordt 
behandeld in de eerste lijn. Omdat rokers met COPD moeite hebben om te 
stoppen met roken, ontwikkelden we het SMOCC protocol (Engels acroniem voor 
SMOking Cessation in COPD). Dit protocol is afgestemd op de aandoening van 
deze rokers en houdt rekening met verschillende fasen wat betreft hun motivatie 
om te stoppen met roken. Een gecombineerde implementatiestrategie 
ondersteunde de huisartspraktijken in het toepassen van het protocol en bestond 
uit groepseducatie voor de medewerkers van de praktijken en praktijkbezoeken 
door ervaren praktijkondersteuners. In een gerandomiseerd gecontroleerd 
experiment werd de effectiviteit van deze strategie onderzocht. Praktijken in de 
interventiegroep deden mee aan een vier uur durende groepstraining over COPD, 
roken en stoppen met roken. De praktijkondersteuner gaf tijdens de bezoeken 
advies en feedback op de prestaties van de praktijk (drie bezoeken). Ook 
ontvingen ze patiëntinformatie (een video over stoppen met roken en een folder 
over COPD en stoppen met roken) en een schematische weergave van het 
SMOCC protocol (zie appendix). Het protocol beschrijft de verschillende stappen 
van de stoppen met roken begeleiding, rekening houdend met de motivatiefase 
waarin de patiënt zich bevindt. Patiënten die gemotiveerd waren te stoppen met 
roken werden in het eerste consult met de huisarts geadviseerd om een 
stopdatum vast te stellen en nicotinevervangende middelen en/of bupropion - een 
geregistreerd medicijn dat helpt bij het stoppen met roken - te gebruiken. 
Vervolgens werd een tweede consult gepland, twee weken later. Patiënten die een 
stoppoging ondernamen ontvingen van de praktijkassistent(e) telefonische 
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begeleiding tot maximaal drie gesprekken. Met degenen die een stoppoging 
ondernamen werd een derde consult met de huisarts gepland, twee weken na de 
stopdatum. Praktijken die in de controlegroep van het experiment zaten leverden 
de gebruikelijke zorg aan hun patiënten. 
 
In hoofdstuk 2 worden de verschillen tussen rokers met COPD in drie 
verschillende motivatiefasen met betrekking tot stoppen met roken onderzocht. In 
een cross-sectioneel onderzoek met 633 rokers met COPD uit 67 
huisartspraktijken, werd de motivatiefase gerelateerd aan gezondheidsindicatoren, 
demografie, attitudes, sociale steun, self-efficacy (geloof in eigen kunnen om te 
stoppen met roken), nicotineverslaving en actieplannen. Rokers met COPD 
werden ingedeeld op basis van hun motivatie om te stoppen met roken: 
Voorbereider (bereid om te stoppen binnen 1 maand), Aarzelaar (bereid om te 
stoppen met roken binnen 6 maanden) en Weigeraar (niet bereid om te stoppen 
binnen 6 maanden). Meer dan 50% van de rokers met COPD stonden open voor 
stoppen met roken ondersteuning (bereid om te stoppen met roken binnen zes 
maanden). Echter, Voorbereiders en Aarzelaars verschilden onderling minder dan 
eerdere onderzoeken laten zien. Wel in overeenstemming met de literatuur was 
dat Weigeraars minder voordelen van stoppen met roken zagen dan de 
Voorbereiders en Aarzelaars, en Voorbereiders toonden een beduidend hogere 
self-efficacy dan de minder gemotiveerde patiënten. In tegenstelling tot wat men 
zou verwachten, verschillen Voorbereiders en Aarzelaars niet met betrekking tot 
hun ervaren sociale steun, terwijl Aarzelaars een hogere self-efficacy hadden dan 
de Weigeraars. Ook hadden Weigeraars minder spijt van het roken, ondanks de 
symptomen, dan de Voorbereiders en Aarzelaars. Op basis van de 
overeenkomsten tussen Voorbereiders en Aarzelaars, wordt aanbevolen om met 
stoppen met roken ondersteuning aan rokers met COPD twee groepen te 
onderscheiden. Voordelen van stoppen moet worden besproken met 
ongemotiveerde rokers, en de rokers die gemotiveerd zijn om te stoppen moeten 
worden ondersteund om hun self-efficacy en actieplanning te verbeteren. 
 
De effectiviteit van het SMOCC protocol werd getest in een gerandomiseerd 
gecontroleerd experiment (43 huisartspraktijken, 392 rokers met COPD). In 
hoofdstuk 3 presenteren we de zelfgerapporteerde stopcijfers na zes maanden. 
Huisartsen rapporteerden dat ze in 70-80% de verschillende aspecten van het 
protocol opvolgden. Significant meer rokers in de experimentele groep 
ondernamen een stoppoging (44,9% versus 36,5%) en waren gestopt met roken 
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dan in de controlegroep (16,0% versus 8,8%). We vonden geen verschillen in 
stopcijfers tussen Voorbereiders, Aarzelaars en Weigeraars, wat mogelijk een 
indicator voor het succes van een stage-based aanpak in deze populatie is. 
Omdat het SMOCC protocol goed werd opgevolgd door de huisartsen en de 
zelfgerapporteerde stopcijfers na zes maanden twee keer zo hoog waren in de 
experimentele groep, lijkt het SMOCC protocol een waardevolle bijdrage aan de 
zorg voor COPD patiënten te zijn. 
 
In hoofdstuk 4 wordt een tweede effectiviteitstudie gepresenteerd, waarin de 
effectiviteit wordt vastgesteld op basis van zowel zelfgerapporteerde als 
biochemisch geverifieerde stopcijfers na twaalf maanden. In deze studie namen 
68 huisartspraktijken met 667 rokers met COPD deel. Oorspronkelijk bestond deze 
studie uit drie groepen; een groep leverde de gebruikelijke zorg, en twee groepen 
pasten het SMOCC protocol toe. De twee interventiegroepen waren vergelijkbaar, 
behalve dat huisartsen in één groep aanbevolen werd om nicotine vervangende 
middelen te adviseren aan gemotiveerde rokers met COPD en huisartsen in de 
andere groep werd aanbevolen om nicotine vervangende middelen en bupropion 
aan de gemotiveerd rokers met COPD te adviseren. Aangezien beide groepen 
hetzelfde presteerden, werden de twee interventiegroepen samengenomen in de 
analyses. Meer deelnemers in de interventiegroep rapporteerden gestopt te zijn 
met roken (14,5%) dan patiënten die gebruikelijke zorg ontvingen (7,4%). Echter, 
wanneer deze rapportage biochemisch geverifieerd werd daalde de effectiviteit, 
met stopcijfers van 7,5% (interventie) en 3,4% (gebruikelijke zorg). Dit verschil was 
niet significant en de effectgrootte was klein (Cohen’s h = 0,18). Het gebruik van 
nicotine vervangende middelen en bupropion was laag, ongeveer een kwart 
ontving telefonische begeleiding. Het SMOCC protocol kan gebruikt worden voor 
rokers met COPD in de huisartspraktijk, maar de verwachtingen moeten 
bescheiden zijn. 
 
Hoofdstuk 5 richt zich op de biochemische verificatie van de door patiënten met 
COPD zelfgerapporteerde stopcijfers. Dit cross-sectionele onderzoek onder 
60 patiënten verifieerde de rookstatus door middel van urine analyses. Indien er 
50 ng/ml cotinine of meer werd aangetroffen werd de patiënt als roker aangeduid. 
Op het moment van biochemische verificatie, meldden 55 patiënten dat zij gestopt 
waren met roken, terwijl vijf patiënten weer begonnen waren met roken. De 
zelfgerapporteerde rookstatus werd biochemisch bevestigd bij 43 patiënten (78%) 
en 12 patiënten (22%) werden geclassificeerd als rokers. De sensiviteit van de 
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zelfrapportage was 29% en de specificiteit 100%. Veel eerstelijns patiënten met 
COPD verstrekken onjuiste informatie over hun rookgedrag, waardoor adequate 
therapeutische interventies belemmerd worden. Integratie van biochemische 
controle in de dagelijkse zorg kan dit probleem verhelpen, maar kan ook de arts-
patiënt relatie schaden. 
 
Hoofdstuk 6 onderzoekt relaties met het opnieuw toepassen van het SMOCC 
protocol en onderzoekt kwalitatief de bevorderende en belemmerende factoren 
voor het gebruik van het SMOCC protocol onder 43 huisartsen. Huisartsen vulden 
baseline- en evaluatievragenlijsten in en namen deel aan een semi-gestructureerd 
telefonisch interview. Data werden geanalyseerd vanuit een raamwerk gebaseerd 
op het ASE model – attitudes (A), sociale invloeden (S) en self-efficacy (E) – om 
de naleving van het protocol in kaart te brengen. Naast het adviseren van nicotine 
vervangende middelen (30%) en het verstrekken van een educatieve videoband 
(43%), rapporteerden de huisartsen dat ze de onderdelen van het SMOCC 
protocol goed hadden opgevolgd (gemiddeld 76%). Drieënvijftig procent paste het 
protocol weer toe als de patiënten weer waren gaan roken. Een deel van de 
huisartsen was teleurgesteld in de effectiviteit van het protocol, hetgeen 
samenhing met een negatieve houding, minder sociale steun en een lagere self-
efficacy. Verandering in het ondersteunend personeel in de praktijk of 
ongemotiveerde medewerkers belemmerden huisartsen in het toepassen van het 
procol. Ook het hebben van een negatieve houding, een gebrek aan sociale steun 
ervaren en zich minder zelfverzekerd voelen, belemmeren de toepassing van het 
protocol. Huisartsen moeten realistische verwachtingen hebben met betrekking tot 
stoppen met roken ondersteuning, en het delegeren van deze ondersteuning aan 
praktijkmedewerkers is zinvol wanneer huisartsen geconfronteerd worden met 
gebrek aan tijd en/of zelfvertrouwen om deze begeleiding te bieden. Ook kan de 
roker doorverwezen worden naar meer gespecialiseerde zorginstellingen. 
 
In hoofdstuk 7 wordt de haalbaarheid van een wervings- en inclusieprocedure 
gericht op rokers met COPD om hen een stoppen met roken programma aan te 
bieden in 152 huisartspraktijken besproken. De procedure bestond uit hulp bij het 
opsporen van rokers met COPD uit de elektronische patiëntendossiers door 
middel van een software-programma, een korte vragenlijst over rookgedrag en 
een uitnodiging om deel te nemen aan het programma. In totaal werden 9.786 
patiënten met COPD opgespoord, waarvan 926 rokers reageerden (9,5%). Van 
hen wilden 366 rokers deelnemen aan het programma. Rokers die wilden 
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deelnemen aan het programma waren meer gemotiveerd om te stoppen met 
roken (met name Aarzelaars) en hadden vaker geprobeerd om te stoppen met 
roken. Andere kenmerken van patiënten, noch de praktijkkenmerken waren 
gerelateerd aan het besluit deel te nemen. Belemmeringen bij het werven van 
rokers met COPD waren problemen met het opsporen van patiënten met COPD 
uit het elektronische patiëntendossier en het beoordelen van hun rookgedrag door 
middel van een korte vragenlijst die de huisartspraktijk moest versturen. Een meer 
persoonlijke en geleidelijke benadering van patiënten die ingebed is in de 
dagelijkse praktijkvoering lijkt nodig om rokers met COPD te includeren in een 
stoppen met roken programma. 
 
Hoofdstuk 8 is de algemene discussie van het huidige onderzoek. Naast de 
belangrijkste conclusies, worden ook een aantal methodologische kanttekeningen, 
richtlijnen voor de zorg voor patiënten met COPD en voor toekomstig onderzoek 
besproken. Gezien het gebrek aan interventies op maat voor rokers met COPD en 
de vaststelling dat het SMOCC protocol de stopcijfers verdubbelt, wordt de 
implementatie van het SMOCC protocol aanbevolen. In Nederland worden 
ongeveer 55-60% van de patiënten met een milde tot matige COPD behandeld in 
de huisartspraktijk. In lijn met richtlijnen voor de huisartspraktijk die de nadruk 
leggen op stoppen met roken, biedt het SMOCC protocol een instrument speciaal 
gericht op rokers met COPD. Het protocol kan makkelijk worden opgenomen in 
een stepped care benadering en, indien niet succesvol, kunnen patiënten worden 
verwezen naar meer gespecialiseerde zorg. Tegelijkertijd is meer onderzoek nodig 
om te bepalen hoe het huidige protocol te optimaliseren is, bijvoorbeeld door 
elementen van computergestuurde interventies die effectief zijn. De implementatie 
van het protocol kan de huisartspraktijk helpen om invulling te geven aan de 
richtlijnen. Elementen van het protocol, zoals herhaalde registratie van de 
rookstatus van patiënten en hun motivatie om te stoppen met roken, zijn een 
voorwaarde voor een adequate stoppen met roken begeleiding en behandeling in 
de stepped care benadering door de eerste lijn en gespecialiseerde zorg. 
 
Aanbevelingen voor de praktijk 
De organisatie van de Nederlandse huisartsgeneeskunde is in de afgelopen tien 
jaar veranderd. Ten tijde van het moment van onderzoek hadden slechts drie van 
de deelnemende praktijken een praktijkondersteuner naast een receptioniste of 
doktersassistente, tegenwoordig hebben veel praktijken een praktijkondersteuner. 
Praktijkondersteuners voeren gedelegeerde taken uit, met name het verstrekken 
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van geprotocoliseerde zorg aan patiënten met chronische aandoeningen, inclusief 
leefstijlinterventies zoals stoppen met roken ondersteuning. Praktijkondersteuners 
hebben meer tijd voor patiëntvoorlichting en -begeleiding tijdens consulten. 
Waarschijnlijk past het SMOCC protocol beter in de huidige structuur van de 
huisartsgeneeskunde dan ten tijde van het experiment. 
 Registratie van rookstatus en het geven van stoppen met roken ondersteuning 
is een onderdeel van de kwaliteitsindicatoren voor adequate behandeling van 
patiënten met COPD. De implementatie van het protocol kan professionals in de 
huisartspraktijk helpen te voldoen aan de gevraagde kwaliteit. Het SMOCC 
protocol kan worden beschouwd als een meer op maat gesneden interventie van 
de stoppen met roken module die wordt opgenomen in een gemeenschappelijk 
elektronisch patiëntendossier (EPD), toegankelijk voor alle zorgverleners die bij de 
behandeling van patiënten met COPD betrokken zijn. Het opnemen van het 
SMOCC protocol in de module zal een verbetering van de kwaliteit van zorg voor 
deze patiënten. 
 Computergestuurde interventies kunnen significante effecten op 
leefstijlveranderingen teweegbrengen. Hier ligt ook een uitdaging om het huidige 
protocol te vertalen naar een interactieve e-health benadering die het stoppen met 
roken vergemakkelijkt voor rokers met COPD. Omdat terugval in rookgedrag een 
groot probleem is, kan deze benadering voortbouwen op recente ontwikkelingen 
van computergestuurde programma’s om op maat terugval te voorkomen. Deze 
programma’s resulteren in continue abstinentiecijfers boven 40% na twaalf 
maanden. Stoppen met roken als indicator voor goede kwaliteit van de 
zorgverlening kan praktijken mogelijk stimuleren om stoppen met roken 
ondersteuning in hun dagelijkse zorgverlening op te nemen. 
 
Toekomstig onderzoek 
Farmacologische middelen voor het stoppen met roken bestaan uit verschillende 
vormen van nicotine vervangende middelen, bupropion, nortryptiline en 
varenicline, om de belangrijkste te noemen. Varenicline is een relatief nieuw 
middel, dat effectiever is dan placebo en nicotine vervangende middelen. Omdat 
het daadwerkelijk gebruik van farmacotherapie essentieel is en in het huidige 
onderzoek laag was, is naast onderzoek naar effectiviteit ook nodig te kijken naar 
daadwerkelijk gebruik en effectiviteit in ongecontroleerde situaties. Hoewel 
varenicline in verband is gebracht met ernstige bijwerkingen, zijn er ook 
onderzoeken die laten zien dat dit middel veilig is voor rokers met COPD.  
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Stoppen met roken is een inspanning, maar de stoppoging volhouden vraagt ook 
om extra aandacht. Om dit beter te begrijpen en om terugval te voorkomen, is 
meer onderzoek nodig. Onderzoek zal zich moeten richten op de determinanten 
van terugval bij deze patiënten en op basis hiervan moeten de stoppen met roken 
interventies aangepast worden. Symptomen zoals een toename van hoesten 
tijdens een stoppoging vragen om een beter inzicht. Het voorschrijven van extra 
luchtwegverwijders moet worden getest als terugvalpreventie. 
 Tenslotte, zoals hierboven al is betoogd, leidt effectiviteit van een interventie 
niet automatisch tot een volksgezondheidseffect. Dit betekent dat niet alleen een 
effectief programma nodig is, maar ook gunstige voorwaarden voor een brede 
implementatie. Onderzoek is daarom noodzakelijk om te beoordelen wat de beste 
voorwaarden voor de grootschalige invoering van het huidige programma zijn en 
welke mogelijkheden er zijn om betere programma’s om stoppen met roken in 
deze populatie te ondersteunen. 
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Er zijn dagen geweest dat ik mezelf een chronische promovendus voelde, langer 
bezig met het afronden van dit boekje dan met het onderzoek zelf. Het hele traject 
heeft dan ook even geduurd. Veel mensen leverden hun bijdrage en waren 
betrokken bij de totstandkoming van deze proeve. 
 
Allereerst mijn promotoren en copromotor: Richard, Hein en Annelies. 
Richard, je overkoepelende blik bood geregeld structuur om nogmaals het 
onderscheid tussen implementatiestrategie en patiëntgerichte interventie te 
beschrijven. Het duurde even voor we elkaars humor doorhadden, maar ik 
herinner me de overleggen waarin inhoud en humor goed gemixt werden. Je 
vermogen om verbanden te leggen met ander onderzoek was verbazingwekkend 
en heeft me telkens weer op weg geholpen. 
Hein, als tweede promotor stond je meer op afstand, zeker nadat ik Maastricht 
verliet toen Nijmegen mijn vaste stek werd. Bij het schrijfproces was je nauw 
betrokken, dacht je constructief mee om naast de implementatie ook de 
psychologie een plek te geven en kwam je enthousiast met bijna gepubliceerd 
onderzoek om de nieuwste inzichten met betrekking tot gedragsverandering en 
gedragsbehoud een plek te geven.  
Annelies, ik weet nog goed dat ik bij je op gesprek kwam en dat je me vroeg of dit 
een oriënterend of een sollicitatiegesprek was. We hebben het laatste ervan 
gemaakt en een maand later kon ik het SMOCC onderzoek overnemen. Als 
copromotor acteerde je nadrukkelijk, gaf richting, schreef actief mee aan de 
output. Je hebt me niet alleen geholpen met het voederen van brood met 
leverworst (dat je als overtuigd vegetariër zonder enig protest deed), maar je hield 
ook het boekje op mijn agenda, rekening houdend met mijn andere tijdrovende 
ambities en andere kwalen. Dank voor je betrokkenheid, je geduld, je vertrouwen 
en je helpende hand bij het voltooien van dit werkje. 
 
Toen ik in 2002 begon stapte ik in op een rijdende trein: de SMOCC studie was al 
twee jaar eerder gestart. Regina, dank voor de gedegen opzet. De omvang van de 
studie was enorm, en met circa 85 huisartspraktijken die bij aanvang bereid waren 
deel te nemen heb je enorm veel werk verzet om de gegevens boven tafel te 
krijgen. Marie-Louise was hierin ook zeer belangrijk: je verzorgde de logistiek van 
de vragenlijsten en hierop kon ik blindelings vertrouwen. En natuurlijk Margriet en 
Janine: jullie reisden stad en land af om de huisartspraktijken te ondersteunen met 
de implementatie van het protocol, het uitspoelen van de HISsen en het motiveren 
van de huisartsteams. Janine, ook dank voor je BV activiteiten! Jan en Reinier: 
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jullie support bij de uitspoelen van de HISsen was fantastisch om de relevante 
gegevens uit de databerg te filteren. Jolanda bedankt voor de secretariële 
ondersteuning, het aanvragen van de vele artikelen, de assistentie bij het 
gereedmaken van de eindrapporten en de ondersteuning bij het opmaken van dit 
boekje! Als laatste Sanne die mij als student-assistent de eerste dag in Maastricht 
wegwijs maakte in wat de stand van het onderzoek was. Later heb je als stagiaire 
de biochemische validering uitstekend voorbereid en de basis gelegd voor de 
uiteindelijke publicatie. 
 
De begeleidingscommissie; Rien, Ben, Maryanne, Jean. Met zoveel expertise op 
alle relevante terreinen was het prettig om inhoudelijk te discussiëren over de 
koers van het onderzoek. Bedankt voor jullie inzet en medewerking. 
 
Inge, Bertus, Lotje, Josine, Irma, Carla en Erny; we hebben in wisselende 
bezetting de kamer gedeeld. Naast de etentjes, weekendevaluaties en 
koffiemomenten, waren er ook de hand en spandiensten. Dank voor de humor en 
de hulp! 
 
Bert (liever het baasje dan het haasje), Anja en Ido; met het ‘taxi anders’ concept 
hebben we heel wat kilometers afgelegd – waarvoor UWV dank. Geen tijdstip was 
te gek, en de bijkomende service (sjouwen met dozen vragenlijsten, laptop 
aansluiten, mac’en) heeft me enorm geholpen!. 
 
Rien, naast lid van de begeleidingcommissie ben je vooral mijn opleider. Bij jou 
kon ik mijn onderzoekstage doen en maakte ik kennis met het onderzoek naar 
roken. Je inspireerde, gaf wetenschappelijk onderzoek voor mij ‘smoel’ en 
doceerde. En soms was het leerzame onverwacht. Uit het literatuuronderzoek 
naar compulsive smoking ontdekten we het bestaan van het pathologische wortel 
eten.   
 
Collega’s vanuit de revalidatie (Marij, Diana, Bionka, Elise, Rita, Karel, Ieteke, 
Thea, Egbert), het Kenniscentrum Zorginnovatie (Susan, Heleen, Jane, Marjolijn, 
Adriaan, AnneLoes, Mieke), de BOSK (Martijn, Bert, Johannes, Eric, Twink): dank 
voor jullie blijvende belangstelling. 
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AnneLoes en Adriaan, vanuit de Hogeschool Rotterdam hebben jullie ervoor 
gezorgd dat ik gedurende een jaar een dag per week vrijgesteld werd om aan het 
boekje te werken. Dank voor deze ruimte! 
 
Neeltje, we doen snel weer een concert! Ilona, binnenkort weer een kip in 
bladerdeeg. Sjaak en Sjan, Didi en Peter, we hebben een lange geschiedenis; van 
een marathon examen met kroepoek, festivals en concerten, Bobo-ondersteuning 
tijdens E-hockey en IPC tripjes, tot het aanbrengen van structuur in mijn 
chaotische archief en relaxen op de ark. Keep on rockin’ in a free world! 
 
Martin, we hebben beiden het onderzoekende karakter, de vasthoudendheid, het 
zoeken naar nieuwe uitdagingen. We zien elkaar niet vaak, maar het is fijn dat wij 
deze herkenning hebben. 
 
Jaroen en Marja, de weekenden in Lelystad zijn altijd een verademing. Vooral op 
het plein aan het water. Soms praten we over het werk en het onderzoek, maar 
meestal over veel leukere dingen. Het is goed om zo’n tweede thuis te hebben! 
 
Lieve Pa en Ma, het is dan eindelijk zover. Jullie hebben me laten ontwikkelen tot 
een zelfstandig persoon, vroeg ruimte en steun geboden om aan mijn anders-zijn 
een eigen draai te geven. Thanks for life! 
 
Lieve Ronja, je bent inmiddels een volwassen meid die na een ‘bere-goed’ 
avontuur in Thailand inmiddels weer het lerende leventje heeft opgepakt. Ik ben 
ontzettend trots op hoe je in de wereld staat en prijs mezelf een gelukkige Papshi 
met zo’n Roversdochter!  
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  • Make an inventory of (dis)advantages of smoking 
• Hand out aids (leaflet & video) • Hand out aids (leaflet & video) 
• Make appointments for follow-up consults • Make appointments for follow-up consults 
• Make notes in HIS • Make notes in HIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SMOCC 
General 
Practitioner 
Regular check up consult after 6 months 
• Provide feedback from 1st and 2nd consult. Expressly 
check motivation stage, (dis)advantages, social support 
and barriers 
• Give quit smoking advise in addition to regular check up
Regular check up consult after 6 months
• Provide feedback from 1st consult.  
• Give quit smoking advise in addition to 
the regular check up consult 
First Consult (duration double consult) 
1. Check up policy 
 • Apply if necessary spirometry 
 • Explain the check up policy of COPD 
 • Evaluate medication, inhalation techniques and compliance 
 • Evaluate complaints, sleep, and restraints (by means of questionnaire) 
2. Smoking behaviour 
 • Discuss relationship COPD, complaints, smoking and if possible the result 
of spirometry 
 • Give quit smoking advise 
 • Discuss motivation stage (by means of questionnaire): “Do you intend to 
quit smoking?” 
  Result doesn’t want to quit at all (precontemplator) 
   wants to quit, but not within 1 month (comtemplator) 
   wants to quit within 1 month (preparer) 
Second Consult (after 2 weeks) 
• Provide feedback from 1st consult Æ notes HIS 
• Discuss motivation stage 
 Result doesn’t want to quit at all anymore  
  wants to quit, but not within 1 month 
  wants to quit within 1 month 
 
• Discuss especially (dis)advantages smoking (leaflet & 
video) 
• Assess if necessary social support and barriers 
• Give a quit smoking advise again 
• Assess motivation stage 
 Result doesn’t want to quit at all anymore  
  wants to quit, but not within 1 month 
  wants to quit within 1 month 
 
• Make an appointments for follow-up consults (at the very 
latest after 6 months, if desired sooner) 
• Make notes in HIS
 PRECONTEMPLATOR  CONTEMPLATOR 
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SMOCC: 
GP              Consult 
Assistant   Consult 
 
 
 
• Make an inventory of and discuss (dis)advantages of smoking 
• Hand out aids (leaflet & video) 
• Make appointments for follow-up consult & homework test leaflet 
• Make notes in HIS 
 PREPARER 
Regular check up consult after 6 months 
Third telephone consult by AS (7 weeks after quit date) 
If desired continuation of the telephone counselling 
Second telephone consult by AS (3 weeks after quit date) 
Third Consult (1 week after quit date) 
• Positive reinforcement in case of quit smoking 
• Provide support in case of relapse and discuss risk situations 
• Discuss and advise nicotine substitution again 
• Make notes in HIS 
First telephone consult by AS (2 weeks after quit date) 
Second Consult (after 2 weeks) 
• Provide feedback from 1st consult Æ notes HIS 
• Discuss motivation stage 
 Result doesn’t want to quit at all anymore (       precontemplator) 
  wants to quit, but not within 1 month 
  wants to quit within 1 month 
 
• Discuss if necessary shortly (dis)advantages smoking (leaflet & video) 
• Assess and discuss especially social support and barriers 
• Assess nicotine dependence Æ test leaflet 
• Discuss preparations 
• Prescribe aids (nicotine substitution) 
• Schedule quit date 
• Make appointments for follow-up consults (if desired an additional second consult) 
and provide information about the telephone counselling 
• Make notes in HIS and notify assistant 
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SMOCC 
 
The assistant 
 
• Give compliment 
 
 
• Stimulate that the patient rewards him/her self 
 
 
• Discuss possible slip: 
  ‘Did you have had a smoke after the  
   quit date?’ 
• If yes: Don’t punish, but: Slip is a learning 
experience & discuss accompanying risk 
situation  
 
 
• Discuss (other) risk situations: 
‘Have you been in situations where it was 
difficult to refrain from smoking?’ 
• If yes: Ask further to clarify the risk situations 
& discuss the skills to cope with these 
situations 
 
 
• Discuss possible use nicotine substitution 
 consult after 2 days en 3 & 7 weeks: 
Motivate to continue with nicotine substitution. 
 consult after 7 weeks: Motivate to continue 
with nicotine substitution 
 
• Acknowledge or make (telephone) follow-up 
consults, both with GP as with assistant 
 
 
• Make notes in the journal & SMOCC-
registration 
• Ask for reason
 
• Assess: slip or relapse 
‘Have you smoked once, or do you smoke as 
usual?’ 
In case of slip: Don’t punish, but: Slip is a 
learning experience & discuss accompanying 
risk situations and skills to cope with these 
risk situations 
• In case of relapse:  
Ask for motivational stage: 
‘Do you intend to quit smoking in the future?’ 
→ within 1 month 
- Make an appointment for consult with GP 
(2nd consult Preparer) 
- Advise to read the folder 
→ not for the moment 
- Tell that the GP will discuss quit smoking 
again during the next regular check up 
consult 
- Advise to read the leaflet 
- Patient is allowed to contact the practice 
to ask for telephone counselling 
 
• Patients possibly needs (in case of relapse) to 
stop taking nicotine substitution  
 
• Cancel (in case of relapse) previously 
appointed consults, both with the GP as with 
the assistant 
• Acknowledge or make (in case of slip) 
(telephone) follow-up consults, both with GP 
as with assistant  
 
• Make notes in the journal & SMOCC-
registration 
Telephone counselling by assistant
(2 days and 3 & 7 weeks after quit day) 
• Ask: ‘How are you doing?’ 
• Ask: ‘How are you doing with respect to quit smoking 
QUITTED, BUT STARTED AGAIN QUITTED 
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• Ask for reason 
 
• Discuss barriers & possible solutions 
‘Which difficulties hinder quit smoking?’ 
‘How can you resolve these difficulties?’ 
 
 
• Ask for the motivation stage: 
‘Do you intend to quit smoking in the future?’ 
→ within 1 month 
- Schedule a new quit date 
- Advise to read the leaflet (in particular the 
preparations) 
- Make an appointment for consult with GP 
(3rd consult Preparer; 1 week after quit 
date) 
- Make appointments for telephone 
counselling (2 days, 3&7 weeks after quit 
date) 
→ not for the moment 
- Tell that the GP will discuss quit smoking 
again during the next regular check up 
consult 
- Advise to read the leaflet 
- Patient is allowed to contact the practice 
to ask for telephone counselling 
- Check if the patient used nicotine 
substitution 
 
 
• Cancel previously appointed consults, both 
with the GP as with the assistant 
 
 
• Make notes in the journal & SMOCC-
registration 
 
Outline SMOCC consults  
(See also flowchart GP) 
 
 
 
 
2nd consult GP 
(after 2 weeks) 
2nd consult GP 
(after 2 weeks)
2nd  consult AS 
(3 weeks after quit date)
3rd consult GP 
(1 week after quit date) 
1st  consult AS 
(2 days after quit date)
3rd  consult AS 
(7 weeks after quit date)
Precon- 
templator 
Contemplator Preparer 
Regular check up consult GP (after 6 months) 
NOT QUITTED 
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SMOCC: 
 
GP              Consult 
Assistant   Consult 
 
